

UKKW 2023

ABSTRACTS

Oral Presentations

UK Kidney Week
5-7 June 2023
ICC Wales, Newport

Contents

The Renal Services Transformation Programme

Submission: 481

Review of the haemodialysis processes in a single satellite dialysis unit with an aim to reduce carbon footprint and wastage

Dr Venkata Gullapudi, Ms Alison Hardy, Mr Terence Simpson, Mr Peter Jones, Dr Mark Wright

Leeds Teaching Hospitals NHS Trust, Leeds

Background and aims: Haemodialysis (HD) is lifesaving therapy for patients with kidney failure. However, it comes with huge environmental costs as it involves usage of vast amount of medical consumables, water, and electricity. It is estimated that 3.8 tonnes of carbon-dioxide equivalent emissions are produced by one patient's dialysis treatment per year. We reviewed the dialysis service in our satellite unit with an aim to identify potentials ways of reducing our carbon footprint and wastage.

Methods: Process mapping the events in a satellite dialysis unit over a 24-hour period helped us to identify areas with scope for improvement and planned few changes. These included: 1) Replacing heat disinfection cycle with a rinse (resulting in one heated clean cycle per day and three rinses) 2) Building and priming the machine when the patient arrived so they weren't idling before dialysis 3) Reduction of pharmacy deliveries from weekly to fortnightly.

We calculated the consumption of power and water for each disinfection, rinse cycle and one minute of priming. In addition, dialysate acid consumption was also measured. We collected data regarding number of disinfection cycles/ rinse cycles required for current service delivery and idle times of the primed dialysis machines prior to connecting patients over a period of one week. These details enabled us to estimate the environmental and financial impact of the proposed changes over one year.

Results: With the details of the consumption of the power, water and acid during the various tasks outlines above, we estimated of the potential impact with the proposed changes to our practice at the satellite dialysis unit over one year period which is summarised in Table 1.

Table 1: Summary of the environmental and financial impact from the proposed changed practice in Satellite dialysis unit

Table 1	Savings per year	Environmental impact		Financial Impact	
		kgCO2e/ unit	Total kgCO2e	Pence/ unit	Total (£)
Electricity (Kwh)	5740.8	0.2913	1672.29504	22.4	1285.9392
Water (m3)	114.192	0.3666	41.8627872	232	264.92544
Travel (miles)	104	0.09489	9.86856	56	58.24
Acid savings (L)	3508.596	0.155	190.341333	35	1228.0086

*Kwh- kilo watt per hour; m^3- cubic meters; L- litres and kgCO2e -Carbon Dioxide Equivalent in kg

We currently care for 550 in-centre dialysis patients in 8 different dialysis units. After taking into consideration HD shift patterns in each unit, implementation of the above changes across our entire

HD services will lead to much higher savings and these estimations have been summarised in the Table 2.

Table 2: Estimated impact from proposed changed practice on implementation across the whole Haemodialysis services

Savings per year	Changing to 1 heat disinfection + 2 rinses per day	Dialysis fluid flow off during the standby for patient
Total reduction in power consumption (Kwh)	41353.2	38
Total reduction in water consumption (m3)	509.3868	3236
Power kgCO2e	12046.19	11
Water kgCO2e	186.7412	1186
Acid kgCO2e	NA	2398.284
Total reduction in kgCO2e	12232.93	3595.284
Power (£)	9263.296	8.512
Water (£)	1183.2	7507.52
Acid (£)	NA	15472.8
Total cost savings(£)	10446.5	22988.83

**Kwh- kilo watt per hour; m^3- cubic meters; L- litres, £- pounds and kgCO2e -Carbon Dioxide Equivalent in kg*

Based on the above calculations, a reduction of 0.1845 kgCO2e/patient/dialysis session can be achieved with the implementation of the above proposed changes.

Conclusion: HD services have significant financial and environmental implications. We have demonstrated that these could be reduced with careful review of our practice. If similar changes were to be made across the entire HD services in UK, the impact would be substantial.

The Renal Services Transformation Programme

Submission: 220

Improving quality and safety for in-centre haemodialysis patients: Development of a national nursing workforce monitoring tool

Submitted on behalf of the Welsh Kidney Network (WKN)

Welsh Kidney Network, Cardiff

Introduction: According to the Royal College of Nursing (2010), appropriate staffing is important for the delivery of safe and effective healthcare. While the 'Nurse Staffing Levels (Wales) Act 2016' (Welsh Government, 2021) requires Welsh health boards to "have regard for the provision of appropriate nurse staffing levels" in different healthcare settings, the Act does not however include the in-centre haemodialysis (ICHD) setting. The Welsh Kidney Network (WKN) are responsible for commissioning ICHD services in Wales and in their service specification, based on recommendations from the British Renal Society (BRS, 2002; 2020), outline a minimum requirement of a 1:3 nurse-to-patient ratio and a 70:30% ratio of registered and non-registered nursing staff.

While successful periodic audits using manual data collection methods had been undertaken by the authors previously, following a number of concerns raised by patients, the aim of the work here was to develop a tool which could be used to continually, in real-time, monitor the ICHD nursing workforce across all of Wales, an important aim given ~1,400 adult Welsh residents currently require Kidney Replacement Therapy (KRT), and need for such services forecasted to grow by up to 5% per annum (Welsh Government, 2022).

Methods: The work first involved development of a centralised electronic 'Microsoft SharePoint' data collection form accessible to all 20 dialysis units in Wales (Figure 1), and piloting said form at two units before implementing nationally. Following this was delivery of a virtual staff education programme to different service providers across Wales, including 'NHS', 'BBraun', 'Fresenius Medical Care' and 'Renal Services', development of a RAG scoring system to identify and escalate areas of high risk (Figure 2), and finally, development of an electronic 'Microsoft Power BI' dashboard to securely display and feedback data to stakeholders.

Results: Since successful all Wales implementation in October 2021, outcomes to date include positive feedback from all stakeholders regarding the operational utility of the tool and data it generates, including from service managers and nursing staff. Whilst audit submission compliance, and the number and proportion of dialysis sessions compliant with a 1:3 nurse-to-patient ratio and a 70:30% ratio of registered and non-registered nursing staff has varied between units, Figure 3 shows the all Wales rates to date.

Discussion: The work here demonstrates that the monitoring tool described offers significant opportunity for system-wide quality assurance for patients requiring ICHD in Wales. Requiring little resource, the tool remains a cost-effective method for assuring safety of kidney services provided on behalf of NHS Wales and therefore aligns with a value based healthcare approach. Following Welsh Government's (2022) recent 'Quality statement for kidney disease', the authors also suggest the tool be used to inform both resource allocation for ICHD and a new service specification for ICHD in Wales. Moreover, given research on ICHD nursing ratios and roles is limited, the data generated by this tool could inform future published staffing recommendations. Finally, while this work concentrates on ICHD, a similar tool could offer similar opportunities for home dialysis services.

Figure 1: Screenshot of electronic data collection form developed in 'Microsoft SharePoint' software



Figure 2: RAG system developed to risk score dialysis sessions in Wales

Compliant	if compliant with 1:3 and compliant with 70:30
Low risk	if compliant with 1:3 but non-compliant with 70:30 OR if non-compliant with 1:3 but compliant with 70:30
High risk	if non-compliant with 1:3 and non-compliant with 70:30

Figure 3: Screenshot of electronic dashboard developed in 'Microsoft Power BI' software

Month	Audits submitted	Audits expected	Sessions with audits missing	Submission compliance (Target=95%)	Sessions compliant with 1:3	% compliant with 1:3	Sessions compliant with 70:30	% compliant with 70:30	RAG = Compliant (%)	RAG = Low risk (%)	RAG = High risk (%)	Bank/ Agency (Ave. %)
January	804	1066	262	75.4%	640	80%	618	76.9%	70%	17%	13%	8.0%
February	778	984	206	79.1%	655	84%	606	77.9%	73%	17%	11%	7.2%
March	889	1103	214	80.6%	750	84%	713	80.2%	75%	15%	10%	9.0%
April	812	1066	254	76.2%	650	80%	641	78.9%	71%	16%	12%	8.7%
May	956	1066	110	89.7%	785	82%	713	74.6%	69%	18%	13%	9.3%
June	946	1066	120	88.7%	748	79%	723	76.4%	68%	20%	12%	11.0%
July	931	1066	135	87.3%	699	75%	671	72.1%	63%	22%	15%	9.9%
August	955	1111	156	86.0%	732	77%	673	70.5%	63%	21%	16%	11.0%
September	863	1066	203	81.0%	653	76%	587	68.0%	60%	23%	17%	11.4%
October	864	1066	202	81.1%	673	78%	586	67.8%	62%	22%	16%	8.9%
November	925	1066	141	86.8%	750	81%	662	71.6%	66%	20%	14%	8.7%
December		1103	1103									

References:

British Renal Society (2002) The Renal Team: A Multi-Professional Renal Workforce Plan For Adults and Children with Renal Disease: Recommendations of the National Renal Workforce Planning Group 2002. Available at: http://www.wales.nhs.uk/sites3/documents/434/Workforce.pdf (Accessed: December 2022).

British Renal Society (2020) 2020 BRS Multi-Professional Workforce Plan for adults and children living with kidney disease. Available at: https://www.researchgate.net/publication/345426977_2020_BRS_Multi-Professional_Workforce_Plan_for_adults_and_children_living_with_kidney_disease (Accessed: December 2022).

Royal College of Nursing (2010) GUIDANCE: Safe Nurse Staffing Levels in the UK. Available at: https://www.rcn.org.uk/About-us/Our-Influencing-work/Policy-briefings/pol-003860#tab1 (Accessed: December 2022).

Welsh Government (2021) Nurse Staffing Levels (Wales) Act 2016: statutory guidance (version 2). Available at: https://gov.wales/nurse-staffing-levels-wales-act-2016-statutory-guidance-version-2-html (Accessed: December 2022).

Welsh Government (2022) Quality statement for kidney disease. Available at: https://gov.wales/quality-statement-kidney-disease-html (Accessed: December 2022).

Learning together with the International Society of Nephrology; how global perspectives on CKD can inform UK practice

Submission: 292

Using the Kidney Failure Risk Equation to predict end-stage kidney disease in CKD patients of South Asian ethnicity: an external validation study.

Miss Francesca Maher[1], Doctor Lucy Teece[1], Doctor Rupert Major[2], Doctor Sarah Booth[1], Professor Laura Gray[1]

[1]University of Leicester, Leicester.
[2]University Hospitals of Leicester NHS Trust, Leicester

Introduction: The Kidney Failure Risk Equation (KFRE) predicts the 5-year risk of needing kidney replacement therapy (KRT) using four risk factors – age, sex, urine albumin-to-creatinine ratio (ACR), and estimated glomerular filtration rate (eGFR). Although the KFRE has been recalibrated in a UK cohort, this did not consider minority ethnic groups. Further validation of the KFRE in different ethnicities is a research priority. The KFRE also does not consider the competing risk of death, which may lead to overestimation of KRT risk. This study externally validates the KFRE for patients of South Asian ethnicity and compares methods for accounting for ethnicity and the competing event of death.

Methods: Data were gathered from an established UK cohort containing 35,539 individuals diagnosed with chronic kidney disease. The KFRE was externally validated and updated in several ways to take into account ethnicity. Recognised methods for time-to-event data were used. Taking the competing risk of death into account was also considered. A clinical impact assessment compared the updated models through consideration of referrals made to secondary care.

Results: The external validation showed risk of KRT differed by ethnicity. Model validation performance improved when incorporating ethnicity and its interactions with ACR and eGFR as additional risk factors. Further, accounting for the competing risk of death improved prediction. Using a criteria of 5 year ≥5% predicted KRT risk, the competing risks model reduced unnecessary referrals by 4 (1.10%) and missed 2 (5.9%) fewer end-stage kidney disease (ESKD) cases (compared to the previous best model). A hybrid criteria of predicted risk using the competing risks model and the previous guidelines (CKD-EPI eGFR <30ml/min/1.73 and/or ACR ≥70mg/mmol) should be used in referrals to secondary care renal services.

Discussion: The accuracy of KFRE prediction improves when updated to consider South Asian ethnicity and to account for the competing risk of death. This may reduce referrals whilst identifying risks of KRT and could further individualise the KFRE and improve its clinical utility. Further research should consider other ethnicities.

CaReMe UK - Heart failure in CKD - stepping up to the challenge & working across boundaries to deliver the best outcomes for people with kidney disease & heart failure

Submission: 312

Sodium-Glucose Co-transporter 2 Inhibitors and Kidney Outcomes in Real-world Type 2 Diabetes Populations: A Systematic Review & Meta-analysis

Dr Anna Forbes[1,2], Dr Rebecca Suckling[1], Mr William Hinton[2], Dr Nicholas Cole[1], Professor Debasish Banerjee[3], Professor Michael Feher[2], Professor Simon de Lusignan[2], Dr Pauline Swift[1]

[1]Epsom & St Helier University Hospitals, London.
[2]Clinical Informatics & Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford.
[3]St George's University of London, London

Introduction: The cardio-renal benefits of SGLT2 inhibitors in patients with and without T2D have been well established in several large randomised controlled trials. Determining the generalisability of the SGLT2i clinical trial findings to the broader population of people treated in routine clinical practice is of great importance in establishing the external validity of these trials, and magnitude of their potential benefit for people living with diabetes in the real-world. Well-designed and carefully conducted observational studies, evaluating the comparative effectiveness of SGLT2 inhibitors can address this issue, and complement the findings from randomised controlled trials. The aim of this systematic review is to explore how the kidney benefits of SGLT2 inhibitors in people with T2D observed in randomised controlled trials apply to the broader population of people with T2D treated in routine clinical practice. To our knowledge this is the first systematic review comprehensively examining real-world evidence to explore the association between SGLT2 inhibitors and kidney disease progression in adults living with T2D.

Methods: We searched MEDLINE, Embase and Web of Science for observational studies that investigated kidney disease progression in adults with T2D treated with SGLT2 inhibitors compared to other non-SGLT2 inhibitor glucose-lowering therapies. Studies published from inception to July 2022 were independently reviewed by two authors and evaluated using the Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) assessment tool. A random effects meta-analysis was performed with data from studies with comparable outcomes and reported as hazard ratios (HRs) with 95% confidence intervals (CIs).

Results: We identified 34 studies with a total population of 1,494,373 for inclusion in the systematic review. Included studies were from 15 counties and published between 2018 and 2022. Twenty-two studies were included in the meta-analysis, and the primary outcome of interest was a standardised composite of end stage kidney disease (ESKD), comprising kidney transplantation, maintenance dialysis, death from kidney failure, sustained eGFR <15 ml/min/1.73m2 or sustained declined in kidney function (defined as ≥40%, ≥50%, or ≥57% decline in eGFR from baseline). SGLT2 inhibitors when compared with other non-SGLT2 inhibitor glucose lowering drugs were associated with a 46% lower risk of ESKD (HR 0.54, 95% CI 0.47 to 0.63). This finding was consistent across multiple sensitivity analyses. Sub-group analysis showed the benefit of SGLT2 inhibitors was independent of baseline CKD status or eGFR category (CKD at baseline; HR 0.49, 95% CI 0.33 to 0.72, No CKD at baseline; HR 0.56, 95% CI 0.34 to 0.93, eGFR ≥90 ml/min/1.73m2; HR 0.62, 95% CI 0.44 to 0.88, eGFR 60-89 ml/min/1.73m2; HR 0.65, 95% CI 0.60 to 0.71, and eGFR <60 ml/min/1.73m2; HR 0.63, 95% CI 0.48 to 0.82).

Discussion: The findings from this systematic review of real-world observational data supports the extension of SGLT2 inhibitor kidney benefits to the broader population of people with T2D treated in routine clinical practice. The lower risk of ESKD observed with SGLT2 inhibitors appears to be independent of CKD status or eGFR category at baseline.

Where next for psychosocial health in kidney disease? Identifying the evidence gaps & way forward for research

Submission: 310

Mental health status before and after the COVID-19 vaccine rollout in people with kidney disease and their significant others

Ms Naeema A Patel[1,2], Ms Gurneet K Sohansoha[1,2], Ms Ella C Ford[1,2], Dr Thomas J Wilkinson[1,3], Dr Courtney J Lightfoot[1,2], Professor Alice C Smith[1,2]

[1]Leicester Kidney Lifestyle Team, Department of Population Health Sciences, University of Leicester, Leicester.
[2]Leicester NIHR Biomedical Research Centre, Leicester.
[3]NIHR Applied Research Collaboration East Midlands, Leicester Diabetes Centre, Leicester

Introduction: The COVID-19 pandemic has had significant impacts on mental health due to fear of infection, severe illness and death, and restricted freedoms and usual activities imposed by lockdowns and shielding. Clinical populations, such as those with chronic kidney disease (CKD), are more susceptible to COVID-19 infection and at risk of worse outcomes than healthy individuals, and may consequently suffer from higher levels of psychological distress, including depression, anxiety, and stress. The national launch of the vaccine programme in early 2021 resulted in lower health risks and relaxed social restrictions. Thus, we hypothesised that this would result in improved mental health in people living with CKD. We used a survey to assess levels of general depression, anxiety, stress and health anxiety in people with non-dialysis CKD (ND-CKD), kidney transplant recipients (KTRs) and their significant others (SOs) at two timepoints: during the UK tiered lockdowns of Autumn 2020, and in May 2021 after the vaccine roll-out.

Methods: Participants from 11 hospital sites in England were invited to complete an online survey between August-December 2020, and a follow-up in May 2021. The survey included two validated mental health questionnaires: the Depression, Anxiety and Stress Scale (DASS-21) and the Short Health Anxiety Index (SHAI). Higher scores are indicative of higher levels of depression, stress and anxiety, and health anxiety. A one-way ANOVA was used to compare questionnaire scores between participant groups, and paired sample t-tests were used to assess changes between the two timepoints.

Results: A total of 381 participants completed the survey in Autumn 2020: 123 ND-CKD (61% male, mean age 64[SD:14] years), 150 KTRs (51% male, 59[SD:12] years), and 108 SOs (39% male, 60[SD:13] years). 318 completed the follow-up survey in May 2021, with 174 participants completing both timepoints. In Autumn 2020, ND-CKD had significantly higher DASS-21 anxiety scores than SOs ($p=0.029$). Both ND-CKD and KTRs had significantly higher health anxiety scores than SOs at baseline ($P<0.001$), and at follow-up (ND-CKD, $P=0.006$; KTR, $P=0.010$). In May 2021, 95% of participants had received the Covid-19 vaccine. There were no significant changes in DASS-21 subscale scores or SHAI scores between the Autumn 2020 and May 2021 timepoints for any of the participant groups.

Discussion: The COVID-19 vaccine programme reduced health risks and allowed relaxation of social restrictions, which may be expected to result in improved population mental health. Our results show that during the pandemic, people living with ND-CKD and KTRs had higher levels of health-related anxiety than their SOs. After the vaccine rollout, we found no improvement in depression, anxiety, stress, or health anxiety among people living with CKD or their SOs despite nearly all the

participants having received the vaccine. It is likely that reduced general social distancing and widespread abandonment of mask-wearing in public locations led to persistent impact on mental health in vulnerable people and those who live with them, even while others were returning to normal. This situation persists today and indicates an urgent need for mental health support among the kidney community.

Where next for psychosocial health in kidney disease? Identifying the evidence gaps & way forward for research

Submission: 251

How do we measure the burden of dialysis? Findings from a scoping review of treatment burden measures.

Miss Emma Caton[1], Dr Shivani Sharma[1], Dr Enric Vilar[2,1], Professor Ken Farrington[2,1]

[1]University of Hertfordshire, Hertfordshire.
[2]Department of Renal Medicine, Lister Hospital, Stevenage

Introduction: Dialysis is a life-sustaining treatment for patients with advanced kidney failure, but it is extremely burdensome. Despite this, there are very few tools available to assess treatment burden within the dialysis population.

Methods: We conducted a scoping review to identify the use of generic and disease-specific measures of treatment burden in chronic kidney disease, and assess their suitability for use within the dialysis population. We searched CINAHL, MEDLINE and Cochrane Library for kidney disease-specific measures of treatment burden. Studies were initially included if they described the development, validation or use of a treatment burden measure or associated concept (e.g. measures of treatment satisfaction, quality of life, illness intrusiveness, disease burden, symptom burden or caregiver burden) in adult patients with chronic kidney disease. We also updated a previous scoping review exploring the implementation of disease general measures of treatment burden in patients with chronic disease.

Results: One-hundred and one measures of treatment burden or associated concepts were identified. Six measures (four direct measures of treatment burden and the two most relevant and frequently used indirect measures) were assessed for suitability for use within the dialysis population. The selected measures were: the Treatment Burden Questionnaire (TBQ), the Multimorbidity Treatment Burden Questionnaire (MTBQ), the Patient Experience and Self-management (PETS) questionnaire, the Haemodialysis Stressor Scale (HSS), the Illness Intrusiveness Rating Scale (IIRS) and the Kidney Disease Quality of Life- 36 Item (KDQoL-36) questionnaire. Assessment was conducted using adapted established criteria; the researchers outlined 8 key dimensions of treatment burden: medication, financial, administrative, lifestyle, healthcare, time/travel, dialysis-specific factors, and health inequalities. None of the measures identified adequately assessed all dimensions of treatment burden.

Discussion: Current measures of treatment burden in dialysis are inadequate to capture the spectrum of issues that matter to patients. There is a need for dialysis-specific burdens to be assessed in order to advance care that can help maximise quality of life for patients.

Submission: 166

Using peer review to improve the quality of kidney services: Implementation of a national clinical peer review programme

Submitted on behalf of the Welsh Kidney Network (WKN)

Welsh Kidney Network, Cardiff

Submitted on behalf of the Welsh Kidney Network (WKN)

Introduction: NHS Wales aims to provide high quality, equitable healthcare that is evidence-based and meets the needs of the population (Welsh Government, 2018). Clinical peer review is a quality assurance tool which involves teams of qualified healthcare professionals evaluating the performance of others within the same specialty and of similar expertise. By identifying and facilitating the spread of good practice, this collaborative process can be used to improve and reduce variation in healthcare.

In 2017, following a review of healthcare quality in the UK which recommended peer review become more widespread in NHS Wales (OECD, 2016), Welsh Government (2017) published the NHS Wales Peer Review Framework. While successful peer reviews had been undertaken by the authors previously, of renal vascular access services in Wales, the aim of the work here was to extend the method of peer review for quality assuring other services also commissioned by the Welsh Kidney Network (WKN), an important aim given ~1,400 adult Welsh residents currently require Kidney Replacement Therapy (KRT), and need for such services forecasted to grow by up to 5% per annum (Welsh Government, 2022).

Methods: By applying the NHS Wales Peer Review Framework (2017) model, work involved development of a 3-year cyclical plan for the following services commissioned by the WKN: home dialysis (including peritoneal dialysis and home haemodialysis), in-centre haemodialysis, and renal vascular access (Figure 1). Following this was the management of the entire peer review process (Figure 2).

Results: Outcomes of the work to date include:

- Development of an ongoing training programme, involving delivery of 9 training sessions to 66 multidisciplinary delegates over the 3-year period of 2020 to 2022.
- A register of 51 currently active qualified peer reviewers.
- Successful undertaking of peer reviews:
    - in 2021, of the home dialysis service at all 5 centres in Wales, and
    - in 2022, of the renal vascular access service at all 5 centres in Wales.
- Improvements in practice as a result of said reviews (Table 1).
- A peer review of the in-centre haemodialysis service at all 21 units in Wales planned for 2023.
- Continued monitoring by WKN's Quality and Patient Safety sub-group of recommendations of all peer reviews completed to date.
- Positive feedback received from all peer review participants, including reviewers and reviewees.

Discussion: The work here demonstrates that the peer review programme described offers significant opportunity for system-wide continuous improvement for Welsh patients requiring KRT. While it may require some resource, the programme remains a cost-effective method for assuring and improving quality and safety of kidney services provided by NHS Wales and therefore aligns with a value based healthcare approach. Following Welsh Government's (2022) recent 'Quality statement for kidney disease', the authors also suggest the recommendations of previous and upcoming peer reviews be used to inform the development of new service specifications for kidney disease pathways in Wales. Moreover, the work described could also inform the next all Wales 'Integrated Commissioning Plan for Specialised Services' and therefore resource allocation for patients with kidney disease in Wales.

Table 1: Examples of improvements in practice produced by WKN national peer review programme to date

Region of Wales	Change/improvement in practice resulting from peer review process
North	• Secured dedicated vascular access lists • Re-banding of vascular access nursing team members • Support for staffing in home dialysis team
South East	• Improved access to theatres for kidney transplant cases • Expansion of vascular access nursing team • Implementation of additional Doppler sessions • Improved Nephrology input into the vascular access MDT • Support for staffing in home dialysis team
South West	• Support for staffing in home dialysis team

Figure 1: 3-year cyclical plan for WKN national peer review programme



Figure 2: Management process for WKN national peer review programme

Management included:
• development and implementation of a peer review training programme, • identification of quality indicators for each service undergoing review, • development of a self-assessment document for each service undergoing review, • collaboration with health board colleagues to recruit 'peers', • coordination of peer review visits, • collation of data sets to inform visits, and • provision of timely feedback reports following visits.

References:

OECD (2016) Reviews of Health Care Quality: United Kingdom 2016. Paris: OECD Publishing.

Welsh Government (2017) NHS Wales Peer Review Framework: July 2017. Available at: http://www.wales.nhs.uk/sitesplus/documents/1064/NHS%20Wales%20Peer%20Review%20Framework%20%28July%202017%29.pdf (Accessed: December 2022).

Welsh Government (2018) A Healthier Wales: our Plan for Health and Social Care. Available at: https://gov.wales/healthier-wales-long-term-plan-health-and-social-care (Accessed: December 2022).

Welsh Government (2022) Quality statement for kidney disease. Available at: https://gov.wales/quality-statement-kidney-disease-html (Accessed: December 2022).

Submission: 291

Chronic kidney disease and acute kidney injury programmes: a 'virtual hug of support'

Dr Emma Vaux[1], Ms Emma Bishop[2], Miss Becca Sharman[2], Dr Tim Ringrose[2], Mr Jake Sykes[2], Mrs Daisy Allington[2], Mr Andy Begg[2], Mr Mohammad Hamza[2], Mr Rick Knowles[2]

[1]Royal Berkshire NHS Foundation Trust, Reading.
[2]Cognitant Group Ltd, Oxford

Background: Low health literacy in chronic kidney disease (CKD) is associated with worsening kidney function, increased hospitalisation and mortality. In general, patients from ethnic minority backgrounds have lower health literacy rates owing to language and cultural barriers, compared with their white counterparts. The Royal Berkshire NHS Foundation Trust partnered with Cognitant, a healthcare technology company, to develop a digital interactive care model to improve patient health literacy and understanding of CKD. The pilot programme received positive feedback from users, who reported that the digital information was easy to understand and more effective in increasing their knowledge of CKD compared with traditional printed information. In this Phase 2 expansion, the aim was to improve accessibility of the digital platform and the existing CKD material, particularly for ethnic minority groups, and to develop a digital platform for patients with acute kidney injury (AKI).

Methods: A multidisciplinary co-creation approach was used (patients, nephrology, primary care, pharmacy and dieticians). Languages most appropriate for the Berkshire region were identified using data from local practice records regarding translator requests during patient consultations. To further improve accessibility, patient feedback from the pilot programme was assessed. User engagement was measured by time spent per session, and a digital feedback questionnaire assessed ease of use, effectiveness and patients' preferences using a 5-point Likert scale, ranging from 'No' – 'Sort of/It was ok' – 'Yes'. A co-creation approach was adopted to develop a similar programme for patients with AKI.

Results: Consultation records indicated that Polish, Nepali, Punjabi and Urdu were highly requested for translation in local Berkshire practices during patient consultations. Cultural adaption of the CKD programme included translation into these languages, the inclusion of culturally appropriate avatars and culturally specific changes to the content, such as nutritional advice. Based on patients' feedback from Phase 1, the programme was redeveloped to be fully web-based. Metric data on patient engagement indicated that on average, users spent 9 minutes 23 seconds on the programme per session and feedback from the questionnaire was generally positive. Most patients who provided responses reported that they enjoyed the video about CKD, they found the site easy to use and they knew more about CKD after watching the video (**Figure**). The co-creation process for the AKI programme enabled the development of similar materials for patients with AKI, including an interactive video, available in multiple languages, and a quiz to improve engagement and knowledge retention.

Discussion: Expansion of the CKD digital interactive care model supports the aim of increasing accessibility of visual digital information, particularly for patients from ethnic minority backgrounds. Translation into regionally relevant languages and cultural adaptation has wide applicability and the

potential to tackle health inequalities by empowering underserved patients with reliable and easy-to-understand information. The next steps of the programme include gathering data on engagement with the translated services, extending the CKD education programme to more regions, and launching and analysing the AKI programme.

Figure. Patient responses from feedback questionnaire using a Likert scale to assess attitudes towards the digital platform and the information presented.



Empowering partnerships through information and technology to improve outcomes

Submission: 078

Development of a virtual-reality based educational tool for training in peritoneal dialysis of patients, families, and staff

Dr Ben Reynolds[1], Professor Vassilis Charissis[2], Ms Claire Hagerty[1], Dr Soheeb Khan[2], Mr Lyall Campbell[2]

[1]Royal Hospital for Children, Glasgow.
[2]Glasgow Caledonian University, Glasgow

Introduction: Undertaking training of patients/families in peritoneal dialysis can be stressful, and requires face to face availability of educators. In paediatrics, children often require inpatient admission for training to occur. The rarity of paediatric kidney disease limits opportunities for families to meet peers/others, so the decision to undertake peritoneal dialysis may not be truly informed or shared between clinicians and families.

We hypothesized that virtual reality could offer a supplemental route for training of patients, families, and staff in dialysis, and provide the 'experience' of undertaking PD. We aimed to develop a prototype as proof of concept of VR in patient education.

Methods: Qualitative interviews were conducted with families, nursing staff, and educators to determine the key elements and main objectives of the VR program. A multimedia library was compiled to permit 3D modelling of all aspects of PD. A VR application was developed with stages of preparation/machine set-up, connection, and disconnection of a dialysis session. Two brief troubleshooting scenarios were included. Several iterations were completed with feedback from staff and patients at each stage, including addition of a tutorial, audio instruction, and control simplification. A technology acceptance model(TAM) tool was evaluated with patients, parents and nursing staff, scores of 0-7 allocated for meeting learning needs, and ease of use for each program section.

Results: A prototype VR peritoneal dialysis educational tool has been developed for the MetaQuest 2 VR headset. 8 patients/families and 12 nurses completed the TAM. Scores for 'meeting needs' were 5.88-6.67, for 'ease of use' were 6-6.83, demonstrating high acceptability and usability. Informal feedback sought from families familiar with PD has been generally positive. One parent had significant motion sickness and could not tolerate VR. One family with prior experience of both VR and PD reported the application was ‘epic’. Two families have used the tool before undertaking any PD training – both reported that the tool alleviated anxiety, and that they could relate the VR experience to their training or nurses setting up the machine on the ward. Both families have since completed training in three days (usually five to seven in our unit).

Conclusions: VR offers a useful supplement to training in medical technologies such as dialysis. Training duration for families may be shortened. Formal evaluation of the application’s utility as an educational tool is needed, as is objective evidence of benefit to patients/families. Multiple potential alternative uses of VR in medical education also exist.

Transplantation at the margins

Submission: 096

Assessment of 'molecular organ age' in retrieval kidney biopsies

Dr Roy Zhang[1], Dr Patrick B Trotter[1], Dr James McCaffrey[1,2], Dr Benjamin J Stewart[3,1], Dr John R Ferdinand[1], Dr Kevin W Loudon[1], Dr Alexandra Riding[1], Dr Jonathan West[1], Dr Ashley Ferro[1], Dr Robert Kirkpatrick[4], Professor Menna R Clatworthy[1,3]

[1]Molecular Immunity Unit, University of Cambridge Department of Medicine, Cambridge.
[2]Department of Pathology, Cambridge Universities NHS Foundation Trust, Cambridg.
[3]Cellular Genetics, Wellcome Sanger Institute, Hinxton.
[4]Glaxo-Smith-Kline, Stevenage

Introduction: Kidney transplantation is an excellent treatment for end-stage kidney failure but organ shortage remains a problem. The use of marginal donor kidneys is hampered by variable outcomes and an inability to accurately predict post-transplant function. Transcriptomic profiling enables an in-depth assessment of the dominant molecular processes occurring in kidneys, quantifying the expression of ~25,000 genes, with the potential to identify novel outcome-associated biomarkers.

Methods: Retrieval biopsies were obtained via the Quality in Organ Donation (QUOD) biobank from n=271 deceased circulatory death kidneys and processed for bulk RNA-sequencing and histological assessment. Transcriptional features associated with delayed graft function (DGF) and 12-month estimated glomerular filtration rate (eGFR) were assessed using differential gene expression and pathway enrichment. Weighted gene co-expression network analysis (WGCNA) was used to identify gene modules co-associated with outcome and age.

Results: Following adjustment for variable tissue composition, we found enrichment of neutrophil and acute inflammatory gene signatures associated with better transplant outcomes, including DGF and 12-month eGFR. In contrast, kidneys with a worse prognosis showed positive enrichment for fibrosis- and adaptive immune-gene signatures (Figure 1), with increased interstitial lymphocyte infiltration confirmed histologically. WGCNA of cortical biopsies identified an adaptive immune gene-rich module that significantly associated with increasing age and worse outcomes (Figure 2). Cellular deconvolution using human kidney reference single cell transcriptomes confirmed an increase in kidney-specific B and T cell signatures, as well as kidney macrophage, myofibroblast and fibroblast genesets in this module, corroborating our differential expression analysis and localising these findings to the cortex.

Discussion: Altogether, our work reveals the cellular molecular features of pathological organ ageing, identifiable at organ retrieval, and supports the use of transcriptomic assessment of 'molecular organ age' in pre-transplant kidney assessment.

Figure 1: Gene set enrichment analysis (GSEA) of the differential expression of 12-month EGFR against kidney-specific gene sets from Stewart et al. (2019) . Only significant pathways (FDR q-value <0.05) are plotted. Red dots indicate positive enrichment (high 12-month EGFR) and blue negative (low 12-month EGFR), the size of the dot is inversely correlated with the FDR q-value and the position indicates the normalized enrichment score (NES).



Figure 2: Module-trait relationships for cortical samples between identified modules (rows) and clinical parameters of interest (columns). Heatmap colours indicate correlation between module eigengene and clinical parameter. Asterisks indicate nominally-significant p-values of correlations (*, < 0.05; **, <0.01; ***, <0.001; ****, < 0.0001).



Transplantation at the margins

Submission: 237

Deceased donor C-reactive protein and kidney transplant outcomes: a UK cohort study

Dr George Greenhall[1] Ms Rachel Johnson[1], Mr Chris Callaghan[2], Prof Christopher Watson[3], Dr Gareth Jones[4]

[1]NHS Blood and Transplant, Bristol
[2]Guy's Hospital, London
[3]University of Cambridge, Cambridge
[4]Royal Free Hospital, London

Introduction
Systemic inflammation in deceased donors may influence transplant outcomes or organ acceptance decisions. Evidence on the clinical utility of donor C-reactive protein (CRP) as a marker of organ quality is lacking.

Methods
This national cohort study used data from the UK Transplant Registry on all primary single kidney transplants between 1st January 2016 and 31st December 2021. We divided transplants into three groups based on the last donor CRP result prior to donation (<100, 100 to 200 and >200 mg/L). Using Cox regression, we estimated the hazard ratio (HR) of death-censored graft failure, adjusted for: donor age, sex, type, cause of death, diabetes, hypertension, smoking, BMI, terminal creatinine and presence of infection; recipient age, sex, diabetes, dialysis status and sensitisation; HLA mismatch level and cold ischaemia time. We also compared the odds of delayed graft function (DGF) between the three groups.

In secondary analyses, we explored the influence of the CRP trend (rising vs stable/falling, based on the last two CRP results) as well as the relationship between CRP and kidney utilisation.

Results
There were 3812 (41%), 2997 (32%) and 2570 (27%) transplants with donor CRP <100, 100 to 200 and >200 mg/L, respectively. Over a median (IQR) of 2 (1 to 4) years, graft failure occurred in 9% (332/3812), 8% (235/2997) and 6% (159/2570) in these three groups. Although there was a trend towards better survival in grafts from donors with higher CRP results, there was no evidence of a survival difference between the three groups after adjustment for confounders (CRP 100 to 200 vs <100, HR 1.02, 95% CI 0.86 to 1.23; CRP >200 vs <100, HR 0.84, 0.69 to 1.03). Similarly, the adjusted odds of DGF did not differ between the three groups (CRP 100 to 200 vs <100, OR 1.04, 0.91 to 1.19; CRP >200 vs <100, OR 0.94, 95% CI 0.82 to 1.09).

While a rising donor CRP at the time of donation was associated with a lower incidence of DGF (OR 0.84, 0.73 to 0.96), there was no difference in the rate of graft failure (HR 0.91, 0.74 to 1.12) after confounder adjustment.

In the same period, CRP results were available for 10 178 consented donors where kidneys were offered for transplantation. Of these, 44% (4510) had CRP <100 mg/L, 30% (3095) had CRP 100 to 200 mg/L and 25% (2573) had CRP >200 mg/L. After adjustment for the same donor covariates,

higher donor CRP was associated with a greater likelihood of kidney utilisation (CRP<100, 64% [2873/4510] utilised; CRP 100 to 200, 71% [2206/3095] utilised, OR vs CRP<100 1.3, 1.2 to 1.5; CRP>200, 73% [1885/2573], OR vs CRP<100 1.4, 1.3 to 1.6).

Discussion

In the UK, there is no evidence to support either the absolute value or the trend of donor CRP as a biomarker of graft quality in deceased donor kidney transplantation. Contrary to expectations, kidneys from donors with higher CRP are more likely to be utilised.



Peer Support in Renal Services

Submission: 439

Renal Peer Support – Working Collaboratively

Ms Jacqueline Byfield, Mrs Alison Danbury-lee

ENH Trust, Stevenage

Introduction: Approximately 3 million people in the UK have chronic kidney disease. Faced with making decisions about future treatments, they have an overwhelming choice. The value of speaking to a peer supporter (fellow patient with experience of the different treatment options) is known to be beneficial.

Background: With support and discussions with Kings College, who already had an existing Peer Support (PS) service, in 2018, our Trust renal support team set up the Peer Support Service for patients across our patch. In 2020, Covid-19 necessitated new ways of working. In discussion with Kings College and National Kidney Federation (NKF) the delivery was moved from in-person to telephone support with patient needs being met.

During COVID-19 our volunteer training changed from in-person to online, with added modules, precluding a number of volunteers from continuing in the service.

Methods: Kings and NKF shared virtual training presentations and Kings allowed the PS co-ordinator to sit in their virtual training sessions. As PS numbers dropped due to virtual trust training requirements NKF and Kings took on our patient referrals where we could not meet the need.

16 new patients expressed interest in becoming PS volunteers. The Kidney Care UK (KCUK) PS Tool Kit was used for developing our service. In November 2022 I attended the first symposium of renal peer support services around the UK.

Results: Trust training delivery changes are barriers to our service recruiting volunteers. Our volunteer numbers have dropped from 15 to 9. Only 2 of the 16 initially interested in volunteering completed the Trust training, with IT issues, module number and paperwork required reported as main barriers.

Throughout 2022, the NKF peer supported 27 of our patients; Kings College 2, thanks to network development with NKF & Kings. This collaborative working enhanced our skills on delivering renal PS virtual training.

The KCUK Tool Kit will continue to be used as an invaluable resource in structuring our service, and was received by PS positively.

The PS symposium shared updated information which highlighted the invaluable service of PS and evidenced the need to continue collaboration to promote and develop PS as an integrated part of health education for all renal patients.

PS feedback after each session provides evidence of how invaluable PS can be for both volunteer and patient. It supports the need to develop PS services within all renal departments to assist patients living with a chronic condition and life-changing implications.

“The session had been absolutely amazing. The session really helped me and made a difference in my attitude, thinking and my perception of my situation. The session gave me hope that there was light at the end of the tunnel. I can’t thank Peer Support enough. Please pass this message onto Peer Support”. (Patient)

Conclusion:

- Collaborative working enables patients to access PS when service not held locally
- Ideally PS would be in all pre-dialysis clinics
- Continued partnership to promote and develop PS services across UK
- A need to explore barriers to PS development and ways of reducing them

Peer Support in Renal Services

Submission: 087

Development of a young person's transition day – a poster presentation

Dr Rosalind Cooper, Mrs Kathryn Taylor, Mrs Joanna Woodland

Bristol Royal Hospital For Children, Bristol

Introduction: The importance of a successful transition from paediatric to adult services in terms of health outcomes and quality of life is well documented (e.g. Watson, 2000; Shaw et al., 2014). Ready, Steady, Go and Hello is an established transition program used throughout UK hospitals to support this process, providing a structure and framework for healthcare professionals to work through with young people and their families. Its aim is to empower young people and adults by equipping them with the skills, knowledge and confidence to manage their condition from children's services through to adult services.

This process can occur through a number of methods, traditionally within clinic settings and appointments. However, the paediatric renal team identified that some young people may benefit from alternative formats to support this process. One idea was to host a young person's day, with a series of workshops from different healthcare professionals, along with time and opportunity to connect with other young people with a renal condition of a similar age.

Methods: A young person's transition day was organised and attended by eight young people aged between 14-17 years old. Presentations and activities were facilitated by different members of the multidisciplinary team, covering different aspects of the biopsychosocial model of care relevant to transition. This also included team building and social games to strengthen peer support.

Results: Attendees took part in a telephone interview feedback following the day. One hundred percent of participants said that they would take part in another day like this. Participants rated their confidence in coming forward with worries or questions about transition as greater following the day compared to prior.

Qualitative feedback was gathered via the interviews and will be presented via the poster. For example, one patient said 'my favourite part was being able to see everyone and learning new things about the kidney'.

In terms of suggested improvements, space to speak 1:1 with members of the MDT was highlighted as a helpful addition that could be incorporated in the future.

Discussion: Moving forwards, the team have proposed hosting a parallel complimentary session for parents. It would also be helpful to have a young person who has recently transitioned to the adult service to attend in person. In summary, the day was rated as useful by both patients and staff, and the team plan to establish the young person's transition day as a regular annual event and useful addition to the service's transition program.

Submission: 319

Interim analysis (IA) of a global phase 2 RCT of sibeprenlimab (VIS649), an APRIL-neutralizing monoclonal antibody, in IgA nephropathy

Dr. Laura Kooienga[1], Dr. Yusuke Suzuki[2], Dr. Bobby Chacko[3,4], Dr. Muh Geot Wong[5,6], Dr. Jonathan Barratt[7], Dr. Kook-Hwan Chris Oh[8], Dr. Manisha Sahay[9], Dr. Mohit Mathur[10], Dr. Xiaofeng Wang[11], Ms. Jill Yarbrough[10], Dr. Brian Pereira[10]

[1]Colorado Kidney Care, Denver, CO.
[2]Juntendo University, Tokyo.
[3]John Hunter Hospital, Newcastle, New South Wales.
[4]University of Newcastle, Newcastle, New South Wales.
[5]University of Sydney, Sydney, New South Wales.
[6]Concord Repatriation General Hospital, Concord, New South Wales.
[7]University of Leicester, Leicester, England.
[8]Seoul National University, Seoul.
[9]Osmania General Hospital, Hyderabad, Telangana.
[10]Visterra, Inc., Waltham, MA.
[11]Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ

Background**:** The pathogenesis of primary Immunoglobulin A Nephropathy (IgAN) is driven by A Proliferation-Inducing Ligand (APRIL). Sibeprenlimab is a humanized IgG2 monoclonal antibody that prevents APRIL signaling.

Methods**:** VIS649-201 (NCT04287985) is a global multicenter, randomized controlled study evaluating monthly intravenous (IV) sibeprenlimab (2, 4, or 8 mg/kg) versus placebo in adults with IgAN on optimized supportive treatment, who have estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2 and proteinuria ≥ 1.0 g/d or urine protein creatinine ratio (uPCR) ≥ 0.75 g/g. A protocol specified group unblinded IA was conducted when 72 participants completed month-9 of a 12-month study course.

Results**:** Among pooled sibeprenlimab recipients there was a 43% placebo-adjusted reduction from baseline in 24-hour uPCR values at month 9 (Figure 1a) with reduction in serum APRIL, total IgA, and galactose-deficient IgA1. Among subjects with ≥ 9 months on study, the estimated annualized eGFR slope was stable (+1.2 mL/min/1.73m^2/year) in pooled sibeprenlimab recipients versus declining (-6.5 mL/min/1.73m^2 /year) in the placebo group, with a slope difference of +7.7 mL/min/1.73m^2/year (95% CI 1.32 to 14.01). The mean of eGFR change from baseline over time is shown in Figure 1b. No serious adverse events were considered study-drug related and most adverse events were mild or moderate in severity.

Discussion**:** This phase 2 IA of a precision therapeutic for IgAN, sibeprenlimab, demonstrated acceptable safety and tolerability with robust uPCR reduction associated with eGFR stability when compared to the placebo arm at 9 months of study follow up.



Figure 1

Funding Source: Otsuka Pharmaceutical Development and Commercialization Inc.

Submission: 294

Long-term use of voclosporin in patients with class V lupus nephritis: Results from the AURORA 2 continuation study

Professor Amit Saxena[1], Dr Dawn Caster[2], Dr Salem Almaani[3], Ms Amber Rosales[4], Dr Henry Leher[4], Akita Patel[4]

[1]NYU School of Medicine, New York. [2]University of Louisville School of Medicine, Louisville. [3]The Ohio State University Medical Centre, Columbus. [4]Aurinia Pharmaceuticals Inc, Victoria

Background: Persistent proteinuria increases the risk of comorbidities in lupus nephritis, and rapid reductions in protein have shown to be predictive of improved long-term renal health. Patients with Class V lupus nephritis may take longer to respond to therapy, and treatments that efficiently reduce proteinuria in this population are needed. We report here on a post-hoc analysis of voclosporin in patients with Class V lupus nephritis using three years of pooled data from the Phase 3 AURORA 1 and AURORA 2 studies.

Methods: AURORA 1 enrolled patients with biopsy-proven active lupus nephritis, urine protein creatinine ratio (UPCR) ≥1.5 mg/mg (≥2.0 mg/mg for pure Class V), and estimated glomerular filtration rate (eGFR) >45 mL/min/1.73 m2. Patients completing AURORA 1 were eligible to enter AURORA 2 on the same blinded therapy (voclosporin or placebo) in combination with mycophenolate mofetil (MMF) and low-dose steroids for up to 3 years of treatment. Hazard ratios (HR) for the time to UPCR ≤0.5 mg/mg and mean eGFR levels were assessed in patients with pure and mixed Class V lupus nephritis.

Results: A total of 80 patients with Class V lupus nephritis continued treatment in AURORA 2, 31 with pure Class V disease and 49 with mixed lesions. Mean baseline UPCR was 3.4 and 3.3 mg/mg in patients with pure Class V disease treated with voclosporin and control, respectively, and 3.4 and 3.9 mg/mg in voclosporin- and control-treated patients with mixed lesions. The differences between treatment arms in UPCR reductions were apparent within the first month and sustained at three years in both pure and mixed disease. For patients with pure Class V disease, the median times to UPCR ≤0.5 mg/mg were 3.7 and 16.3 months in the voclosporin and control arms, respectively (HR 2.54; p=0.0004, Figure 1). For patients with mixed lesions, the median times to this outcome were 3.7 and 18.0 months, respectively (HR 5.07; p<0.0001). Mean corrected eGFR levels were similar in all treatment arms and stable throughout the study (Figure 2).

Conclusion: Voclosporin-treated patients with pure and mixed Class V lupus nephritis saw substantial reductions in UPCR that occurred faster than in those treated with MMF and low-dose steroids alone. Voclosporin may be beneficial in limiting the negative long-term impact of proteinuria in this population.

Figure 1. Time to UPCR ≤0.5 mg/mg in Pure (A) and Mixed (B) Class V LN Patients



Analysis of AURORA 2 patients with Class V disease includes pooled data from AURORA 1 and AURORA 2. Time to UPCR ≤0.5 mg/mg was assessed with a Kaplan Meier analysis. UPCR, urine protein creatinine ratio.

Figure 2. Mean Corrected eGFR Over Time in Pure (A) and Mixed (B) Class V LN Patients



Analysis of AURORA 2 patients with Class V disease includes pooled data from AURORA 1 and AURORA 2. Renal function was assessed with corrected eGFR (Chronic Kidney Disease Epidemiology Collaboration equation) using a prespecified ceiling of 90 mL/min/1.73 m2. Analysis of LS mean corrected eGFR over time includes data from a follow up visit at four weeks after study drug discontinuation. CI, confidence interval; eGFR, estimated glomerular filtration rate; FUP, follow-up; LS, least squares.

Submission: 212

An overview of current use of apixaban in patients undergoing maintenance dialysis in UK renal units

Mr Isaac Chen[1], Mrs Natasha Moore[2], Mr Robert Brown[3], Mr Dane Howard[4], Miss Kathrine Parker[5,6]

[1]Oxford Kidney Centre, Oxford.
[2]Guys and St Thomas's, London.
[3]North Bristol NHS Trust, Bristol.
[4]Leeds Teaching Hospitals, Leeds.
[5]Manchester University NHS Foundation Trust, Manchester.
[6]University of Manchester, Manchester

Introduction: Retrospective cohort studies and a small-randomised control trial have demonstrated comparable safety and efficacy of apixaban versus warfarin for atrial fibrillation (AF) in dialysis. Apixaban is licensed for use in dialysis patients in the United States but not in Europe. A recent UK prescribing practice survey found that there are a number of renal units in the UK using apixaban in patients on dialysis, while warfarin remains the mainstay of treatment. Warfarin has many interactions and requires frequent monitoring, so alternative options with a simpler regime are attractive for patients. This audit examines the current practice of apixaban use in dialysis patients in five UK renal units.

Methods: This was a retrospective audit undertaken locally by renal pharmacists in five UK centres. A data collection tool included demographic information along with information on indication, dose and thrombotic or bleeding outcomes. Bleeding events were categorised by International Society Thrombosis and Haemostasis classifications. All data was anonymised at the local centre.

Results: Eighty-two dialysis patients taking apixaban were identified from five NHS Trusts, with indications for apixaban and monitoring practice collated in table 1. All centres were undertaking apixaban level monitoring. Thirty-nine patients had data to evaluate clinical outcomes and apixaban levels (table 2). The median age was 72 years, weight 86 kilograms, and the majority (87%) received in-centre haemodialysis (HD). Seventy-two percent of patients were prescribed apixaban for AF. Most patients were prescribed apixaban 2.5mg twice daily (BD) with only one patient prescribed 5mg BD due to trough and peak apixaban levels below the respective 5th-9th percentile reference range for the general population.5 Monitoring was undertaken in 87% of the patients. Barriers to level monitoring included limited laboratory support for blood sample processing in satellite renal units and insufficient guidance on the interpretation of apixaban levels for dose adjustment. The mean ± standard deviation (SD) for trough and peak levels were 72.9 ± 14.4 ng/ml and 101.2 ± 10.5 ng/ml, respectively, when apixaban was dosed at 2.5mg BD (table 2). The median follow-up period was 6 months with 36 years of patient exposure to apixaban. Reported thrombotic outcomes included one stroke related to patient non-compliance, one systemic embolism (retinal artery occlusion) in a patient with CHA2DS2-VASc score of 6, and two arteriovenous fistula thrombosis. One major bleeding, three clinically relevant non-major bleeding and one minor bleeding were observed during follow-up and these patients had HASBLED of >3 (table 2).

Discussion: This audit highlights that apixaban is used by renal clinicians in dialysis patients in a number of clinical scenarios. The monitoring frequency for apixaban varies across renal units and

barriers to monitoring exist. The available data suggests no evidence of apixaban accumulation, in keeping with a recent pharmacokinetic profiling analysis. All units undertook level monitoring, but it remains unclear whether this adds clinical value. The utility of apixaban level monitoring for optimal dosing strategy requires further investigation. There is currently no consensus on the prescribing and monitoring of apixaban in dialysis and a best-practice guideline would support clinicians in this area.

Table 1. Overview and comparison of prescribing practice of apixaban in UK renal units

NHS Trust	Patient numbers and dialysis modalities	Apixaban level monitoring	Dosing	Indications	Criteria for initiation or switch	Comments
Trust 1	43 (n=39 HD; n=2 home HD; n=1 [automated peritoneal dialysis] APD; n= 1 [continuous ambulatory PD] CAPD)	Trough and peak levels	2.5mg BD	• AF • VTE prophylaxis (post-acute episode)	• Time in therapeutic range (TTR) <65% • Those with compliance aids • Calciphylaxis	• Drive to switch during COVID-19 pandemic to reduce monitoring • Level and outcome data not available • Patients on transplant waiting list are not activated until they are switched back to warfarin • Level monitoring often missed by staff • Haematology team organise follow-up
Trust 2	25 (n=21 HD; n=2 CAPD; n=2 home HD)	Trough and peak levels	2.5mg BD (n=24); 5mg BD (n=1)	• AF • Secondary VTE/PE prevention • Dialysis access patency	• High risk of calciphylaxis • Labile INR • Poor medication adherence • TTR<65% • Unable to comply with INR monitoring	• Level and outcome data included • Renal Pharmacy Team co-ordinate monitoring • Monitoring at 1 week, 1 month and 3 months after starting apixaban or change in dialysis frequency • Patient undergoing transplant assessment or on transplant waiting list ineligible for apixaban
Trust 3	11 (n=10 HD; n=1 home HD)	Trough levels	2.5mg BD	• AF • Secondary prevention of VTE • Dialysis access patency	• Labile INR • Calciphylaxis • Unable to comply with INR monitoring	• Level and outcome data included • Level monitoring not undertaken in satellite dialysis patients • Patients on transplant waiting list to remain on warfarin if possible • Renal Pharmacist co-ordinates monitoring
Trust 4	2 (n=2 HD)	Trough and peak levels	2.5mg BD	• AF • Secondary prevention of PE	• Calciphylaxis	• Level and outcome data included
Trust 5	1 (n=1 HD)	Trough and peak levels	2.5mg BD	• Upper limb thrombosis	• Calciphylaxis and HIT	• Level and outcome data included

Table 2. Patient demographics and outcome parameters

Patient demographics (*n*=39)	
Age (years), median (IQR)	72 (56-79)
Men, *n* (%)	27 (69%)
Weight (kg), median (IQR)	86 (63-96.5)
Clinical characteristics	
Dialysis modality, *n* (%)	
HD	34 (87%)
Home HD	3 (8%)
CAPD	2 (5%)
Risk prediction, median (IQR)	
CHA_2DS_2-VASc score	3.5 (2.5-5)
HAS-BLED score	1.5 (1-3)
Indication for apixaban, *n* (%)	
AF	28 (72%)
VTE/PE prevention	9 (23%)
Dialysis access patency	2 (5%)
Reasons for prescribing apixaban, *n* (%)	
Calciphylaxis	10 (26%)
Labile INR	2 (5%)
Poor medication adherence	3 (8%)
Patient preference	2 (5%)
No clear clinical reasons	22 (56%)
Apixaban level monitoring (ng/ml), mean ± SD	
Trough	72.9 ± 14.4
Peak	101.2 ± 10.5
Outcome parameters	
Stroke or thromboembolic events, *n* (%)	
Stroke	1 (3%)
Systemic embolism	1 (3%)
Arteriovenous fistula thrombosis	2 (5%)
Bleeding events, *n* (%)	
Major bleeding	1 (3%)
Clinically relevant non-major bleeding	3 (8%)
Minor bleeding	1 (3%)

Submission: 097

Efficacy and Safety of Cotadutide, a Dual GLP1-glucagon Receptor Agonist, in Patients with Chronic Kidney Disease and T2DM

Dr Viknesh Selvarajah[1], Dr Darren Roberts[1], Dr Lars Hansen[2], Dr Lutz Jermutus[1], Dr Kirsten Smith[1], Ms Celeste Frickleton[1], Ms Angela Coggi[1], Dr Jose Sanchez[3], Dr Yi-ting Chang[2], Dr Victoria Parker[1]

[1]Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge.
[2]Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg.
[3]Early Biometrics & Statistical Innovation, Data Science & Artificial Intelligence, R&D, AstraZeneca, Gothenburg

Introduction**:** Cotadutide is a dual GLP1-glucagon receptor agonist under development for NASH and CKD with T2DM. Incretin-based therapies have been shown to promote improvements in albuminuria; the renal benefits of dual GLP1-glucagon receptor agonism are unknown. We evaluated the efficacy and safety of cotadutide in patients with CKD and T2DM.

Methods**:** In this randomised, double-blind, phase 2b study, patients with T2DM and CKD on insulin and/or oral therapy including ≥ 40% treated with SGLT-2i (HbA1c ≥ 6.5 and ≤ 10.5%), eGFR ≥ 20 and < 90 ml/min/1.73m2, UACR ≥ 50 mg/g and BMI ≥ 25 (23 in Japan) kg/m2 were treated for 26 weeks. Patients were randomised (n = 45 per arm) to receive once-daily SC cotadutide titrated up to 100, 300 or 600 µg, or placebo. The primary endpoint was percentage change in UACR (log-transformed) versus placebo from baseline to the end of 14 weeks. Secondary endpoints evaluated UACR at 26 weeks, eGFR, and safety and tolerability.

Results**:** The primary endpoint was met; dose-dependent reductions in UACR from baseline were observed after 14 weeks treatment with 300 and 600 µg of cotadutide, -43.9% (95% CI -54.7, -30.6) and -49.9% (95% CI -59.3, -38.4) vs placebo (P <0.001) and were sustained at 26 weeks. Comparable changes were observed in patients on background SGLT2i therapy. There was no observed change in eGFR early in dosing. At 26 weeks a small increase in eGFR (+5.5 ml/min/1.73m2) was observed at 600 µg (p=0.028). A significant increase in pulse rate was observed (+4.8 bpm), alongside a numerical reduction in systolic BP (-8.3 mmHg) at 600 µg on office-based measures. SAEs were balanced across all arms and there were fewer AE-related discontinuations at 100 and 300 µg versus placebo, but more discontinuations at 600 µg.

Discussion**:** In patients with CKD with T2DM, cotadutide promoted clinically important effects on UACR with an acceptable tolerability profile. The results suggest cotadutide has potential to provide benefit to patients with CKD and T2DM, but larger studies are warranted.

UK Renal Registry & Joint Renal Health Data Network

Submission: 473

A longitudinal analysis of home therapy uptake in patients starting renal replacement therapy in England between 2005 and 2019

Dr Jessica Potts[1], Dr Camille Pearse[1], Dr Iestyn Williams[2], Dr Kerry Allen[2], Dr Sarah Damery[2], Dr James Fotheringham[3], Dr Mark Lambie[1], Professor Simon Davies[1], Dr Ivonne Solis-Trapala[1]

[1]Keele University, Stoke-on-Trent. [2]University of Birmingham, Birmingham. [3]Sheffield University, Sheffield

Introduction: Despite continued efforts to increase the use of home therapy (HT), uptake remains low and varies greatly between Renal Units. The UK NIHR-funded Inter-CEPt study uses a mixed-methods approach to identify modifiable factors to produce a bundle of interventions to increase the uptake of HT. We investigated HT uptake and outcomes for patients starting renal replacement therapy (RRT) in England from 2005 to 2019 to inform the intervention development of Inter-CEPt.

Methods: We used UK Renal Registry (UKRR) data to describe the proportion of patients who were on home therapy (HT) at any time point within one year of starting RRT considering demographic characteristics including ethnicity and Index of Multiple Deprivation (IMD). A multistate model was developed to describe the full modality history and mortality of patients in the 14-year period. This included modelling the hazard rates and probability of transitions between treatment modalities (peritoneal dialysis (PD), home haemodialysis (HHD), in-centre HD (ICHD), and transplantation) and to death.

Results: Over the past 14 years, the proportion of patients whose initial RRT treatment is HT has remained stable, approximately 20% each year, increasing up to 25% when considering HT use within a year of starting RRT. HT uptake varies within ethnicities and indices of deprivation quintiles, noting that in the least deprived group the largest ethnic proportion is white and in the most deprived group the largest ethnic proportion is black.



Figure 1a/1b: Proportion of patients on HT within 1 year of starting RRT by ethnicity and deprivation group

Before 2012 there were differences in the proportion of patients receiving HT within one year of therapy initiation in Asian, Black, and White ethnicity groups (Figure 1a). The uptake in black patients dropped as low as 16% in 2006 and 2008. In more recent years, uptake of HT is similar in each ethnic group, and close to the overall uptake of 25%. Uptake of HT in the two most deprived quintiles has increased over the 14 years (Figure 1b). Similarly, patients in the least deprived quintile have had a higher uptake over time (approximately 33%), this increased in 2016 to over 43%, however the increase was not sustained.



Figure 2: Five year probability of transition from PD in most and least deprived quintiles

Patients change treatment modality several times over time. Figure 2 illustrates the 5-year probability of transitioning from PD as initial treatment to other states (HHD, ICHD, transplantation and death) for an average patient (white, male, aged 62) contrasting the transition probabilities for the least and most deprived groups. Patients in the most deprived group have higher probability of moving to ICHD or dying and lower probability of receiving a transplant than those in the least deprived group.

Discussion: HT uptake has not increased in England despite guidelines encouraging greater use. We showed an underuse of HT in ethnic minority groups and more deprived areas but there does appear to be an increase in the proportions of patients within these groups receiving HT within the first year of treatment.

UK Renal Registry & Joint Renal Health Data Network

Submission: 428

Safety of native and transplant kidney biopsy in a national cohort

Dr Emily McQuarrie[1], Dr Samira Bell[2], Ms Jacqueline Campbell[3], Ms Chrissie Watters[3], Mr Joe Lakey[3], Dr Wendy Metcalfe[4], Dr Robert Hunter[4], Dr Kate Stevens[1], Dr Jamie Traynor[1], Dr Zoe Cousland[5], Dr Nicola Joss[6], Dr David Walbaum[7], Dr David Kipgen[1], Dr Jana Crosby[1], Dr Michael Kelly[8], Dr Vishal Dey[9], Dr Kate Buck[10], Dr Shona Methven[7], Dr Graham Stewart[2], Dr Kiru Murugan[10], Dr Lorna Henderson[4], Dr Bryan Conway[4], Professor Colin Geddes[1]

[1]Queen Elizabeth University Hospital, Glasgow. [2]Ninewells Hospital, Dundee. [3]Publich Health Scotland, N/A. [4]Royal Infirmary of Edinburgh, Edinburgh. [5]University Hospital Monklandds, Airdrie. [6]Raigmore Hospital, Inverness. [7]Aberdeen Royal Infirmary, Aberdeen. [8]Dumfries and Galloway Royal Infirmary, Dumfries. [9]University Hospital Crosshouse, Kilmarnock. [10]Victoria Hospital, Kirkcaldy

Introduction: Safety of kidney biopsy is variably reported in different published series. Since 2014, all native kidney biopsies undertaken in the 9 adult renal units in Scotland have been recorded by the Scottish Renal Registry (SRR) and since 2015 all transplant kidney biopsies were included. In this complete national dataset, we report data on safety of kidney biopsy in a current real world setting.

Methods: Major complications of kidney biopsy are recorded using pre-defined terms and include: arteriography and embolisation, arteriography no embolisation, clot retention, blood transfusion only, death within 28 days directly attributable to biopsy, nephrectomy and other.

Biopsies are undertaken under ultrasound guidance using 16G or 18G spring loaded biopsy guns. All centres discontinue clopidogrel, DOACs and warfarin. Some centres continue aspirin. In some centres biopsy is performed by nephrologists and in others by radiologists.

Results: In total, 6979 biopsies in 5755 patients were recorded between 2014 and 2021 (5095 native biopsies and 1884 transplant biopsies), with an adequacy for diagnosis of 98.1%. Table 1 describes the demographics, indications, operator and diagnoses made by biopsy type.

Biopsy Type	**Native**	**Transplant**
Total biopsies (n)	5095	1884
% Male	54.7%	59.4%
Mean age (years)	57.2	48
% Adequate	98.2%	95.1%
Commonest Indication (% of biopsy type)	AKI query cause (30%) Chronically reduced eGFR (28.1%) Nephrotic syndrome (19.7%)	AKI query cause (37.7%) Chronically deteriorating transplant function (25.4%) Achieved transplant function lower than expected (9.1%)
Commonest Diagnosis (% of biopsy type)	1. IgA nephropathy (13.1%)	1. Acute Rejection (34.3%)

	2. Tubulointerstitial nephritis (8.5%) 3. Membranous nephropathy (7.2%)	2. Other (23.9%) 3. Acute tubulodegenerative Change (15.8%)
Biopsies performed by radiology (%)	31.3%	38.3%
Biopsies performed by nephrology (%)	61.9%	57.6%
Median serum creatinine (mg/mmol)	163 (96-271)	212 (156-357)
Mean number of glomeruli	14.6	15.2
Total Complications (% of biopsy type)	121 (2.4%)	26 (1.4%)
Complication Breakdown:	Arteriography and embolisation: 6.1/1000 Arteriography no embolisation: 5.9/1000 Blood transfusion only: 3.5/1000 Clot obstruction: 2/1000 Nephrectomy: 0 Death: 1.6/1000 Surgery no nephrectomy: 0 Other: 4.7/1000	Arteriography and embolisation: 1.6/1000 Arteriography no embolisation: 2.7/1000 Blood transfusion only: 3.7/1000 Clot obstruction: 2.7/1000 Nephrectomy: 0.5/1000 Death: 0 Surgery no nephrectomy: 3 or 1.6/1000 Other: 1.1/1000

Table 1: Baseline demographics and complications recorded in native and transplant biopsies.

Overall, in patients undergoing native kidney biopsy 2.4% suffered a major complication and 1.4% of patients undergoing transplant biopsy. The commonest complication was the requirement for arteriography, with or without embolisation. There were 8 deaths within 28 days attributable to renal biopsy.

Conclusion: Kidney biopsy remains safe for the vast majority of patients and complications are less likely with transplant biopsy.

MicroRNAs as biomarkers and regulators in kidney disease

Submission: 427

Discovery and validation of novel urinary microRNA biomarkers of diabetic kidney disease prognosis through RT-qPCR analysis of a large cohort

Dr Daniel Smith[1], Dr Kate Simpson[1], Ms Amna Noor[1], Dr William Watkins[2], Dr Alice Smith[3], Dr Kevin Ray[3], Professor Donald Fraser[1], Dr Timothy Bowen[1]

[1]Wales Kidney Research Unit, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff.
[2]Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff.
[3]UCB Pharma, Bath Road, Slough

Introduction: MicroRNAs (miRNAs), short non-coding RNAs that regulate the expression of most human genes, have altered expression profiles in a variety of disorders including cancers, cardiovascular, infectious and kidney diseases. We have developed RT-qPCR-based methods to detect urinary miRNAs. Using these techniques, we have identified miRNA panels associated with kidney disorders including acute kidney injury, delayed graft function following kidney transplantation and diabetic kidney disease (DKD). In the present study we hypothesised that miRNAs were associated with rate of decline in kidney function and kidney disease progression.

Methods: In collaboration with UCB Pharma, we profiled 754 urinary miRNAs in a discovery cohort (n = 140) of people with DKD, hypertensive nephropathy and chronic allograft nephropathy. These disease phenotypes were divided into progressive (n = 20) and stable (n = 20) subgroups based on their rate of kidney function decline; we also analysed 20 unaffected control subjects. Initial profiling was carried out by RT-qPCR Taqman low density array (TLDA) analysis. Selected candidate biomarker miRNAs were then analysed in a DKD validation cohort (n = 130) stratified into progressive (n = 41), stable (n = 44) and intermediate (n = 45) rate of kidney function decline, using individual miRNA RT-qPCR assays.

Results: TLDA analysis identified a number of potential biomarker candidates of DKD progression, and the best 8 candidates were taken forward. Following validation of observed expression changes, receiver operating characteristic analysis identified an optimal panel of 4 miRNAs with an area under the curve of 0.87.

Conclusion: We will present the key findings of this project, displaying the strength of our potential candidates as prognostic biomarkers of DKD progression. We will also describe data from ongoing investigations into the mechanisms of action of these miRNA biomarkers in in vitro models of DKD.

Best Science Abstracts

Submission: 429

Elevated urinary miR-141 is associated with MAKE90 endpoint outcome and 2-year survival following sepsis-associated acute kidney injury

Dr Tanya Smith[1,2], Dr Jill Vanmassenhove3[3], Dr Sophie Lobbestael[3], Dr Griet Glorieux[3], Dr William Watkins[1], Dr Wim Van Biesen[3], Professor Donald Fraser[1,2], Dr Timothy Bowen[1,2]

[1]Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff.
[2]Wales Kidney Research Unit, Cardiff.
[3]Gent University Hospital, Ghent

Background: Acute kidney injury (AKI) affects approximately 35% of critically unwell patients admitted to the intensive care unit (ICU) and has a within-ICU mortality of AKI of 50-80%, challenging current diagnostic and treatment strategies. While the natural history of AKI varies, ischaemia reperfusion injury (IRI) during sepsis, termed sepsis-associated AKI (S-AKI), is a key contributor. Current AKI biomarkers have limited ability to classify disease progression and identify underlying pathological mechanisms. MicroRNAs (miRNAs), small noncoding RNAs that regulate expression of most human genes, show promise as AKI biomarkers and have been implicated in disease pathogenesis. We have previously shown that altered miR-141 and miR-192 expression is associated with non-recovery at 90 days in people with AKI. In analyses of animal AKI models, we and others have identified pathological roles for miRNAs, including miR-141. However, far less is known about the role of miRNAs in S-AKI. Here we hypothesised that alterations in urinary miRNA expression would correlate with clinical outcomes on admission to ICU.

Methods: We analysed urine samples from a cohort of adult ICU patients with S-AKI (n = 179). Samples were collected from each patient on admission to ICU at Gent University Hospital, then stored at -80°C prior to analysis. Total RNA was extracted, cDNA generated, and selected miRNAs were quantified by RT-qPCR with expression normalised to miR-191. The major adverse kidney events within 90 days (MAKE90) composite endpoint: persistent renal dysfunction, new onset need for renal replacement therapy and death at 90 days, was used for subgroup analysis. Survival analysis was carried out using the Kaplan-Meier estimator, for which the cohort was subdivided into quartiles corresponding to urinary miRNA expression levels.

Results: A higher urinary expression of miR-141 ($p = 0.035$) was significantly associated with the MAKE90 composite outcome. Survival analysis showed increased expression of urinary miR-141 and miR-192 was associated with reduced survival at 2 years. Kaplan-Meier plots showed that those quartiles corresponding to the highest miRNA expression levels were associated with reduced probability of survival. Differences in urinary miRNA expression were also observed between patients with different sources of sepsis. Elevated urinary expression of miR-192 was observed in people with a primary diagnosis of pneumonia compared to urosepsis patients ($p = 0.048$). In addition, increased urinary abundance of miR-141 and miR-192 was detected in patients with the most severe disease (severe sepsis or septic shock). These data suggest that miRNA expression may be specific to organ pathology and severity. Comparison of S-AKI patients with healthy controls identified altered expression of urinary miR-141 and miR-192. However, no association was found between these transcripts and AKI severity according to RIFLE or AKIN classification.

Discussion: Our data revealed that elevated urinary miR-141 was associated with MAKE90 endpoint outcome following S-AKI, and that elevated levels of miR-141 and miR-192 were associated with

reduced patient survival at 2 years. These results corroborate our previous findings, underlining the potential of urinary miR-141 and miR-192 as biomarkers for predicting outcomes in S-AKI.

Best Science Abstracts

Submission: 242

Transgenic induction of epithelial senescence promotes renal fibrosis independent of injury

Dr Marie-Helena Docherty[1], Mr Ross Campbell[1], Dr Laura Denby[2], Dr David P Baird[1], Dr Katharine J Mylonas[1], Dr David A Ferenbach[1]

[1]Centre for Inflammation Research, University of Edinburgh.
[2]Centre for Cardiovascular Science, University of Edinburgh

Background: Chronic Kidney Disease (CKD) affects over 850 million people worldwide. Progressive renal fibrosis is a hallmark of CKD, irrespective of the initiating aetiology. Any episode of acute kidney injury (AKI) significantly increases the risk of development of CKD, even after apparent complete resolution of the initiating injury. This risk is exacerbated by age and pre-existing CKD. This implies that factors persist within damaged/aging kidneys which drive functional loss, impair complete repair and promote on-going fibrosis.

Senescent cells (SCs) are metabolically active, permanently growth arrested cells produced in response to stress and DNA damage. SCs accumulate with age and persist at the sites of previous disease and injury. Their depletion in animal models is safe and extends organ function and healthspan.

We have shown that pharmacological SC depletion in kidneys significantly improves kidney function and reduces fibrosis post injury. However, models of renal injury induce changes in multiple cell lineages, and pharmacological depletion is non-specific both in terms of cell lineage (i.e. epithelial vs mesenchymal vs leukocyte) and characteristics of senescent cell (i.e. acute vs chronic, primary vs secondary).

We hypothesised that induction of epithelial senescence in the absence of other renal injuries is sufficient to initiate renal fibrosis. We developed a transgenic mouse allowing selective senescence induction in renal epithelia in the absence of injury, with tdTomato labelling of induced cells.

Methods: By crossing existing strains, we produced a triple transgenic Pax8creERT2/mdm2flfl/tdTOMLSL mouse allowing conditional senescence induction by tamoxifen via mdm2 deletion in Pax8 expressing renal epithelia, alongside TdTomato expression. Levels of renal fibrosis, p21cip1 and TdTomato induction were quantified by picrosirius red staining, immunofluorescence and flow cytometry, with downstream image analysis on QuPath 0.3.2. CDKN1A gene expression was quantified by qPCR.

Results: Examination of kidneys and livers from young mice ± tamoxifen demonstrated that tdTomato induction was tissue specific and restricted to renal epithelia (Fig 1A-C). Administration of Tamoxifen resulted in increased expression of tdTomato and *CDKN1A* expression at day 7 in transgenic but not in WT mice. (Fig 1C, 2 A-F).



Fig 1. Expression of tdTomato at day 7 post Tamoxifen administration in young female mice. (A)C57B6 liver (B) Pax8/mdm2/tdTomato liver (C) Pax8/mdm2/tdTom kidney.



Fig 2. (A) Expression of p21cip1 and tdTomato at day 7 post Tamoxifen administration in a young female wild-type mouse and (B) Pax8/mdm2/tdTomato. (C) Expression of tdTomato at FACS. (D) qPCR expression of *CDKN1A* in tdTomato cells sorted by FACS. Representative flow cytometry plots of a young transgenic mouse (E) and wild-type mouse (F) treated with Tamoxifen.

We observed a rapid induction of fibrosis in the first 7 days after tamoxifen induction in both young (Fig 3A,C) and old mice (Fig 3C). This persists to day 42 (Fig 3B). This demonstrated that epithelial senescence alone was sufficient to induce renal fibrosis in young mice, and exacerbate fibrosis in old mice. Further studies assessed the longer-term impact of acute senescence induction, with fibrosis stabilising in both young and old mice at 6 weeks post induction (Fig 3D).

Discussion: Using a novel transgenic mouse line, we demonstrate for the first time that induction of renal epithelial senescence in the absence of injury is sufficient to induce renal fibrosis in the early aftermath of SC induction. The evolution and/or clearance of senescent cells over time is the focus of on-going study and will be presented at UKKW.

Best Science Abstracts

Submission: 289

Enalapril but not Dapagliflozin (DAPA) reduces kidney inflammation in adriamycin-induced nephrotic syndrome.

Dr Gisele Lincevicius, Miss Misha Sedoo, Miss Stephanie Butler, Miss Jessica Wills, Mr Connor Levers, Dr Jonathan Davies, Dr Steve Vickers, Dr Sharon Cheetham, Dr Wioletta Pijacka

Sygnature Discovery Ltd., Nottingham

Nephrotic syndrome (NS) is the combination of proteinuria, low serum albumin levels and oedema. Adriamycin induces NS in rodents by damaging the filtration barrier, hence mimicking the human condition. Proteinuria in turn induces and maintains kidney secretion of proinflammatory and profibrotic cytokines driving subsequent renal inflammation. Enalapril, an angiotensin conversion enzyme-1 inhibitor is currently used as a standard of care in chronic kidney disease (CKD). The sodium-glucose cotransporter 2 inhibitor, Dapagliflozin (DAPA), was recently approved by the FDA for CKD treatment. The effect of DAPA as well as enalapril in NS is poorly understood. We hypothesise that DAPA and Enalapril will reduce IL-6 released in the first stage of inflammation, leading to a decrease in IFN-γ, TNF-α, IL-1β and therefore improve kidney function.

11-week-old male BALB/c OLA mice (n=17/18) were dosed with Vehicle or Adriamycin (11.25 mg/kg, i.v) on Day 0. Enalapril (30mg/kg), DAPA (1.5 mg/kg) or vehicle were dosed p.o. from Day 8 to 27. Oedema, absence/presence, was evaluated for 28 days. Urine was collected on days 7, 14 and 28. Mice were terminated on day 28. Plasma creatinine and urea as well as urine creatinine, albumin and protein were analysed by COBAS (Roche) and data are shown as albumin/creatinine (uACR) or protein/creatinine (uPCR) ratio. Plasma inflammatory cytokine (IFN-γ, TNF-α, IL-6, IL-1β) profile was evaluated by multiplex antibody-based detection with mesoscale (MSD).

Adriamycin-induced proteinuria was confirmed on day 7 (Adriamycin vs Vehicle uACR: 1.2±0.1 vs 35±7, $p<0.001$; uPCR 33±1 vs 63±9, $p<0.05$). Enalapril decreased uACR and uPCR vs Adriamycin on day 28 but not on day 14 (uACR 24.8±12 vs 7.8±1.4, $p<0.01$; uPCR 54.3±16 vs 24.0±2.5, $p<0.01$). DAPA did not produce any effect on renal function. Plasma creatinine and urea were also reduced by Enalapril ($p<0.01$) but not by DAPA on day 28 (creatinine: 0.42±0.1 vs 0.21±0.04 vs 0.37±0.1 mg/dL; urea: 114.1±31 vs 48.7±12 vs 106±40 mg/dL). Oedema induced by Adriamycin (10 out of 18 mice) was prevented by Enalapril (0 out of 17 mice) but not by DAPA (9 out 17 mice). Adriamycin, significantly increased plasma levels of IFN-γ, TNF-α and IL-6 but not IL-1β. Enalapril treatment normalized both plasma IFN-γ (0.83±0.08 vs 0.54±0.07 pg/ml, $p<0.05$) and IL-6 (14.3±3 vs 3.4±0.9 pg/ml, $p<0.001$) and decreased plasma TNF-α (13±2 vs 8±0.7 pg/ml, $p<0.01$). DAPA did not have significant effect on the inflammatory cytokines evaluated in the study ($p>0.05$).

We have shown that IL-6, IFN-γ and TNF-α but not IL-1β are involved in the maintenance of the NS in the Adriamycin-induced mouse model. For the first time we report that Enalapril but not DAPA reduces IFN-γ, TNF-α, IL-6 in this model. This finding was associated with decrease in oedema, albuminuria and plasma creatinine and therefore with increase in kidney function. The mechanisms for these remain to be further investigated.

Best Science Abstracts

Submission: 103

Single nuclei RNA-seq differentiates between mouse models of lupus nephritis and highlights pathways for therapeutic intervention

Ms Aneesha Bhandari[1], Dr Rose Hodgson[1], Dr Mukta Deobagkar[2], Ms Tanya Cheetham[2], Professor Richard Cornall[1], Dr Katherine Bull[2]

[1]Nuffield Department of Medicine, University of Oxford, Oxford.
[2]Wellcome Centre for Human Genetics, University of Oxford, Oxford

Introduction: Lupus Nephritis (LN) is characterised by renal immune-complex (IC) deposition, but how these deposits trigger inflammatory mediators, and the signalling between resident and recruited cells remains unclear. Access to human tissue remains challenging: lupus single cell kidney datasets have focused on immune populations with limited or no glomerular, tubular, or stromal context; and mechanistic understanding can be hampered by non-specific signals of fibrosis and scarring. Mouse lupus models share many of the clinical features of human disease including autoantibodies and renal involvement. In this study, using single nuclei RNA sequencing (snRNA-seq), we compare two different murine models of early LN, to identify disease drivers and therapeutic targets, and to establish a general approach that can be applied to human tissue in the future.

Methods: Kidneys were harvested from autoimmune (MRL/lpr) mice aged 16 weeks, or Balb/c mice treated for 8 weeks with topical TLR7 agonist (IMQ) with MRL and Balb/c controls. Kidney sections were processed for histology and immunofluorescence. Kidney snRNA-seq libraries were prepared (10x Genomics), sequenced (Illumina), and analysed (Seurat). Immortalised human mesangial cells were edited using CRISPR-Cas9.

Results: IMQ kidneys showed glomerular IC deposition, mesangial expansion, and endothelial proliferation consistent with class-II LN. MRL/lpr mice additionally developed crescents, and a class-III like disease. Sequential clustering of transcriptomic data from >90k nuclei identified clusters corresponding to resident and immune populations. Early S1 / S2 proximal tubules segments were identified as interferon susceptible targets in both models, particularly in MRL/lpr. Glomerular stromal analysis and immunofluorescence showed evidence of mesangial de-differentiation into a PDGFRβ^{+} fibroblast-like population. Gene editing experiments in mesangial cells are starting to make it possible to model these changes and identify the underlying pathways *in-vitro*. Within the immune system, intrarenal T, B, and myeloid cells were enriched in diseased mice. Shared immune renal phenotypes included significantly increased resident macrophages expressing genes implicated in phagocytosis and efferocytosis (Axl,Mertk) and antigen presentation (Cd74, H2-Eb1) and patrolling non-classical monocytes, expressing the proinflammatory transcription factor Nfam. Shared enhanced immune receptor–mesangial ligand interactions highlight potential novel pharmacological target for LN. The MRL/lpr mice had the largest immune cell infiltrate, including CD8 T cells and NK cells expressing markers of cytotoxicity and exhaustion (Gzma, Tbx21, Klrg1). In contrast in IMQ kidney there were significant increases in innate populations, and a unique Fcrl5^{+} monocyte signature.

Discussion: Integrated kidney snRNA-seq, incorporating all immune and tissue cell types in two LN disease models, delineates shared and common pathways of disease and its pathogenesis. Our data suggest that a common early step with profound effects on function may be the interferon mediated

damage to the proximal tubules. Mesangial de-differentiation leads to fibrosis. These effects may be linked by infiltrating immune cells and their interactions with both tubule and endothelium including cytotoxic T cells, and a novel TLR7 driven Fcrl5^{+} monocyte population. Our comprehensive kidney single nuclei approach is generalisable and highlights candidate genes for *in-vitro* and *in-vivo* rescue experiments. A similar integrated approach can be directly applicable to human pathology.

Best Science Abstracts

Submission: 399

Heparanase inhibition in a rat model of minimal change disease restores glomerular endothelial glycocalyx damage and reduces proteinuria

Dr Michael Crompton[1], Dr Raina Ramnath[1], Dr Kai Betteridge[1], Dr Karen Onions[1], Ms Viktoriia Vasylchenko[1], Dr Matthew Butler[1], Dr Monica Gamez[1], Dr Sara Desideri[1], Dr Lulu Jiang[1], Dr Christopher Neal[1], Professor Jeremy Turnbull[2], Dr Olga Zubkova[3], Professor Hiroshi Kawachi[4], Dr Andrew Salmon[1], Professor Gavin Welsh[1], Professor Simon Satchell[1], Dr Rebecca Foster[1]

[1]University of Bristol, Bristol.
[2]Keele University, Keele.
[3]Victoria University of Wellington, Wellington.
[4]Niigata University Graduate School of Medical and Dental Sciences, Niigata

Introduction**:** All vascular endothelial cells are lined with a luminal proteoglycan layer, the endothelial glycocalyx (eGlx), critical for maintaining vascular permeability. The glomerular eGlx forms the first part of the glomerular filtration barrier. Proteinuric kidney diseases are associated with widespread vascular dysfunction. Heparanase (HPSE), which cleaves heparan sulphate (HS), an essential component of eGlx, is upregulated by injured podocytes in proteinuric disease. Using a model of targeted podocyte injury to induce proteinuria, we sought to determine whether this caused glomerular eGlx damage and whether a novel class of HPSE inhibitor (Zubkova et al., 2018, PMID: 30480427) could prevent the development of proteinuria, by preserving the glomerular eGlx.

Methods**:** Female Lewis rats were injected with mAb 5-1-6 (5 mg/rat, i.v.) to induce proteinuria (5-1-6 nephropathy model). OVZ/HS-1635 (HPSE inhibitor) or vehicle was given daily (20 mg/kg, i.p.) from day 1 of mAb 5-1-6 treatment, until day 7. Ringer-BSA perfused kidneys were processed for immunofluorescence and/or glomeruli were isolated for qPCR. We applied our fluorescence profile peak-to-peak confocal imaging technique to assess glomerular eGlx damage. Alcian blue perfused kidneys were processed for transmission electron microscopy and glomerular capillary wall ultrastructural changes were quantified. Urines were collected to analyse urinary albumin:creatinine ratios (uACR). Blood pressure was measured using a tail cuff method.

Results**:** The 5-1-6 nephropathy model targeted podocytes specifically, with colocalisation of anti-5-1-6 with podocin, a podocyte specific marker. Nephrin mRNA expression was significantly reduced (-1.5-fold change compared to control, $P = 0.014$), confirming podocyte injury. In 5-1-6 rats, glomerular eGlx was significantly reduced (control, 225 ± 11.7 nm; 5-1-6, 112 ± 3.8 nm, $P < 0.001$) with significantly increased uACR (control, 24 ± 4 mg/mmol; 5-1-6, 17,483 ± 5,269 mg/mmol, $P < 0.001$) compared to control rats. 5-1-6 induced-proteinuria was independent of changes in blood pressure or body weight. OVZ/HS-1635-treated 5-1-6 rats had a significant reduction in uACR (5-1-6 + OVZ/HS-1635, 7,250 ± 2,016 mg/mmol, $P < 0.01$) and glomerular eGlx was significantly restored (5-1-6 + OVZ/HS-1635, 154 ± 4.8 nm, $P = 0.002$), compared to 5-1-6 rats.

Discussion**:** We have shown that targeted podocyte injury induced-proteinuria is associated with glomerular eGlx dysfunction. We also demonstrated that HPSE inhibition, using a novel and clinically relevant inhibitor, protected against glomerular eGlx damage and prevented proteinuria progression. This has therapeutic implications for targeting eGlx to prevent renal and potentially cardiovascular complications. This work was funded by British Heart Foundation.

Submission: 382

Participant characteristics and initial feasibility of a structured, home-based exercise programme in kidney transplant recipients: Results from the ECSERT study, a pilot randomised controlled trial

Miss Roseanne Billany[1], Miss Zahra Mubaarak[1], Miss Stephanie Burns[2], Dr Hannah Young[1,2], Prof Nicolette Bishop[3], Prof Alice Smith[1], Dr Matthew Graham-Brown[1,2]

[1]University of Leicester, Leicester.
[2]University Hospitals of Leicester NHS Trust, Leicester.
[3]Loughborough University, Leicester

Introduction: Kidney transplant recipients (KTR) are prone to high rates of infection, malignancy and cardiovascular disease. Poor physical fitness and physical inactivity remain pertinent targets to improve post-transplant clinical outcomes. Only 27% of KTR are classified as physically active for health. The ECSERT pilot study aims to assess the feasibility of delivering a structured, home-based exercise intervention in 50 KTR at increased cardiometabolic risk and evaluate the putative effects on cardiovascular structure and function, cardiorespiratory fitness, physical function, quality of life and metabolic and inflammatory markers. We present interim feasibility data describing engagement with the home-based programme of exercise for all patients who have completed the programme to date.

Methods: Potential KTR were screened for eligibility and approached by their consultant nephrologist, and if interested, further study details were explained by a researcher. Those who consented to take part were randomised (1:1) to either a 12-week structured home-based exercise programme (INT, n=19) or 12-week usual care control (CTR, n=22). Figure 1 outlines the home-based exercise programme. The a priori thresholds for specific feasibility and acceptability criteria are as follows: recruitment success of 20% of eligible participants (≥2 participants per month), adherence (an average of three exercise sessions per week) and attrition (≤30%).

Results: Ninety patients were approached and 41 (45.6%) were recruited across 22 months of recruitment. Participant characteristics were: 51±14 years (INT 50±13; CTR 52±16), 21 male (INT 8; CTR 13), eGFR 60±19 ml/min/1.73 m^2 (INT 64±19; CTR 58±19), 28 White British (WB) and 13 Asian ethnicity (INT 12 WB, 7 Asian; CNR 16 WB, 6 Asian). Two participants withdrew from the intervention group (1 due to COVID-19 infection, 1 due to recurrent urine infections unrelated to the trial) and one from the control group (lost to follow-up; 7.3% attrition). There were no adverse events reported related to the exercise intervention or trial procedures. Participants completed an average of 4.5±1.4 exercise sessions per week (aerobic 2.9±1.2; strength 1.6±0.4). Completion of key baseline outcome measures was: cardiac MRI scan 95%, cardiopulmonary exercise test 88%, accelerometry 100%, physical function 100%, body composition 100%, blood sampling 100% and questionnaire packs 97.6%.

Discussion: Results suggest engagement with the home-based exercise programme in KTRs is excellent. The study is comfortably exceeding a priori thresholds relating to recruitment, retention and completion suggesting patients are interested in the study and the programme of exercise despite the current evidence showing physical activity levels are low. The groups are well-matched and there is an encouraging representation of female participants and participants from a non-white

background. These initial results support study continuation and further assessment and development of home-based programmes of exercise and activity for KTR.



Figure 1. ECSERT 12-week exercise programme.

Personalising care & valuing patient contribution: Shared decision-making & Partnership

Submission: 221

Improving accessibility of home therapies: Development of a universal approach to reimbursement for excess utility costs associated with home dialysis

Submitted on behalf of the Welsh Kidney Network (WKN)

Welsh Kidney Network, Cardiff

Submitted on behalf of the Welsh Kidney Network (WKN)

Introduction: NHS Wales aims to provide high quality, equitable healthcare that is evidence-based and meets the needs of the population (Welsh Government, 2018). There is much evidence that home dialysis can improve quality of life for patients with kidney disease and in Wales is promoted to all suitable patients. The Welsh Kidney Network (WKN) are responsible for commissioning home dialysis services in Wales and in their current strategy, aspire for 30% of all patients requiring KRT in Wales to be on a home-based therapy; either home haemodialysis or peritoneal dialysis. However, costs associated with increases in energy and water usage due to dialysis treatment at home has potential to cause anxiety for patients and therefore deter patients from opting for this mode of KRT. While prior to the work described here, patients receiving dialysis at home in Wales were being reimbursed for utility costs associated with their dialysis, the methodologies used across Wales varied significantly and did not take account of treatment prescription. This was problematic given there is no 'one size fits all' for dialysis treatment prescription. Following the current energy crisis and a number of concerns raised by patients, the aim of the work here was to develop a consistent, individualised method for reimbursing patients for home dialysis associated excess utility costs.

Methods: Work first involved a scoping exercise to identify average household energy and water prices across Wales, and collaborating with renal technical services colleagues to understand electricity and water usage associated with dialysis equipment. Following this was agreement of a reimbursement methodology with finance colleagues, and development of a calculator tool in 'Microsoft Excel' software (Figure 1). Finally, to accompany the tool, a patient agreement form, fact sheet and staff education package was also developed.

Results: Since its successful April 2021 all Wales implementation, it can be said all Welsh patients receiving dialysis at home (which has varied between 233 and 262) have been realising the benefits of the tool, in the form of accurate reimbursement for excess utility costs arising from their exact treatment prescription. Other outcomes and developments to date include positive feedback from all stakeholders regarding the operational utility of the tool, and commitment from WKN to undertake annual, or in the event of continued extreme energy price increases, more frequent tariff reviews.

Discussion: The work described here offers significant opportunity for improving accessibility of home dialysis services provided by NHS Wales. Given Kidney Care UK (2022) write "kidney patients feel they are being priced out of existence by increases in costs of utilities", and in their recent survey, identified Wales as the only home nation providing equitable reimbursement for home dialysis patients, the authors suggest that this work could inform the next 'National reimbursement guidance for people undertaking dialysis at home' issued by the UK Kidney Association. Moreover,

while this work concentrates on adult services, a similar tool could offer similar opportunities for paediatric nephrology. Finally, given it requires little resource, the tool also aligns with a value based healthcare approach.

Figure 1: Screenshot of electronic calculator tool developed in 'Microsoft Excel' software



References:

Welsh Government (2018) A Healthier Wales: our Plan for Health and Social Care. Available at: https://gov.wales/healthier-wales-long-term-plan-health-and-social-care (Accessed: December 2022).

Implementing trials in clinical practice

Submission: 484

Optimising outcomes for people with proteinuric Chronic Kidney Disease: Piloting a new model of care.

Dr Camilla Pillay, Ms Sheela Thomas, Dr Catriona Shaw, Dr Jonathan Dick, Ms Eleri Wood

King's College Hospital NHS Trust, London

Introduction: Current recommendations by NICE (ref, 2022) are that people with proteinuric chronic kidney disease (CKD) be pharmacologically 'optimised' with timely initiation and uptitration of ACEi, ARB-II, SGLT2i, and statin medicines. The London Kidney Network (LKN) promotes a 'three-in-three months' model for the purposes of optimising these categories of within this time frame. Limitations to the capacity of outpatient nephrology clinics have been identified as a barrier to facilitating the frequency of monitoring required. Medication optimisation therefore typically took 6-12 months, a delay associated potential negative outcomes inclusive of progressive kidney dysfunction and cardiovascular disease. We aimed to improve the timeliness and efficiency of care provided to people with CKD by creating and piloting a nurse-led CKD optimisation clinic.

Method: A multidisciplinary group created a protocol for a pilot CKD optimisation clinic concordant with national guidance. Eligibility criteria for the clinic is outlined in Table 1. For the purposes of the pilot, criteria were deliberately restrictive to minimise person risk. Eligible patients were assessed and followed by a CKD-specialist nurse in accordance with the intervention schedule in Table 2.

Table 1 – Eligibility criteria for optimisation clinic

Eligibility criteria	Exclusion criteria
Diabetic OR Non-diabetic with uACR >25mg/mmol eGFR >30ml/min	Insulin-managed diabetes CKD 5 or kidney replacement therapy. Already on full dose ACE/ARB SGLT2i, and statin.

Table 2 – Optimisation Clinic Schedule:

Referral (week zero)	
Visit 1 (week 2-4)	Check of BP and eGFR/potassium ACE/ARB uptitration Commencement of statin (if required)
Visit 2 (week 4-6)	Check of BP and eGFR/potassium Potassium lowering advice/intervention (if required) ACE/ARB maximum uptitration Lifestyle advice to reduce renal progression and cardiovascular risk (stop smoking, increase exercise, reduce/maintain weght, reduce salt/alcohol intake)
Visit 3 (week 6-8)	Check of BP and eGFR/potassium Initiation of SGLT2i Discharge back to general nephrology clinic

Results: Between 1/6/22 and 30/9/22 66 patients were referred, 71% of whom from the four clinicians who had developed the service. 4 (6%) were rejected for not meeting referral criteria.

By 30/9/22:

- 53 patients had been seen; 51 (96%) had been given appointment within target of six weeks. 8/55 (15%) had not been prescribed an ACE/ARB, 52 (98)% not an SGLT2i, and 14 (26%) not a statin prior to referral.
- 26 patients (49%) had been discharged back to nephrology clinic.

Of the 26 discharged patients:

- 24 (92%) were prescribed maximum tolerated RAAS blockade; 1 (4%) required a potassium binder.
- 19 (100% of those eligible) were prescribed a SGLT2i.
- 17 (65% of those eligible) were prescribed a statin.
- 17 (65%) were fully optimised (target: 80%).

No adverse outcomes were noted; we observed one 'near miss' event for a patient inadvertently prescribed an ACE-i in addition to a previously prescribed ARB due to current medication not being adequately documented prior to referral.

Discussion: The pilot of this CKD optimisation clinic was largely successful. 96% of patients were seen within target time, and 65% efficiently optimised by a CKD-specialist nurse. This reduced the general nephrology clinic time being used on simple protocolised care and enabled people living with CKD to benefit from medication optimisation in much reduced timescale.

A higher than ideal proportion of patients were not optimised due to omission of statin prescriptions. Statin guidance was erroneously omitted from first draft of protocol; full optimisation rates are expected to improve with inclusion of statin prescribing in subsequent versions.

Referrals were largely appropriate but mostly from clinicians involved with optimisation clinic. There is a need to raise awareness across the entire nephrology team to enable access to all patients who stand to benefit.

Conclusion: the successful pilot resulted in continuation and expansion of the optimisation clinic.

Joint session with British and Irish Hypertension Society

Submission: 302

Lack of association between fluid status and blood pressure with dialysis centre clinical practices related to fluid management: analysis of data from the BISTRO trial.

Dr Radha Sharma[1,2], Dr Neena Johal[1], Dr John Belcher[1], Professor Simon Davies[1]

[1]Renal Research Group, School of Medicine, Keele University, Stoke-on-Trent.
[2]University Hospital North Midlands, Stoke-on-Trent

Background: Fluid management in haemodialysis patients impacts morbidity and mortality. Assessment of fluid status challenges clinicians; the evidence for different practices remains poor. Survey data from the BISTRO (Bioelectrical Impedance Spectroscopy to preserve Renal Output) trial confirmed variation in centre-level practices that may affect fluid status. This investigation aims to determine if centre-level clinical practice patterns that potentially impact volume management associate with the fluid status of haemodialysis patients.

Methods: We performed a secondary analysis of pooled data from the BISTRO trial: 2501 fluid assessments in 32 centres, and two completed surveys of centre-level clinical practice patterns for volume management. The outcomes of interest were: 1) fluid status, expressed as the difference between target weight and normally hydrated weight (TW-NHW), 2) pre- and post-dialysis systolic (SBP) and diastolic (DBP) blood pressure. The practice patterns interrogated were: 1) dialysate sodium concentration [dNa+], 2) dialysate temperature (T·), having a standard fluid assessment protocol for new patients and the routine use of additional methods of assessing fluid status (e.g. bioimpedance, ECHO, Chest X-ray and others). We conducted multilevel data analysis to account for repeated measures clustering, centre size, and, adjusted for age, comorbidity score and gender. Both surveys were analysed independently.

Results: Before inclusion of practice patterns and demographic adjustment, centre-level interclass correlations were extremely low for all five outcomes studied, whereas patient-level clustering was observed (see table). Lower pre-dialysis DBPs were consistently associated with increasing age and comorbidity, whereas post-dialysis, it was associated with age and male gender. Over the range of [dNA+] 135 to 140 mmol/l used, no differences in the five outcomes were observed. Over the range of T· 35-37o, the only difference seen was a higher TW-NHW in one centre using 35o. In survey one, this was non-significant compared to 36.5o, +0.58 kg, P=0.096. In survey 2 (which had more centres) this was +0.79 kg compared to T· 36o, P=0.038, and +0.88 kilograms compared to T· 36.5o, P=0.023. No effects on BP were seen. The use of a standard fluid assessment protocol for patients new to haemodialysis (survey 1: 9 centres, survey 2: 3 centres) did not affect outcomes. No consistent effects of the routine use of bioimpedance, chest X-ray, ECHO, central vein diameter, blood volume monitoring, lung ultrasound or orthostatic BP in fluid assessments were seen.

Conclusions: Hydration status, (TW-NHW) and blood pressure are not different by centre and have no apparent relationship to practice patterns associated with fluid management. Instead, these outcomes are related to patient-level characteristics. Limitations surrounding the nature of the study (post-hoc analysis of observational data) hinders accounting for practice pattern clustering. Sufficiently powered trials are needed to address value of specific practices.

Table: *Summary of unadjusted centre and patient level inter-class correlation (ICCs).*

Outcomes of interest	Centre-Level Correlation		Patient-Level Correlation	
	ICC	95%CI	ICC	95%CI
TW-NHW	0.004	0.0002, 0.44	0.27	0.23, 0.32
Pre-dialysis SBP	0.006	0.0002, 0.15	0.472	0.43, 0.52
Pre-dialysis DBP	0.011	0.112, 0.054	0.210	0.174, 0.25
Post-dialysis SBP	0.01	0.001, 0.089	0.39	0.344, 0.435
Post-dialysis DBP	0.013	0.004, 0.043	0.12	0.094-0.16

Calciphylaxis

Submission: 142

Calciphylaxis: diagnosis, management, and outcome in Sussex Kidney unit: A single Centre experience

Dr Muhammad Fahad[1], Dr Farid Ghalli[1,2]

[1]Sussex Kidney Unit, University Hospitals Sussex NHS Foundation Trust, Brighton.
[2]Brighton and Sussex Medical School, Brighton

Introduction**:** Calciphylaxis (AKA: Calcific Uraemic Arteriopathy) is a rare disease, predominantly affecting patients with chronic kidney disease (CKD) and is associated with significant morbidity and mortality due to progressive cutaneous calcification, necrotic ulceration, and infection. This work aimed at better understanding the risk factors and evaluating treatments and disease outcomes of calciphylaxis in patients diagnosed with the condition in Sussex Kidney Unit.

Methods**:** Data Collected for patients diagnosed with Calciphylaxis between 2013 – 2022 at SKU. Patient data and lab results were collected from CV 5, which is the electronic record system of our renal department. The data collected were in 8 groups, including demographics, co-morbidities, laboratory results at the time of diagnosis, laboratory results in an average of 12 months pre-diagnosis, diagnosis of Calciphylaxis, medications over the last year pre-diagnosis, medication prescribed at the time of diagnosis of calciphylaxis and Management Strategies.

Results**:** Between 2013 and 2022, 21 cases of calciphylaxis were diagnosed at SKU. The mean patient age was 65 years and 33% had a body weight > 100 kg, with a higher proportion of females (52%). White British ethnicity constituted 95% of patients. Sixty-two were on unit hemodialysis, 9% on home hemodialysis and 14% on PD with median dialysis vintage 4 years. Two patients (10%) were kidney transplant recipients. One patient (5%) had CKD and started dialysis with the diagnosis.

Dialysis vintage was lower in patients on warfarin which points to warfarin as an independent risk factor for calciphylaxis. Forty-two per cent of patients were diabetic, while 47% received vitamin K antagonists (VKAs) before diagnosis (Warfarin). At the time of diagnosis, the median corrected calcium was 2.43 mmol/l, with 62% of patients towards the high limit or above target (33.3% above target). The median parathyroid hormone level at diagnosis was 32 pmol/L. The median serum phosphate level was 1.83 mmol/l with, 66.6% above the target. Average levels 12 months pre-diagnosis, median corrected calcium was 2.4 mmol/l. The median serum phosphate was 2.4 mol/l and 86% of patients were above target. The median parathyroid level showed no significant difference between patients on warfarin and patients not on it. Patients with calciphylaxis had a high comorbidity burden, including cardiovascular disease, arrhythmias, and metabolic syndrome. The most common site of calciphylaxis was the lower limbs (71%), with 38% of patients having more than one area involved. Three patients (14%) had calciphylaxis recovery. One patient moved out of the area. Seventeen died, with 81% mortality.

Conclusion**:** The resolution of calciphylaxis is uncommon despite multimodal therapy, and mortality from calciphylaxis in the first year following diagnosis remains high. Our work studied risk factors for calciphylaxis, including diabetes, obesity, cardiovascular risk factors including vascular calcification, and VKA use. Control of serum phosphate, calcium levels and PTH is recommended. Reviewing the indications for warfarin use in dialysis and CKD patient cohorts and looking at an alternative as

apixaban is required. Increasing awareness about calciphylaxis risk factors, prevention, diagnosis and management is important for this disease with a high fatal outcome.

The greatest public health challenge – obesity-related ill health

Submission: 373

Investigating the association of obesity and multi-morbidity on mortality and renal outcomes in a non-dialysis chronic kidney disease population

Dr Saif Al-Chalabi[1,2], Dr Rajkumar Chinnadurai[1], Prof Philip A. Kalra[1], Prof Smeeta Sinha[1]

[1]Northern Care Alliance NHS Foundation Trust, Salford. [2]University of Manchester, Manchester

Introduction: Mounting evidence in the literature describes a reverse association whereby obesity may have a protective effect on mortality "obesity paradox". Several reports question this claiming methodology flaws such as collider stratification bias. In this study, we aimed to examine the effects of obesity on the combined outcomes of all-cause mortality (ACM) and renal replacement therapy (RRT) incidence in a cohort of patients with non-dialysis CKD (ND-CKD) by correcting for major risk factors to reduce the risk of bias.

Methods**:** This retrospective study was undertaken on all patients with a documented body mass index (BMI) in the Salford Kidney Study database from October 2002 until December 2016. Patients were grouped according to their BMI into normal weight, overweight and obese, and also according to their level of co-morbidity into 4 groups: group 1 had CKD only; group 2 had CKD and heart failure (HF); group 3 had CKD and DM; and group 4 had CKD, DM, and HF. Univariate and multivariate cox regression analysis were performed to study the strength of association between BMI categories and combined outcomes across the 4 groups of different clusters of co-morbidity.

Results**:** A total of 2416 patients were included in the analysis. The median age of the cohort was 67.3 years, 61.8% were male, and 96.4% were Caucasian. The median BMI was 28.1 kg/m2 and the median eGFR was 30.7 ml/min/1.73m2. At baseline, patients with increasing level of co-morbidity tended to be older with higher prevalence of hypertension (HTN), angina, myocardial infarction (MI), and stroke with lower baseline eGFR. The risk of combined outcomes followed the same trend in the three BMI groups, risk is higher with higher index of co-morbidity ($p < 0.001$). Further analysis of four subgroups of co-morbidity was undertaken. A univariate cox regression analysis for group 1 [n=1351], and group 2 [n=227] showed that patients with obesity had significantly lower rates of combined outcomes compared to patients with normal BMI (HR 0.75; p=0.001 and HR 0.56; p=0.003 for group 1 and group 2 respectively). In multivariate models, obesity consistently proved to be a strong protective factor against combined outcomes (HR 0.77; p=0.005 for group 1 and HR 0.53; p=0.005 for group 2). This was independent of age, gender, HTN, angina, stroke, MI, and prescription of statins and angiotensin converting enzyme inhibitors. For group 3 [n=614], and group 4 [n=190], there was no significant differences in the combined outcomes between the different BMI groups (for patients with obesity: HR 0.78; p=0.060 and HR 0.70; p=0.166 for both groups respectively).

Conclusion: There is evidence of increasing risk of RRT or ACM as comorbidity increases irrespective of BMI. However, when comparing the effect of BMI within groups, obesity was protective against adverse outcomes only in groups 1 (CKD alone) and group 2 (CKD + HF). This 'protective' effect was not seen in patients who had concomitant diabetes. These data suggest that diabetes is a potent predictor of adverse outcomes irrespective of BMI, however, in patients without diabetes, obesity may play a protective role.



Figure 1: Kaplan-Meier curves for the 4 groups.

Submission: 137

Kidney Kitchen; The story so far, on the development of a practical dietary resource for patients and renal dietitians.

Mrs Angeline Taylor

Royal Devon University Healthcare NHS Foundation Trust, Exeter

Introduction: Kidney Kitchen (KK) was the dream of kidney patient and Kidney Matters editor Deborah Duval. Deborah, who was diagnosed with type 1 diabetes at 11 and developed end stage kidney disease by 28, was one of many patients given the typical renal diet sheets with several dietary restrictions, that meant she struggled to find foods and meals that were both appetizing and enjoyable.

A common theme you hear from renal patients is that the diet is bland, food is boring and often they are just given a diet sheet without being provided with practical meal ideas. What patients really need is an easy-to-access resource turning dietary restrictions into something that can be enjoyed and be nutritionally adequate.

Method: Deborah's close friend, Chef Paul Ripley, was surprised by how limited and bland the renal diet was. In 2018 Deborah and Chef Ripley, together with Renal Dietitians, a professional food photographer and a filmmaker, brought KK to life. KK aims to provide safe, tasty, family-friendly recipe ideas for patients with all stages of kidney disease.

It is important to the KK team that the messages provided by Kidney Kitchen are of a gold standard, therefore the Renal Nutrition Group of the British Dietetic Association (RNG) worked with the Renal Dietitians to develop nutritional parameters for which analyised recipes must meet to be considered suitable. These parameters were, in part, guided by the BDA Digest from the Food Service Specialist Group. In addition, all recipes, go through a thorough review process before the day of cooking, filming and photographing to ensure a consistent message is provided to all.

Results and Discussion: Since its launch in 2018, KK have developed over 170 RNG approved recipes, available online, with downloadable recipe cards, and many with accompanying videos. Furthermore, KK have invited a number guest chefs to the kitchen to create recipes from a range of culturally diverse cuisines. In 2021 Kidney Kitchen produced a printed recipe book, making this free resource available to all renal dietitians and patients . In 2022, and in response to the cost of living crisis, Kidney Kitchen developed another free resource of 21 budget friendly recipes in a second recipe book, along with a guide for Foodbanks. 2023 will see the launch of two further free resources, a weight loss recipe book and a recipe book specific to a South Asian diet. In addition, the website will continue to add more online recipes and content, as well as work with Renal Dietitian's in Wales to support a food box scheme containing KK recipes and ingredients.

Analytics from 2021 indicated the following:

- 168,100 total hits for Kidney Kitchen
- 7,847 downloads

- The top 5 recipes were: Vegetable Crumble (1,698 views), Shepherd's Pie (1,665 views), Chicken Biryani (1,619 views), Pork Medallions with Apples and Mustard (1,465 views) and Lemonade Scones (1,365 views).

In summary, KK have produced a resource, valued by both patients and dietitians, that provides practical guidance on implementing renal dietary restrictions in a safe, enjoyable and nutritionally adequate way.

We don't have enough psychosocial staff to meet patient need': developing integrated patient pathways for psychosocial support and therapy

Submission: 328

The relationship between psychological flexibility and clinical outcomes in renal populations: A systematic literature review

Miss Laurie Hufton[1], Dr Nima Moghaddam[1], Miss Jessica Tunmore[1], Dr Dave Dawson[1], Dr Emma Coyne[2]

[1]University of Lincoln, Lincoln.
[2]Nottingham University Hospitals NHS Trust, Nottingham

Introduction: The global incidence and prevalence of chronic kidney disease (CKD) is growing. Living with CKD can have a profound impact on quality of life (QoL), particularly during later stages of the disease. Psychological flexibility (PF) appears to be associated with greater QoL when living with long-term physical health conditions. Treatments targeting PF, like Acceptance and Commitment Therapy (ACT), hold promise for promoting better outcomes in the context of these conditions. However, there has been little research on the role of PF in chronic renal conditions. The aim of this systematic review was to determine the associations between PF or ACT on clinical outcomes.

Method: A systematic review of the literature was completed using six electronic databases: Academic Search Complete, MEDLINE, APA PsycInfo, CINAHL, SocINDEX, and OpenDissertations. Studies were eligible for inclusion if they used a renal sample and either: (1) investigated associations between PF and clinical outcomes, or (2) administered an ACT intervention and explored clinical outcomes. All study designs were included, and the quality of the studies was assessed using the Mixed Method Appraisal Tool (MMAT) due to the heterogeneity in methodology. Findings were reported using a narrative synthesis.

Results: Seven studies were identified across six countries: UK, Israel, Iran, Spain, USA, and Japan. A total of seven-hundred and sixty renal participants were included across all studies with a mean age ranging from 49.2 to 71 years. Four studies adopted a cross-sectional design, one study was a case study, one study was quasi-experimental with randomisation, and the final study was a feasibility randomised control trial (RCT) with a cross-sectional component. The MMAT reflected overall average study quality. Level of agreement between reviewers was assessed and, prior to resolving discrepancies, overall free-marginal kappa = .68 ('substantial' agreement). Associations were found between PF and various outcomes, including depression, anxiety, health related QoL, subjective happiness, and medical variables such as phosphorus levels. Measures of PF, psychological distress, and QoL were heterogenous across studies. The most consistent association was found between PF and depression and anxiety. These associations were consistently statistically significant although effect sizes were variable. ACT interventions showed mixed outcomes however generalisability of results was limited due to the small number and heterogeneity of eligible studies. Heterogeneity was observed across study design, method of ACT delivery, and selection of outcome variables.

Discussion: There is some emerging evidence for PF and ACT on clinical outcomes in renal populations, but the limited number, variable methods, and differing aims necessitate cautious interpretation of the findings. The variability in effect sizes for the associations between PF and psychological distress may be accounted for by heterogeneity of measures for both PF and psychological distress. There are reported discriminant validity issues with the Acceptance and

Action Questionnaire II (AAQ-II) which may limit conclusions around associations between PF and distress. The review identified the paucity of literature on PF and ACT within renal populations.

We don't have enough psychosocial staff to meet patient need': developing integrated patient pathways for psychosocial support and therapy

Submission: 115

Motivations, experiences, and support needs of adult living kidney donors: A systematic review and thematic synthesis of qualitative studies

Miss Lauren Fitzgerald[1], Dr Buse Keskindag[1], Dr Abigail Hucker[1], Dr Hannah Maple[2], Dr Shivani Sharma[1]

[1]University of Hertfordshire, Hertfordshire.
[2]Guys and St Thomas, London

Background: Living donor kidney transplantation [LDKT] is recognised as a gold-standard treatment to manage chronic kidney disease [CKD] (Biabani et al., 2023; Nardelli et al., 2022). However, for the donor as well as the intended recipient, there can be a range of psychological and existential challenges.

Objectives: This study reports on the findings of a pre-registered (CRD42021256002) systematic review of qualitative studies on the motivation, experiences, and support needs of living kidney donors [LKD]. In doing so, the research acts as an up-to-date evidence synthesis, adding to previous reviews on this theme. The following questions were explored: (i) What motivates people to become a living kidney donor? (ii) What are the experiences of those who have donated an organ? (iii) What are the psychological support needs of LKD? As compared to previous reviews, an important aim of this study was to additionally consider the inclusivity of LKD research in terms of communities who are considered as traditionally underserved, with emphasis on ethnicity.

Methods: A search strategy was developed using the PICO (population; intervention; comparator; outcome) framework. The search was implemented in PubMed, Scopus, and Web of Science. Titles/abstracts of records yielded were screened for eligibility against inclusion criteria (n=3330). Of those that met criteria (n=32), articles were obtained for full screening. A second researcher reviewed eligibility of all included studies as well as 15% of excluded studies to ensure consistency. Discrepancies were resolved through discussion with the wider team.

Results: Thirty-two studies were included, and data analysed using thematic synthesis as per Thomas & Harden, (2008). Three main themes were identified: 'Motivational Considerations', 'An Individuals Experience', and 'Care as a Continuum'. Collectively, the themes addressed drivers of donation, personal aspects of the LKD journey, and the view that care for LKDs is an ongoing process. 65.63% of included studies did not report on ethnicity. Where participant ethnicity was reported [28.12%] 11.2% of which were reported clearly, 55.5% of studies reported a majority White/Caucasian sample, and the remaining 33.3% were focused exclusively on LKD experience as part of unmet need in underserved communities.

Conclusion: LKD is the treatment of choice for eligible patients. There continue to be challenges described by donors as part of their individual journey, though the unique personal gains are also emphasised. The evidence synthesis suggest that there are further opportunities to advance psychological care for donors. The review also suggests that a key priority for future research should be progressing knowledge on support needs across a range of LKD communities.

Submission: 497

The transcription factor GATA3 specifies a discrete sub-population in kidney stroma associated with reno-protection

Dr Irina Grigorieva, Ms Aeliya Zaidi, Dr Yueh-An Lu, Dr Usman Khalid, Dr Soma Meran

Cardiff University, Cardiff

Introduction: Renal stromal mesenchymal cells are key mediators of both recovery and progression of tissue damage following renal insults. In development, renal stromal cells promote nephron progenitor differentiation and vasculature patterning. In mature kidney they reside in few numbers between tubules and are essential for tissue homeostasis. Following injury, the stromal cell population expands to support adaptive repair processes. However, in maladaptive repair, stromal cells drive excessive fibrosis and inflammation. Single-cell transcriptomic advances have uncovered existence of different stromal sub-populations. But the biological functions of these sub-populations, the roles they play in homeostasis, repair and regeneration, as well as the factors that influence subtype differentiation are unknown. This study delineates the critical role of the transcription factor GATA3 in dictating stromal cell subtype differentiation during development, in health and disease using loss of function studies *in vivo* and *in vitro*. We show that GATA3 specifies a discrete sub-population in the stroma associated kidney repair and fibrosis prevention.

Methods: We established a renal stroma reporter model using the Foxd1-Cre line for lineage-labelling by Cre-recombinase dependent expression of tdTomato. *Gata3* was selectively inactivated in the renal stroma by crossing reporter and floxed *Gata3* mice (*Gata3-KO*$^{Foxd1\text{-}tdTom}$). Bilateral ischaemia-reperfusion-injury (IRI) and aristocholic-acid nephropathy were performed in these mice to induce renal injury. Ischaemic pre-conditioning (IPC) was used to convey renal protection prior to IRI. Kidneys were evaluated histologically by multiplexed immunofluorescence imaging. Reporter tdTom+ stromal cells were isolated by FACS for gene expression analyses. Primary human fibroblasts were used to test the role of GATA3 in TGFβ1-driven myofibroblast differentiation using siRNA and plasmids for GATA3 knockdown/over-expression.

Results: Lineage-tracing confirmed that GATA3+ stromal cells arise from Foxd1+ progenitors from embryonic-day 13.5. In postnatal kidneys, GATA3+ cells make up a small fraction of total tdTom+ stromal cells but expand during the reparative phase post IRI localising to repairing tubules and capillary-dense niches. This expansion was enhanced in IPC-mediated IRI protection. Single-nucleus RNA-sequence analysis confirmed that GATA3 marks a transcriptionally distinct stromal cell-type. *In vitro*, GATA3 expression was upregulated by the reno-protective growth factor BMP7 and down regulated by the fibrotic mediator TGFβ1. GATA3 prevented TGFβ1-driven myofibroblast differentiation as demonstrated by enhanced expression of α-SMA, EDA-fibronectin and the pro-fibrotic HA-synthase-2 with siRNA mediated GATA3 knockdown. *In vivo*, homozygous inactivation of *Gata3* in the Foxd1-lineage revealed an embryonically lethal phonotype with abnormal kidney development. Heterozygous inactivation gave rise to apparent normal kidneys, however kidney injury in *Gata3-Het*$^{Foxd1\text{-}tdTom}$ mice resulted in exaggerated fibrosis and tissue damage compared to wild-type mice, demonstrated by greater nephron injury (H&E score and E-cadherin immunostaining), excessive inflammation, increased collagen deposition and α-SMA+ myofibroblast number. In human studies, stromal GATA3 expression was attenuated in scarred kidneys from CKD patients.

Discussion: Our findings reveal that GATA3 specifies a molecularly distinct subset within the Foxd1-stromal-lineage that confers renal protection and limits fibrosis progression. Further studies to identify GATA3-regulated genes and pathways associated with the reno-protective stromal cell responses will inform potential stroma-targeted therapeutic interventions to shift the balance in favour of kidney regeneration after injury.

The science of multimorbidity in chronic kidney disease

Submission: 411

Insulin signalling improves bioenergetics in podocytes.

Dr Virginie Betin, Dr Jenny Hurcombe, Professor Richard Coward

University of Bristol, Bristol

Introduction: Our group is interested in the role insulin resistance plays in podocyte dysfunction, and consequently damage to the glomerular filtration barrier, in Diabetic Nephropathy (DN). Podocytes are terminally differentiated and highly insulin sensitive cells like neurons and a direct interplay between mitochondrial functions and insulin signalling has been shown in neurons and hepatocytes[1,2]. A key role of mitochondria is to produce energy efficiently using the complex oxidative phosphorylation pathway (OXPHOS). In this project, we wanted to understand how insulin signalling affects energy production in podocytes, especially by mitochondria, and participates in their fate during DN.

Methods: We studied conditionally immortalised mouse podocytes and induced insulin resistance through chronic exposure to hyperglycaemia, hyperinsulinaemia and pro-inflammatory cytokines[3]. Reduced insulin signalling was also modelled with conditional knockdown (kd) of the insulin receptor (IR) or inhibition using chemical compounds of the PI3K and MAPK pathways. Conversely, increased sensitivity to insulin was obtained by i. stable: overexpression of the IR or ii. individual knock-down of negative regulators of the insulin signalling pathway - phosphatase and tensin homologue deleted chromosome 10 (PTEN) or protein tyrosine-phosphatase 1B (PTP1B). Using Seahorse technology, we dissected the capacity of podocytes for ATP production by mitochondria and glycolysis in basal and diabetic conditions. Finally, we studied the effect of the loss of ATP production by mitochondria or glycolysis on podocytes' survival and the importance of insulin sensitivity, using an high throughput imaging system.

Results: We discovered that insulin resistance is detrimental to mitochondrial ATP production at basal and maximum capacities in podocytes, with a significantly increased proton leak consistent with a permanently reduced membrane potential (mostly attributed to hyperglycaemia). Conversely, enhancing insulin sensitivity by either PTENkd or PTP1Bkd, increased mitochondrial ATP production. Interestingly, PTP1Bkd podocytes were protected from diabetic effects on mitochondria. However, PTENkd were overly sensitive to diabetic conditions or PI3K/Akt inhibition both causing excessive proton leak. PI3K/AKT inhibition partially restored the increased ATP production and spare capacity observed in PTENkd and PTP1Bkd podocytes, confirming these changes to be mediated through the PI3K pathway.

Under non-stressed conditions OXPHOS and anaerobic glycolysis equally contribute to podocyte ATP production but glycolysis is key for rapid metabolic plasticity as switching glycolysis off caused high levels of cellular death. Inhibition of OXPHOS and glycolysis simultaneously was fatal for these cells. PTENkd and PTP1Bkd podocytes intrinsic higher ATP production levels did not improve cell survival when switching either pathway off. When glycolysis was switched off (and the cell depended entirely on OXPHOS for ATP) increasing insulin sensitivity improved podocyte survival, whilst inhibiting insulin signalling increased cell death.

Conclusion: Insulin signalling plays an important protective role on podocytes' mitochondrial bioenergetics and is particularly important when glycolytic ATP production is suppressed.

1. Huang et al. Mol Cell Neurosci. 2005; 28(1):42-54.
2. Li C et al. Free Radic Biol Med. 2013; 60:29-40
3. Lay AC et al. Diabetologia. 2017; 60(11):2299-2311.

Submission: 198

The UK aHUS Registry: Patient demographics and baseline disease characteristics from the first Registry data analysis

Dr Rodney Gilbert[1], Dr Imad Al-Dakkak[2], Dr Clare Booth[3], Dr Daniel Gale[4], Dr Sian Griffin[5], Prof Stephen D Marks[6], Prof Marie Scully[7], Dr Mohan Shenoy[8], Dr Aoife Waters[6], Prof Neil Sheerin[9]

[1]Southampton Children's Hospital, Southampton.
[2]Alexion, AstraZeneca Rare Disease, Boston, MA.
[3]Alexion Pharma UK, Uxbridge.
[4]Royal Free Hospital, University College London, London.
[5]University Hospital of Wales, Cardiff.
[6]Great Ormond Street Hospital for Children NHS Foundation Trust, London.
[7]University College London Hospital, London.
[8]Royal Manchester Childrens Hospital, Manchester.
[9]Freeman Hospital, Newcastle-upon-Tyne

Introduction: Atypical haemolytic uremic syndrome (aHUS) is an ultra-rare disease associated with thrombotic microangiopathy (TMA), with an incidence of approximately 0.5 per million people per year in the UK. Patients present with a triad of microangiopathic haemolytic anaemia, thrombocytopenia and end-organ damage, principally affecting the kidney and risking progression to end-stage kidney disease (ESKD). The multi-site, multi-national, non-interventional Global aHUS Registry was initiated in 2012.[1] It collects demographic and disease characteristic data both before and after the availability of eculizumab as a treatment option; this provides insight into risk factors and clinical outcomes. This is the first report of UK patients enrolled in the Global aHUS registry.

Methods: Patients of all ages with a clinical diagnosis of aHUS were eligible for enrolment. Data cut-off for this analysis was 5 July 2021, with eligibility dependent on availability of dates of first aHUS presentation and registry enrolment, date of birth and sex. Only patient data prior to treatment initiation has been incorporated. Baseline was defined as enrolment for untreated patients and treatment initiation for treated patients.

Results: At time of analysis, 156 patients with aHUS had been entered into the UK Registry; 64 (41.0%) were paediatric (<18 years of age) and 92 (59%) were adult at time of disease onset. 51.6% of paediatric patients and 39.1% of adult patients were female. Mean age at first manifestation of aHUS was 24.0 years in the overall population, 4.8 years in the paediatric group and 37.3 years in the adult group; median age was 22.8 years (interquartile range [IQR] 4.3–35.1), 2.6 years (IQR 1.1–7.1) and 33.0 years (IQR 25.8–45.9), respectively. Mean age at enrolment was 29.7 years, 12.3 years and 41.0 years, respectively; median age was 29.4 years (IQR 13.5–41.8), 10.0 years (IQR 2.2–17.1) and 39.6 years (IQR 30.1–48.6) in these populations. There was a known family history of aHUS in 16.7%, 21.9% and 13.0% of the overall, paediatric and adult populations, respectively. Of those with available genetic data in the Registry, approximately half had a positively identified pathogenic variant or were positive for anti-CFH antibodies. Half of patients (51.9%, 50.0% and 53.3% in the overall, paediatric and adult populations, respectively) had received dialysis prior to baseline and 36.5%, 21.9% and 46.7% were receiving chronic (>3 months) dialysis. Prior to baseline, 42.2% of the paediatric population and 73.9% of the adult population had received plasma exchange/infusion;

21.9% and 19.6% received at least one kidney transplant, respectively. Probability of ESKD-free survival at 5 years was 0.71 in the paediatric population and 0.51 in adults.

Discussion: These data describe the baseline characteristics and burden of disease before treatment, providing insight into the natural history of aHUS in the UK and allowing comparison with the global data set. They illustrate the significant burden of disease and the importance of early identification of aHUS before progression towards ESKD or chronic dialysis.

[1]ClinicalTrials.gov. Atypical Hemolytic-Uremic Syndrome (aHUS) Registry [Internet]. U.S. National Library of Medicine. [Accessed 2023 Jan 23]. Available from: https://clinicaltrials.gov/ct2/show/NCT01522183

Submission: 196

Cleavage of the Pkhd1 gene product, FPC, releases mitochondria localising fragments, and renal cystogenesis in a digenic PKD model is enhanced by their deletion

Dr Rebecca Walker[1,2], Dr Qin Yao[1], Dr Hangxue Xu[1,1], Dr Anthony Maranto[1], Dr Patricia Outeda[1], Dr Terry Watnick[1], Dr Feng Qian[1]

[1]University of Maryland Baltimore, Baltimore.
[2]University of Sheffield, Sheffield

Introduction: Autosomal recessive polycystic kidney disease is caused by mutations in PKHD1 encoding FPC, and is characterized by severe renal cystogenesis in neonates, yet mouse models do not fully recapitulate the human phenotype. Indeed, even rendering Pkhd1 a null allele does not cause kidney cystogenesis in the mouse. Several cleavage product of FPC are reported yet their function remains unknown.

Methods: Three Pkhd1 mutant mouse lines and the Pkd1V mouse were crossed to produce digenic mice to study renal cystogenesis. Biochemical analysis was used to investigate FPC cleavage patterns. Cell models and electron microscopy revealed underlying mitochondrial defects in Pkhd1 Knockout mice.

Results: Pkhd1 mutation modifies a Pkd1 uncleavable mutant (Pkd1V), enhancing the cystic phenotype in both the kidney and pancreas. The hypomorphic Pkhd1 mutant and Pkhd1 KO both enhance the Pkd1V kidney phenotype, making distal tubule cysts more severe and initiating cystogenesis in the proximal tubules. FPC displays differential cleavage to produce fragments of unknown function. New antibodies were generated to interrogate FPC cleavage products. Three small C terminal cleavage fragments were identified which contain a mitochondrial targeting sequence and are recruited to mitochondria. Mitochondrial ultrastructural changes were evident after deletion of Pkhd1 including mitochondrial fragmentation and dilated cristae, suggesting disrupted mitochondrial function. Deletion of just the C-terminal fragment of FPC (ΔCT), the portion that directly corresponds to the portion that cleaves and localises to the mitochondria, is sufficient to enhance the renal cystic phenotype of the PC1 cleavage mutant. Unlike the other Pkhd1 mutants however, FPC (ΔCT) does not result in the pancreatic cystogenesis when combined with Pkd1V, suggesting that the C terminus in not required to prevent pancreatic cyst development.

Conclusion: Our results suggest that the C-terminus of FPC plays an important role in preventing renal cystogenesis via a novel mitochondria specific function. Our work reveal some aspects of FPC's function, in particular a previously unrecognised mitochondria function that is mediated through FPC cleavage products.

Submission: 233

A retrospective multi-center audit on infection related side-effect outcomes of renal transplant recipients started on SGLT2 inhibitors.

Mr. Dane Howard[1], Mr. Matthew Holloway[2], Mrs. Charlotte Mallindine[3], Mrs. Natasha Moore[4], Miss. Aisha Riaz[4], Mrs. Janette Chu[5], Mr. Robert Brown[6], Mr. Chen Tseng[7], Miss. Kathrine Parker[8]

[1]Pharmacy Department, Leeds Teaching Hospitals NHS Trust, Leeds.
[2]Pharmacy Department, East Kent Hospitals University NHS Foundation Trust,, Kent.
[3]East and North Hertfordshire NHS Trust, Stevenage.
[4]Pharmacy Department, Guy's and St Thomas' NHS Foundation Trust, London.
[5]Manchester Institute of Nephrology and Transplantation, Manchester.
[6]Richard Bright Renal Service, North Bristol NHS Trust, Southmead Hospital, Bristol.
[7]Oxford Kidney Unit, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford.
[8]Division of Pharmacy and Optometry, School of Health Sciences, The University of Manchester, Manchester

Background: The use of Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2 inhibitors), initially licensed for type 2 diabetes mellitus (T2DM), are increasing due to evidence of their renal and cardiovascular benefits from randomised controlled studies (RCTs) in heart failure (HF) and chronic kidney disease (CKD). However, due to exclusion of kidney transplant recipients (KTRs) from RCTs, SGLT2s are not recommended in this population. There may be concerns of increased risk of adverse effects, such as urinary tract infections and thrush, in an immunosuppressed population. Post-transplant diabetes mellitus (PTDM), formerly NODAT, can affect up to 20% of patients in the first year post-transplant and although a small study has examined SGLT2s in this setting further data are warranted. Here we present data on KTRs prescribed SGLT2s from seven UK renal centres, to assess indication, alongside safety and renal function which are areas of current interest to clinicians.

Methods: Renal pharmacists at each renal centre undertook a local audit of current practice. Data collected included indication, SGLT2 used, duration of therapy, safety outcomes and other outcomes of interest such as rejection and kidney function. All KTRs had started an SGLT2 inhibitor prior to December 2022. All data was anonymized at the local centre. Data was pooled for analysis. Two centres were unable to capture infective events that may have presented in primary care such as urinary tract infections or thrush.

Results: Ninety-two renal transplant recipients from seven transplant centers were identified as currently or previously prescribed an SGLT2 inhibitor with a mean duration of follow up of 46 weeks. The majority of patients were taking SGLT2s for both T2DM and PTDM (n=72) with 13 patients taking for CKD amongst other indications, table 1. In terms of adverse events, five patients experienced urinary tract infections which were treated with antibiotics and one with mycotic infection. None of these infections required hospital admission or cessation of therapy, Table 1. Two patients had episodes of rejection during follow up related to immunosuppression non-compliance. Eight patients discontinued SGLT2s including two patients with diabetic ketoacidosis (DKA) (both with T2DM, one compliance related), two patients with episodes of acute kidney injury where dapagliflozin was implicated and four patients who didn't tolerate due to urinary frequency/thirst/drop in blood pressure.

Discussion: Findings from this audit show renal centres are using SGLT2s in KTRs, mainly for treatment of diabetes (T2DM or PTDM). We found the use of SGLT2s in KTRs has a similar safety profile to patients in the DAPA-CKD and EMPA-Kidney trials, despite their exclusion. A limitation to this data is not all units could capture patients who presented to primary care with infections such as thrush. Further studies are required in KTRs to understand the long-term benefits and safety profile, but this work is reassuring from a safety perspective, that carefully selected KTRs could receive SGLT2s.

Table 1. Demographics and adverse outcomes for patients

Patient demographic (n=92)	
Sex	67M/25F
Time since transplant (weeks), Median (IQR)	440 (210-836)
Duration on SGLT2, (weeks), Median (IQR)	32 (23-57)
eGFR (ml/min/1.73m^2) prior to SGLT2 initiation, Median (IQR)	46 (34-61)
Current eGFR (ml/min/1.73m^2), Median(IQR)	43 (32-60)
Immunosuppression Regime	
Calcineurin inhibitor (CNI) + Antimetabolite	37
CNI + Steroid	14
CNI + Antimetabolite + Steroid	25
Other	16
Indication of SGLT2 (some patients had dual indication)	
T2DM, N(%)	49 (53%)
T1DM, N (%)	2 (2%)
PTDM, N (%)	23 (25%)
CKD, N (%)	12 (13%)
HF, N (%)	15 (16%)
Adverse outcomes	
Urinary tract infection, n (%)	5 (5%)
Fungal infection, n (%)	1 (1%)
Gastrointestinal disturbance, n (%)	1 (1%)
Amputation, n (%)	1 (1%)
DKA, n (%)	2 (2%)
Rejection, n (%)	2 (2%)
Reasons for discontinuation	
DKA, n (%)	2 (2%)
Unable to tolerate (hypotension, thirst, urinary frequency), n (%)	4 (4%)
Acute kidney injury, n (%)	2 (2%)

Submission: 195

Immunosuppression modulation and outcomes after first post-transplant cutaneous squamous cell carcinoma: a multicentre cohort study

Dr Tom Crisp[1], Dr Khizr Nawab[2], Dr Maria Angela Gauci[3], Dr Jonathan Gamble[4], Dr Nitin Bhandary[2], Dr Pippa Bailey[3], Dr Sian Griffin[4], Dr Matthew Bottomley[1]

[1]Oxford Kidney Unit, Oxford.
[2]Berkshire Kidney Unit, Reading.
[3]Richard Bright Renal Service, Bristol.
[4]Department of Nephrology and Transplant, Cardiff

Cutaneous squamous cell carcinoma (CSCC) is the commonest malignancy in solid organ transplant recipients (SOTR), with up to 200-fold excess incidence compared to immunocompetent populations[1]. Increased aggression, recurrence, and risk of metastasis result in a significant increase of cancer-specific mortality, nine-fold higher than non-transplanted cohorts[2]. Despite the impact upon transplant recipient well-being, equipoise remains regarding optimal management of immunosuppression in SOTR with CSCC.

Whilst immunosuppression modulation is frequently initiated after recurrent CSCC, the frequency of utilisation and impact of this approach at time of first CSCC is unknown[3].

A multicentre retrospective cohort study was undertaken aiming to investigate the contemporary management and outcomes after first CSCC in kidney transplant recipients in the UK.

Seven kidney units, including five transplanting centres, are contributing to the study. Here, interim results from four centres are presented. Adults with a functioning kidney transplant, diagnosed with a first CSCC between 2016 – 2020, were included. Clinical and demographic data were collected locally using a standardised data collection tool and compiled into a single dataset by the central coordinating centre. Follow-up data were collected until most recent transplant or dermatology clinic appointment, or death. The study was HRA approved.

A time to event analysis was performed where the primary outcome was time from first CSCC to development of next CSCC. Secondary outcomes included time to death, graft loss or other malignancy, and immunosuppression modulation within six months of first CSCC. Transplant recipients were dichotomised based on immunosuppression modification.

74 eligible cases were identified during the study window. The median (interquartile range (IQR)) age at first CSCC was 63.5(56-71.75) years. 80% were male. All whose ethnicity was stated (70/74) were Caucasian. The median (IQR) cumulative duration of immunosuppression at first CSCC was 139(68-190) months. 65(88%), 2(3%), 54(73%) and 37(50%) of cases were receiving a calcineurin inhibitor, mammalian target of rapamycin (MTOR) inhibitor, anti-proliferative and/or corticosteroids at time of first CSCC, respectively. Median (IQR.) duration of follow-up was 33.5(22-49.25) months.

Immunosuppression was modified within six months in 27/74(36%), more commonly in those with a history of non-CSCC malignancy. The agent most frequently changed was the antiproliferative (20/74). An MTOR inhibitor was introduced once.

During follow-up, 30(41%) developed a second CSCC (Figure 1A). Further CSCC was 2.5 times more frequent in those who underwent immunosuppression modification (Figure 1B). 17(23%) patients died during follow-up, 9 being from the immunosuppression modification group. This was not significant, nor were there other significant differences in outcomes between the two groups.

The interim results of this study provide contemporary insight into the management and outcomes of first post-transplant CSCC. Immunosuppression modification is rarely utilised after first CSCC, despite many recipients subsequently developing further lesions. On univariate analysis, early immunosuppression modification does not reduce subsequent CSCC development, though significant residual confounding is likely and will be explored in the final analysis. Our study highlights the need for novel risk stratification and secondary prevention approaches in post-transplant CSCC.

References

1. Garrett, G.L. *et al.* (2017) 'Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States', *JAMA dermatology* , 153(3), pp. 296–303.
2. Bibee, K. et al. (2020) 'Cutaneous squamous cell carcinoma in the organ transplant recipient', Oral oncology, 103, p. 104562.
3. Bottomley, M.J. *et al.* (2022) 'Interventions After First Post-Transplant Cutaneous Squamous Cell Carcinoma: A Proposed Decision Framework', *Transplant international: official journal of the European Society for Organ Transplantation*, 35, p. 10880.



Figure 1: Cumulative incidence of second CSCC after first lesion (A) in whole cohort; (B) stratified by immunosuppression modification within first six months of first CSCC (denoted by vertical line).

Getting it right the first time in access

Submission: 493

Percutaneous arteriovenous fistula: preliminary data and comparison of performance with surgical arteriovenous fistula.

Dr Sivaramakrishnan Ramanarayanan[1,2], Ms Jeannette Cloran[1], Mr Ryan Villanueva[1], Dr Praveen Jeevaratnam[3], Mathew Metcalfe, Dr Kate Steiner[1]

[1]Lister Hospital, E&NHT, Stevenage.
[2]University of Hertfordshire, Hatfield.
[3]Stevenage, Stevenage



Aim
To assess the outcomes of newly initiated percutaneous arteriovenous fistula (pAVF) with propensity matched surgical upper arm arteriovenous fistula (sAVF) in a tertiary care renal unit

Methods
First thirteen pAVFs were compared with similar number of proximal sAVF matched for age, gender, ethnicity, Diabetes and previous access failure status. Outcomes of interest were maturation time (in days), vein calibre (in mm), primary failure rate (in percentage), 6 month survival (in percentage) and number of interventions within first 6 months.

All pAVFs were created using the Ellipsys system by a consultant Intervention Radiologist and a vascular surgeon. All patients for pAVF underwent prior venous mapping with Doppler ultrasound to assess suitability of venous anatomy for anastomosis creation as well as cannulation. Post procedure

all patients post pAVF had doppler evaluation at week 1,4 and 8 to assess maturation and need for post procedure plasty.

Results

Eleven surgical avf created in 11 patients were compared with 13 pAVFs created in 12 patients. one pAVF had device failure and there was one technical failure which was successful on repeat attempt. Eleven pAVFs were included for further analysis. Mean age was 57.5 yrs and 58.85 years in sAVF and pAVF arms respectively. At the end of 6 months, nine out of ten pAVF were patent (90% survival) while eight out of eleven sAVFs were patent (72.7%). The distribution of vein calibre and maturation time were similar across pavf and surgical group (p=0.37 and p= 1 respectively by Mann-Whitney test). On 6 month follow up one out of 10 pAVF needed intervention (1 venoplasty) versus 3 out of 11 sAVFs (2 needed plications and 1 needed superficialization).

Discussion

Based on preliminary data pAVF has similar primary failure rate and patency rate as surgical AVF. Surgical avf need more interventions compared to pAVF. We believe that with more experience with this new technology and improvement in cannulation skills and training of more staff on ultrasound guided cannulation, we aim to be able to achieve better outcomes with much shorter maturation time with pAVF.

Getting it right the first time in access

Submission: 379

Hyperkalaemia – problem or epi-phenomenon following thrombectomy for AV fistulae and AVgrafts.

Dr Karanam Munige Randika Chaminda Wijerathne[1], Dr Meera Patel[2], Dr Benjamin Hawthorn[3], Dr Nalin Khosla[3], Dr Subash Somalanka[1], Dr David Makanjuola[1]

[1]Department of Nephrology, St Helier hospital, Carshalton.
[2]Department of Nephrology, Guys and St Thomas hospital, London.
[3]Department of Radiology, St Helier hospital, Carshalton

Hyperkalaemia – problem or epi-phenomenon following thrombectomy for AV fistulae and AVgrafts.

Background: Arteriovenous fistulae/grafts (AVF/AVG) are felt to be superior to haemodialysis catheters (HDC). Their Achilles' heel however, is thrombosis. This often requires percutaneous mechanical thrombectomy with thrombolysis [PMT] and sometimes other procedures such as venoplasty and stent insertion to 'rescue' the AVF/AVG. Complications of PMT include bleeding, haematoma and perforation. Clot disruption by PMT carries a risk of hyperkalaemia. Some centres have protocols which do not allow the procedure to be carried out if the potassium is > 5.0 mmol/l prior to the PMT. Hyperkalaemia is not much of a concern when performing thrombectomy by suction or Fogarty balloon, but in our centre we perform PMT using Angiojet, a rheolytic thrombectomy device. Hence we decided to find out what the magnitude of the rise in potassium was following PMT, with a bid to developing a guideline for our centre.

Methods: Data were prospectively collected from electronic records for patients who underwent PMT for thrombosed AVF/AVG between November 2021 – January 2023. Demographic characteristics, serum potassium pre and post-PMT, requirements for dialysis prior to the procedure, and complications associated with HDC insertion were recorded. Data were presented as absolute numbers with percentages, mean and range.

Results: Fifteen PMT procedures were performed in 14 patients during this period. AVF:AVG = 9:6 and M:F=10:4. Median age was 62 yrs (range 40-80). Mean time interval between thrombosis and thrombectomy was 3.13 days (range 1-7). Twelve (85.7%) of the patients had been on beta blockers or ACE inhibitors before the procedure. Mean potassium at time of thrombosis was 5.5 (range 4.5 - 7.1).

Twelve patients required HDC for dialysis to lower the potassium to < 5.0 mmol/l. There was one complication from a non-functioning HDC necessitating re-insertion. Mean pre-PMT potassium was 4.58 mmol/l (range 4.2 - 5.3 mmol/l). Mean post-PMT potassium was 4.73mmol/l (range 3.7-5.7); samples were obtained between 1.5 - 9 hours (mean 3.33 hrs) after. Mean change in potassium prior to and after the procedure ('delta K') was +0.15mmol/L (range - 0.9 to +1.3mmol/l).

Conclusion: We report the outcomes of PMT in AVF/AVG with particular focus on the change in potassium pre and post-procedure. Our laboratory's normal range for potassium is 3.5 to 5.3 mmol/l. The average potassium change was +0.15mmol/L. None of the patients had a severe or life-threatening hyperkalaemia following the procedure. Some protocols, if adhered to, would mandate

measures to reduce the potassium even though it was within the normal range prior to PMT and in few cases, this would mean performing dialysis through a new HDC.

A key question is whether we need to delay the PMT depending on the potassium level. More data including larger studies are necessary to make firm conclusions, but the rise in potassium we noted following the procedures in our patients would suggest that the threshold for instituting potassium lowering measures prior to PMT could be raised without necessarily causing severe or life threatening hyperkalaemia following the procedure.

How do we optimise outcomes in AKI?

Submission: 261

Associations between sex and acute kidney injury, kidney replacement therapy, and death amongst patients with advanced chronic kidney disease

Msc graduate Takahiro Tsuji[1], Clinical Lecturer Barnaby Hole[2,3,4], PhD Anna Casula[3,4], Professor of clinical epidemiology Laurie Tomlinson[1], Professor of clinical epidemiology Dorothea Nitsch[1,5,3,4]

[1]London School of Hygiene and Tropical Medicine, London.
[2]University of Bristol, Bristol, Bristol.
[3]UK Renal Registry, Bristol.
[4]UK Kidney Association, Bristol.
[5]Royal Free London NHS Foundation Trust, London

Introduction**:** The association between sex and chronic kidney disease (CKD) progression has been observed, but the reasons are incompletely understood. Understanding these mechanisms will enable development of improved clinical and public health practices. Acute kidney injury (AKI) might contribute to sex differences in CKD progression. Our objectives were to examine if there are sex differences in the incidence of AKI, initiation of kidney replacement therapy (KRT), or death by all causes in UK Renal Registry (UKRR), and to examine if there is an interaction between sex and AKI which explains why more men start dialysis than women.

Methods**:** Our study was historical cohort design based on UKRR secondary data. The follow-up period was from 1st January 2018 to 31st December 2019. The study population was adult prevalent CKD stage 4/5 patients registered in 14 nephrology care centres at end of December 2017. The exposure was sex (females versus males) and we measured time to AKI stage 3, initiation of chronic KRT, and all-cause mortality as outcomes. Crude and adjusted hazard ratio of sex with the survival time to AKI, KRT start, and death were calculated using the Cox proportional hazard model. Interaction between sex and AKI with KRT initiation was also examined.

Results**:** 6,811 females and 8,740 males were included with an average follow-up of 1.74 person-years. Average age was 70.3 years and mean eGFR was 19.8mL/min/1.73sqm. During follow-up, 2,627 (16.9%) stage 3 AKI, 3,001 (19.3%) initiation of KRT, and 5,738 (36.9%) deaths were observed. Males had an increased risk of AKI stage 3 (adjusted HR=1.49, 95%CI: 1.37-1.61), initiation of chronic-KRT (adjusted HR=1.33, 95%CI: 1.24-1.43), and death (adjusted HR=1.23, 95%CI: 1.17-1.30) than females. No interaction between sex and AKI with KRT initiation was observed.

Discussion**:** Male sex was strongly associated with the risk of stage 3 AKI events, initiation of chronic KRT, and all-cause mortality in nephrology care patients in the UK, but we did not find that severe AKI fully explains why there are more men starting KRT when compared to women. Future analysis will explore the impact of comorbidity and hospitalisations using linked Hospital Episode Statistics (HES).


Crude Cumulative incidence of AKI, KRT, and death
AKI stage 3
KRT
Death
Log-Rank p<0.001
Female (n=6,811)
Male (n=8,740)
Cumulative Incidence of AKI stage 3
Cumulative Incidence of KRT
Cumulative Incidence of death
0%
10%
20%
30%
40%
0
200
400
600
800
Days of Follow-Up

How do we optimise outcomes in AKI?

Submission: 183

Comparison of eGFR cystatin C and eGFR creatinine in recently hospitalised individuals

Dr Kerry Horne[1,2], Mrs Rebecca Packington[2], Dr Daniela Viramontes-Horner[1], Dr John Monaghan[2], Dr Sue Shaw[2], Ms Aleli Akani[2], Mr Timothy Reilly[2], Professor Maarten Taal[1,2], Professor Nick Selby[1,2]

[1]University of Nottingham, Nottingham.
[2]University Hospitals of Derby and Burton NHS Foundation Trust, Derby

Introduction: Creatinine and cystatin C are endogenous biomarkers that can be used to estimate GFR. Cystatin C may be less dependent on age, gender and muscle mass. The comparative performance of these markers in patients recently hospitalised patients with acute kidney injury (AKI), who may have experienced changes in body composition, is unclear.

Methods: Two matched cohorts of hospitalised individuals who had survived to 90 days after admission were recruited. The cohorts consisted of people who had sustained AKI during hospital admission and those who had not, and were matched 1:1 for age, baseline eGFR stage and diabetes. Serum creatine and serum cystatin C were measured at 3 months after hospitalisation and eGFR calculated using CKD EPI creatinine (eGFRcr) and CKD EPI cystatin C (eGFRcys) equations. Difference between the measures (eGFRdiff) was calculated as eGFRcys-eGFRcr and percentage difference (eGFR%diff) was relative to the mean of both eGFR measures. Primary outcome was mortality after 5 years of prospective follow up.

Results: 854 individuals were recruited, matched, and had paired creatinine and cystatin C measurements. 427 (50%) had sustained AKI. Median eGFRcys was lower than eGFRcr (53.5ml/min/1.73m^2 [34.4-85.4] vs 68.4ml/min/1.73m^2 [52.6-84.7], p<0.001). eGFRcys and eGFRcr were correlated (r=0.486, p<0.001) but Bland Altman analysis showed variable bias across the eGFR range. More individuals had an eGFR<60ml/min/1.73m^2 using eGFRcys (57%) compared with eGFRcr (35.6%). There was a graded relationship between eGFR%diff and outcome, with a shorter survival time (Figure 1) and a higher proportion of deaths at 5 years (Q1 64 (30.0%), Q2 54 (25.4%), Q3 41 (19.2%), Q4 (31 (14.6%), p<0.001) in the first quartile. Cox proportional hazards analysis showed that eGFR%diff was an independent predictor of 5-year mortality after adjustment for age, Charlson index score and albuminuria (adjusted OR 0.995 [0.992-0.998], p=0.002).

Conclusion: Cystatin C eGFR measures were lower than creatinine eGFR measures in recently hospitalised individuals. Lower eGFRcys relative to eGFRcr was independently associated with increased mortality. A larger difference between eGFRcys and eGFRcr may reflect loss of muscle mass (resulting in relatively lower serum creatinine) in somebody who has recently had an acute illness. Further, these results confirm how eGFRcr may over-estimate kidney function and potentially miss patients with failed renal recovery at 3-months after AKI. The difference between eGFRcys and eGFRcr may be helpful in identifying people at greater risk of early mortality after an acute illness.

Figure1: Kaplan-Meier curve showing 5-year survival, by eGFR%diff quartile.

Median survival times (days): Q1 1544.8 (1477.1-1612.4), Q2 1596.8 (1535.3-1658.4), Q3 1673.2 (1658.4-1748.8), Q4 1703.6 (1658.4-1748.8), Log rank 17.729, p<0.001.


Survival
Cum Survival
1.0
0.9
0.8
0.7
0.6
0.5
0
500
1000
1500
2000
Time (days)
eGFR%diff quartile
1
2
3
4
1-censored
2-censored
3-censored
4-censored

Frailty, function, falls

Submission: 219

People coded with delirium are overrepresented in people in hospital with acute kidney injury – A UK Renal Registry (UKRR) cross-sectional study

Dr Anna Casula[1], Professor Daniel Davis[2], Professor Charlotte Warren-Gash[3], Professor Dorothea Nitsch[3,1]

[1]UKRR, Bristol.
[2]University College London, London.
[3]LSHTM, London

Introduction: Delirium is an acute confusional state with disturbances in attention, and disorientation usually during acute illness. Delirium is at least partially preventable; its risk factors correspond to those of acute kidney injury (AKI). We set out to investigate the prevalence of hospital-coded delirium in AKI patients, and subsequent length of stay (LOS), 30-day mortality, and readmission within 3 months after discharge.

Methods: The UKRR collates the mandated Patient Safety AKI-alerts reported by English laboratories in the Master Patient Index (MPI). After excluding people aged<18 years, the AKI-MPI for 2019 was linked to Hospital Episode Statistics data (HES) to identify a population of hospitalised patients for whom an AKI alert was sent to the UKRR from day of admission onwards.

People with delirium were identified using a list of HES codes provided by the DELPHIC (Delirium and Population Health Informatics Cohort) during the same hospital admission, allowing us to calculate the prevalence of coded delirium by demographic factors and AKI severity, and subsequent LOS, 30-day mortality, and readmission within 3 months after discharge, with logistic regression analyses for key findings.

Results: There were 306,096 hospitalised patients in 2019 in England who had an AKI alert issued, with 16.0% coded to have delirium during the index admission, with comparable distribution for men(16.0%) and women(15.9%), increasing prevalence with age and AKI severity, and an inverse relationship with deprivation status. After adjusting for age and peak AKI severity, 30-day mortality was increased amongst people with delirium compared to others with AKI (OR 1.23 (95%CI: 1.20-1.26)). There was an approximate doubling of LOS from 9 days median time in those without delirium to 19 days amongst those with delirium. Within the subsequent 90 days after AKI, 22.6% without delirium and 36.2% with delirium died; amongst the survivors, 39% and 47% had been readmitted, with an age and peak-AKI severity adjusted OR of 90-day readmissions of 1.23 (95%CI: 1.20, 1.26)).

Conclusion: Delirium is a common co-morbidity in hospitalised patients with AKI which impacts considerably on LOS and mortality. Approximately half of the population of AKI survivors with delirium will have been readmitted within 90 days. Addressing delirium should be a key target for quality improvement initiatives amongst people with AKI.

Table 1. Number and percentage of people with HES diagnoses compatible with delirium amongst people with AKI alerts in 2019 stratified by age, AKI severity and corresponding length of stay.

	Numbers and prevalence			Length of stay (LOS), median IQR	
	Delirium			Delirium	
	without	with	prevalence, %	without	with
Total	257,188	48,908	16.0	9 (5-19)	19 (10-33)
Age group, years					
18-49	36,248	1,832	4.8	6 (3-12)	19 (8.5-36)
50-59	26,088	2,269	8.0	8 (4-18)	20 (10-38)
60-69	41,490	4,645	10.1	9 (5-18)	19 (10-36)
70-79	64,848	11,378	14.9	10 (5-19)	19 (10-35)
80-89	65,698	19,246	22.7	11 (6-21)	19 (10-33)
90+	22,816	9,538	29.5	12 (6-22)	18 (10-30)
Peak AKI severity					
1	172,900	30,942	15.2	9 (4-18)	18 (10-33)
2	49,348	10,439	17.5	10 (5-20)	19 (10-33)
3	34,940	7,527	17.7	11 (6-21)	19 (10-34)

Frailty, function, falls

Submission: 362

Implementing the Serious Illness Care Programme (SICP) within outpatient haemodialysis units: a feasibility study

Dr Hannah Sammut[1], Dr Anirudh Rao[1,2], Dr Asheesh Sharma[1], Ms Tamsin Mc Glinchey[1], Dr Stephen Mason[2]

[1]Liverpool University Foundation Hospital Trust, Liverpool.
[2]University of Liverpool, Liverpool

Introduction: End-stage renal failure affects a frail, elderly, and multimorbid population with high physical and psychological symptoms. Care should integrate core palliative care principles to thoroughly address and support patients' needs.

The Serious Illness Care programme (SICP) is a multi-component intervention that promotes meaningful conversations between clinician and patient. The intervention identifies what matters most to the patient, their goals and priorities, how this aligns with their treatment and care.

The SICP was implemented in two dialysis units in the North of England, we report on the outcomes and learning from this process.

Methods: Using a modified cohort design, we applied the principles and tools of the programme within a renal unit in the North of England. We selected two outpatient dialysis units, Unit A (with a population of 43 patients) and Unit B (with 150 patients). An MDT approach was employed to develop a process specific to each unit (figure 1).

Figure 1



*supported by written information. ** Confirmed with patient if they would like a family member or carer present during the conversation. *** Conversation supported with written guide and patient offered an information leaflet to support discussion with family and carers, **** Flexibility in appointment times within the 43 bed unit was created by adjustments in the consultant timetable..

Clinician training was complemented with mentoring and education of nursing and administration teams. Outcome data collected from August 2019 to February 2022. Outcomes recorded were the number of patients offered a conversation, accepted or declined, the timing of the conversation and follow-up. We applied structured reflection on elements that facilitated participation in the SICP.

Results : Table 1 Describes the participation in the units.

	Unit A N=43	Unit B N=150
Approached N (%)	23	11
Agreed N (%)	16 (70)	4 (36)
Declined N (%)	7 (30)	2 (18)
Conversations occured N (%)	15 (65)	2 (18)

Of the conversations that happened, 10 patients preferred to have the conversation on their own, and 7 patients chose to have a family or carer present. In 17 (100%) patients, the conversation led to a 'statement of wishes' about their health. In 5 (29%) patients, there was a conversation regarding resuscitation decisions in the event of a cardiopulmonary arrest (DNACPR). Three (17%) patients accepted a 'Planning your future care Guide', to help them think about advance care planning conversations in the future. Three (17%) accepted a 'talking to your family and friend's leaflet' to help guide conversations with family.

Structured reflection identified two elements that facilitated participation in the SICP were;

1. Regular focused review of the holistic needs of patients as an MDT, which included the consultant and nursing team
2. Creating flexibility in appointment time for conversations to happen

Over this period, 18 (53%) of the 34 patients offered the conversation died.

Conclusion: This study demonstrates that the SICP can be successfully implemented within a dialysis unit. It is essential to recognise that some patients want to talk about the future of their illness, whilst some prefer not to. Understanding the person-centred illness and environmental factors that enable patients to engage in these 'future care planning' conversations is important for this intervention's progression. For example, the majority within our small sample wanted to have this conversation independently.

We continue to adapt our approach to ensure personalised, holistic care across our dialysis units to enable patients to live as fully as possible with serious illnesses.

Health equalities in research & in practice: Why & how?

Submission: 262

Taking a Core20Plus5 approach: assessing equity across the renal care pathway in the London Kidney Network

Ms Catherine Croucher[1,2], Dr Kate Bramham[3,2], Dr Gavin Dreyer[4,2], Ms Deepa Kariyawasam[5,2]

[1]NHS England, London.
[2]London Kidney Network, London.
[3]Kings College London, London.
[4]Barts Health Kidney Department, London.
[5]King's College Hospital NHS Foundation Trust, London

Background: NHS planning guidance mandates local systems to narrow health inequalities and to take a quality improvement approach to addressing health inequalities, reflecting the Core20PLUS5 approach.

The core purpose of the London Kidney Network (LKN) is to define the optimal pathway; highlight variation; develop strategy and support delivery of improvement. Improving health equity is a core theme running through all the quality improvement programmes, driven by a dedicated Health Equity Group.

In 2022, an equity audit of renal care across London was conducted to prioritise change ideas and identify actionable insights. Our aim was to describe the “Core20” population (i.e., the most deprived 20% of the population), a metric intended to encompass the impact of deprivation on access, experience and outcomes.

Methods: We assessed equity along the whole patient care pathway, using three aggregate data sets; CVD-Prevent, the Secondary User Service and the UK Renal Registry, covering the period 2017-2019 and including 160 thousand nephrology outpatient appointments and 5 thousand RRT incident patients.

To reflect the range of ways patients access renal care, more than twenty different dependent variables were analysed, including Did Not Attend (DNA) rates in Nephrology outpatients, late presentation to specialised care (<90 days between being first seen and starting Renal Replacement Therapy (RRT)), peritoneal dialysis (PD) incidence and transplant at two years after starting RRT.

We used socio-economic status as an explanatory variable, via the Index of Multiple Deprivation (IMD) 2019 quintiles.

We calculated the proportion of patients who experienced each metric for each IMD quintile, plus 95% confidence intervals. If necessary, we adjusted for age using indirect standardisation or simple stratification.

Key Results: The audit found that people from Core20 areas have a higher DNA rate for Nephrology outpatient appointments compared to those from the least deprived areas (13% V 7%, p=<0.001). They are less likely to have had a kidney transplant by two years (19% V 36%, p=<0.001). Younger

adults (<45 years) from Core20 areas are also more likely to present late to renal services (29% v 20%, p=<0.05). We did not find a significant difference for PD incidence (24% v 25%, p=1.07).

Implications: There is substantial inequity in renal health care provision for people from Core20 in London.

Local systems are expected to understand the healthcare needs of their 'Core20PLUS' population, in order to make informed decisions about ensuring equitable access, experience and outcomes. The LKN equity audit is the first of its kind to establish a baseline understanding of inequity in renal care across London. Using the equity baseline results, the LKN subsequently held a consensus event where a range of stakeholders prioritised recommended actions to improve equity along the renal care pathway.

The data and prioritisation exercise have set the direction for taking a "Core20plus5" approach in future quality improvement programmes and will enable re-assessment of health equity in kidney care prospectively. The LKN has set an ambition that quality improvement initiatives within the network monitor outcomes for the "Core20" population in addition to the patient population as a whole.

Health equalities in research & in practice: Why & how?

Submission: 330

Patient education in hard to reach communities

Dr Bnar Talabani

Cardiff University, Cardiff

In January 2021, evidence was published of low uptake of the Covid-19 vaccines in Black and Minority Ethnic (BAME) communities. Colleagues and I joined forces to launch a campaign to combat misinformation among these communities communicate evidence based information in an engaging way to facilitate informed decision making. We organised and delivered over 50 webinars, in over 6 different languages. Here we invited faith and well known community figures to participate as panelists, asking questions of health professionals. These sessions were live streamed and well attended and were also recorded and shared on social media pages. We were subsequently invited to participate in webinars with Public Health Wales and Welsh Government. We also created regular social media content, in several languages. We also set up mosques and other community hubs as vaccination centres, which allowed improved vaccination rates among hard to reach communities, including large numbers of homeless people. This work highlighted the importance of trusted voices, trusted spaces and continuity in delivering health education. We have collaborated with several different groups to ensure our educational tools are far reaching. For example, we collaborated with the UK Black Pharmacists Association to deliver a series of lectures.

We have subsequently expanded to deliver other health education campaigns including mental health workshops and screening workshops.

This year we have partnered up with NHS Blood and Transplant to launch a UK wide social media campaign on organ donation in ethnic minority communities. We will be releasing videos on social media from healthcare professionals, patients and faith leaders addressing common themes around organ donation. We will launch this campaign on the 9th of March on World Kidney Day and will release content, in different languages, weekly, for the rest of this year.

Moving on Up Together: The joys and tribulations of working with young adults

Submission: 313

Associations between change in kidney replacement therapy modality and psychosocial health: a five year follow up of the SPEAK study

Dr Mohammed Al-Talib[1,2], Professor Fergus Caskey[1,2], Dr Carol Inward[3], Professor Yoav Ben-Shlomo[1], Dr Alexander Hamilton[1,4]

[1]University of Bristol, Bristol.
[2]North Bristol NHS Trust, Bristol.
[3]Bristol Royal Hospital for Children, Bristol.
[4]Royal Devon and Exeter NHS Trust, Exeter

The psychosocial impact of kidney failure in young adulthood is implicated in the observed high risk for transplant loss and death. The Surveying People Experiencing young Adult Kidney failure (SPEAK) study found that receiving dialysis, compared to having a transplant, was associated with poorer wellbeing and medication adherence. There have been no longitudinal studies investigating the natural history of psychosocial health outcomes as young adults mature and get older. In SPEAK-2, a five-year follow-up of the SPEAK study, we sought to characterise the psychosocial impact of changes in kidney replacement therapy (KRT) modality.

Respondents to SPEAK were invited to complete a revised online survey. Respondents self-reported their current KRT modality. We used regression to analyse the relationship between change in KRT modality and psychosocial health outcomes. Participants were stratified into four groups depending on how their KRT modality had changed between studies: 1) remained with transplant; 2) moved from dialysis to transplant; 3) moved from transplant to dialysis and; 4) remained with dialysis. In addition to crude models, we developed models adjusted for the outcome measure of interest at baseline.

Data regarding change in modality between studies was available for 142 respondents. Due to small numbers, responses were stratified further into two groups to produce a binary exposure variable: 1) remained with transplant or moved from dialysis to transplant (n =125; 88%) and; 2) remained on dialysis or moved from transplant to dialysis (n=17; 12%).

In the unadjusted analyses, living with a transplant was associated with better psychosocial health outcomes across most domains measured (table 1). However, when adjusting for baseline responses, these associations were almost entirely lost. The exception was with independence with activities of daily living (iADLs), for which living with a transplant was associated with greater odds or being fully independent (OR, 13.87; 95% CI 1.47 – 131.02; P=0.02).

Outcome	Crude			Adjusted		
	β/OR	95% CI	P	β/OR	95% CI	P
iADL scale	12.88	2.82-58.86	0.001	13.87	1.47-131.02	0.02
EuroQoL-5D-3L	0.43	0.27-0.59	<0.001	0.1	-0.04-0.24	0.16

GHQ-12 score ≥4/12	0.28	0.08-0.95	0.04	0.34	0.08-1.52	0.16
WEMWBS	8.18	2.27-14.10	0.01	2.39	-2.57-7.34	0.34

In the first longitudinal study of the psychosocial health of a cohort of young adults with kidney failure as they age and mature, we found that dialysis treatment was associated with consistently worse psychosocial health outcomes. However, this effect was largely lost when controlling for the baseline outcome of interest. This suggests that, among this cohort, psychosocial health early in life strongly determines psychosocial health later: pointing to a longlasting negative legacy of kidney failure in early life that is most pronounced among those receiving dialysis. The exception was with iADL, for which respondents living with a transplant were significantly more likely to be fully independent: a finding that may be explained by those receiving dialysis accruing comorbidity. Our findings highlight the importance of minimising exposure to dialysis in young people who reach end stage kidney disease, and, in those who receive a transplant, strengthen efforts to prolong the lifespan of the graft.

Moving on Up Together: The joys and tribulations of working with young adults

Submission: 376

Outcomes following transition from paediatric to adult transplant unit – revisiting 20 years on

Dr Farida Hussain, Dr Charlotte Bebb, Dr Catherine Byrne, Mr Alun Williams

Nottingham University Hospitals, Nottingham

Introduction: In 2000, Watson first reported results from a single paediatric transplant centre about the significant number of unexpected graft losses amongst patients within the first 36 months of transfer from paediatric to adult transplant unit. Since this time numerous steps, including multi-disciplinary (MDT) discussion, regular joint transition clinics and appointments of both youth workers and young adult workers, have been put in place to smooth the transition process and hopefully improve the patient journey. The aim of this study was to re-visit the number of graft losses, in the same centre, following their introduction.

Methods: All patients who attended a joint transplant transition clinic to a single adult centre, between 2016 to 2022, had their notes reviewed and plasma creatinine levels plotted from 12 months prior to 12 months post-transfer. For those patients whose grafts were lost, histology of biopsies were looked at, as were any mitigating social factors.

Results: A total of 17 patients transferred between 2016 and 2022, with a mean age of 18.6 (range 16.4-19.8yrs). In the 12 months post transfer, 3 patients went onto lose their grafts. Of these 3, none were unexpected losses; one had been treated with ATG for significant T-cell rejection, one had received treatment for antibody mediated rejection, and one was already demonstrating significant worsening of graft function prior to transfer which was secondary to acute kidney injury associated with a cardiac arrest 2 years previously.

Discussion: In the 20 years since Watson's seminal paper first highlighted the problem of graft loss during transition from paediatrics to adult units, where 8 out of 20 transplants failed within 36 months of transfer, of which 7 were unexpected, a number of changes have been made to our practice.

- 'Ready, Steady, Go' is introduced from the age of 12 onwards, to prompt discussion about preparing for the move to adults.
- Teenagers are seen in clinic on their own initially before parents/guardians join them, in order to get used to speaking for themselves and being more actively involved in discussion.
- As a team we hold twice yearly meetings to discuss all patients from the age of 15 upwards. This is attended by adult and paediatric consultants, nurse specialists, youth workers, young adult workers and psychologists, and this is then followed by twice yearly joint transition clinics, which are also attended by the MDT.
- Each patient is reviewed at least twice in the joint clinic prior to transfer to adult services.
- The young adult worker then completes the 'Hello' paperwork to complete this process, and also provides ongoing support to the young person as needed up until the age of 30.

The positive benefits of these interventions are shown in our data, in that there have been no unexpected graft losses in the year following transfer for the last 5 years. Our aim is now to further

improve our support and services for this challenging time period of the patient journey and to hopefully improve long term patient outcomes and transplant longevity.

Improving diabetes care for people on dialysis - Moving from guideline recommendations to implementing change

Submission: 255

Compliance of diabetic monitoring in patients with end-stage kidney disease on maintenance haemodialysis.

Dr Alwyn Yung Zhuang Choo[1,2], Dr Thatoe Aung[3,2], Dr Vivian Yiu[2]

[1]Norfolk and Norwich University Hospital, Norwich.
[2]West Suffolk Hospital, Bury St Edmunds.
[3]Eastbourne District General Hospital, Eastbourne

Introduction**:** Diabetic nephropathy is a major cause of end-stage kidney disease (ESKD) in the UK, accounting for nearly 30% of patients requiring dialysis and in some units over 40% of the people on dialysis have diabetes. GIRFT had highlighted the disjointed and variable care received by these patients, with increasing risk of complications including blindness, foot ulcers and amputations from suboptimal care. Increased monitoring is shown to be cost-effective and multi-disciplinary co-ordination can reduce complications of diabetes especially rates of lower limb amputations.

Methods**:** We performed a cross-sectional review on patients with diabetes on haemodialysis in the satellite unit at a district general hospital to assess compliance with the Joint British Diabetes Societies and the Renal Association UK recommendations on management of adults with diabetes. Subsequently we introduced protocols and template sheets, liaised with clinical staff and administrators to implement changes in monitoring, aiming to achieve satisfactory compliance with recommendations on management and monitoring.

Results**:** We reviewed data from January to April 2021 followed by re-evaluation 12 months later after implementation of changes. Data for 25 patients were reviewed and re-assessed after a year. 7 patients passed away during this period.

Initial review recognised the lack of awareness of good practice management of diabetic patients in the haemodialysis unit. Most patients have type 2 diabetes which carries a higher risk of ESKD. After a year of change in protocols there were significant improvements in monitoring parameters, with greatest improvements seen in glucose monitoring and routine feet inspections.





Discussion**:** The review was based on care standards that included diabetes parameters as part of the recommended nine care processes, and individualised treatment approach. The aims were annual reviews especially the feet, adequate glucose monitoring and rational glycaemic targets and involvement of diabetes specialist team.

The implementations included simple engagement with the haemodialysis team on importance of glucose and HbA1c monitoring, routine feet inspections, and re-emphasising the importance of adequate documentation to allied healthcare teams.

There was improvement in most of the monitoring parameters and clearer documentations from allied healthcare teams. Implementation of recommendations was initially challenging due to the COVID-19 pandemic and staff workload on the unit however with persistence we were able to obtain co-operation from the team.

As expected, patients on insulin/sulphonylureas (SUs) had proper blood glucose monitoring methods. Most were on insulin, and the remaining were on SU and DPP-IV inhibitor, and those with HbA1c <58 mmol/mol declined. One-third of these patients used flash glucose monitoring and with increasing recognition and recommendation by the NHS hopefully more will benefit from this.

This audit showed that simple interventions such as staff engagement and education can improve care and monitoring of patients in this population. With recovery of service provisions post-pandemic, more interventions can be put in place. Following this, we can reaudit amputation rates, gather patient feedback, and together with GP trainees, community and nursing teams, plan interventions and spread awareness to deliver better care to this complex group of patients.

Improving diabetes care for people on dialysis - Moving from guideline recommendations to implementing change

Submission: 206

Correlation between cardiac autonomic neuropathy and progressive decline in renal function in patients with type 1 diabetes mellitus: A 15 year follow up study

Dr Kywe Kywe Soe[1,2], Dr Emma Robinson[3], Dr Misbah Oleolo[1], Professor Simon Heller[1], Professor Solomon Tesfaye[2], Associate Professor Jefferson Marques[4], Professor Steven Sourbron[1], Dr Dinesh Selvarajah[1]

[1]The University of Sheffield, Sheffield.
[2]Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield.
[3]Royal Derby Hospital, Derby.
[4]Federal Universisty of Santa Catarina, Santa Catarina

Introduction**:** Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) and end stage renal failure (ESRF) worldwide with a third of patients with diabetes developing kidney disease over the course of their lifetime. Impairment of autonomic function is widespread among diabetic population, especially among those suffering from diabetes-associated complications. Cardiac autonomic dysfunction may play a role in the pathogenesis of diabetic nephropathy through a relative increase in sympathetic tone, leading to proteinuria, nocturnal hypertension and declining renal function.

Aims**:** To examine the relationship between cardiac autonomic neuropathy (CAN) and progressive renal decline in patients with type 1 diabetes.

Methods**:** 36 subjects with Type 1 diabetes mellitus (31 normoalbuminuria and 5 microalbuminuria) underwent assessment for CAN using cardiovascular reflex testing as per the O'Brien's criteria during baseline visits performed from 2007 to 2010. Cardiac autonomic neuropathy was defined as > 3/5 abnormal reflex tests. Progressive renal decline was defined as decline in eGFR of more than 3 ml/min/1.73 m2/yr and/or incident advancement in the stage of CKD from baseline stage. The baseline eGFR in 2007 ranges from 37 to 91 ml/min/1.73m2/yr. Association with baseline CAN was assessed by logistic regression adjusted for baseline urine ACR, HbA1c and ACEi/ARBs use. Additional sensitivity analysis was performed by adjusting for all variables in the model as well as retinopathy separately.

Results**:** Among the 36 subjects [18 female, mean age 53.4(12.8) years and duration of diabetes 34.6(10.9) years] 12(33.3%) had baseline CAN, 13(36.1%) had progressive decline in eGFR up to 15 years follow-up. Renal decline occurred in 7(58.3%) of the 12 patients with CAN and 6(25.0%) in the those without. Baseline CAN was strongly associated with odd of renal decline [adjusted odds ratio 31.6(95%CI 1.3:796.0); p=0.01]. Results did not substantially change after additionally adjusting for retinopathy.

Discussion**:** In this relatively small but carefully phenotyped study, cardiac autonomic neuropathy was a strong independent predictor of the long-term risk of renal function decline in Type 1 diabetes. Future larger studies are needed to confirm these findings and also to explore the mechanisms by which cardiac autonomic neuropathy leads to renal decline.

Home dialysis - current practice, patient voice. Challenges and future directions

Submission: 308

Intervening to eliminate the centre-effect variation in home dialysis use (Inter-CEPt): results from a survey of renal unit practice in relation to home dialysis organisation and delivery in England

Dr Sarah Damery[1], Professor Simon Davies[2], Dr Mark Lambie[3], Professor Iestyn Williams[1], Dr Ivonne Solis-Trapala[2], Dr Jessica Potts[2], Mr David Coyle[4], Dr James Fotheringham[5], Dr Kerry Allen[1]

[1]University of Birmingham, Birmingham.
[2]Keele University, Keele.
[3]University Hospitals North Midlands, Stoke-on-Trent.
[4]NIHR Devices for Dignity, Stoke.
[5]University of Sheffield, Sheffield

Introduction: Home dialysis uptake rates in England vary substantially, despite attempts to encourage greater use. UK Renal Registry (UKRR) data show that patients from ethnic minority backgrounds and those with lower socioeconomic status are under-represented amongst home dialysis users. The NIHR-funded Inter-CEPt study is using a mixed methods approach to understand the organisational and cultural factors that contribute to centre variation in home dialysis uptake, to identify potentially modifiable factors that could address this variation. One aspect of the study was a quantitative survey of English renal units to identify patterns in unit practice and organisation, and explore correlations with home therapy uptake rates.

Methods: Following literature review and ethnography in four high-performing renal units, a survey was developed and sent electronically to renal staff (clinical leads, unit managers, home therapies consultants and nurses, Advanced Kidney Care (AKC) clinic staff) at all English renal units. Surveys assessed renal unit practice in home dialysis service organisation/delivery, including pre-dialysis education, dialysis training, catheter/vascular access, clinical leadership, finance, commissioning and engagement with regional networks. Individual-level responses from staff at each unit were combined into a single unit-level response following pre-determined rules for data aggregation. Analysis was descriptive, describing unit practice and assessing pairwise correlations between practice and home therapy uptake rates using UKRR 2019 incidence data for home dialysis uptake at 12 months after renal replacement therapy initiation.

Results: 180 responses were received from 50/51 units (98.0%). Non-responder analysis showed no systematic difference in rates of home therapy uptake between responding and non-responding units for each question. Data showed substantial variation in unit practice in the organisation and delivery of pre-dialysis education (including family/carer involvement), unit support for dialysis modality choice, engagement with charities and community groups, use of peer support, catheter/vascular access provision, and support/advice offered to patients choosing home dialysis. However, no specific aspects of practice or service delivery correlated with home therapy uptake rates. In contrast, statistically significant correlations were found between home therapy uptake rates and renal units who reported strong clinical leadership (correlation co-efficient 0.32, 95%CI: 0.05 to 0.55), flexibility in dialysis decision-making processes (0.32, 95%CI: 0.04 to 0.56), and an organisational culture that values trying new initiatives (0.57, 95%CI: 0.34 to 0.73), supports learning

and reflective practice (0.38, 95%CI: 0.11 to 0.60), facilitates research engagement (0.39, 95%CI: 0.13 to 0.61) and promotes continuous quality improvement (0.29, 95%CI: 0.01 to 0.53).

Discussion: Home dialysis offers multiple service and patient benefits, yet renal unit variation in access to home therapies is a recognised contributor to kidney health inequalities in England. It is likely that positive unit engagement with home therapies is driven primarily by organisational culture, leadership and attitudes. These factors combine to provide a supportive clinical environment within which specific components of service organisation and delivery are more likely to be effective in facilitating home therapy uptake. As part of the Inter-CEPt study, these findings will be integrated into the development of an intervention bundle to improve home therapies uptake in the UK.

Home dialysis - current practice, patient voice. Challenges and future directions

Submission: 104

Efficacy and cardiovascular safety of daprodustat for the management of renal anemia in peritoneal dialysis patients: a pre-specified analysis of the ASCEND-D trial

Prof. Indranil Dasgupta[1,2], Mr Stephen Mallett[3], Dr Purav R. Bhatt[4], Dr Anjali Acharya[5], Dr Michael Aarup[6], Prof. Ricardo Correa-Rotter[7], Dr Shruti Gupta[8], Dr Vijay Kher[9], Dr Osvaldo Vieira Neto[10], Prof. Anjay Rastogi[11], Prof. Mai Ots-Rosenberg[12], Prof. Brian Rayner[13], Prof. Muh Geot Wong[14], Prof. Ajay K. Singh[15,8]

[1]University Hospitals of Birmingham NHS Foundation Trust, Birmingham.
[2]Warwick Medical School, University of Warwick, West Midlands.
[3]GSK, Brentford.
[4]GSK, Collegeville.
[5]Albert Einstein College of Medicine, NYC.
[6]Odense University Hospital, Odense.
[7]Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City.
[8]Brigham and Women's Hospital, Boston.
[9]Medanta Kidney and Urology Institute, Medanta Hospital, South Delhi.
[10]Sociedade Brasileira de Nefrologia, São Paulo.
[11]David Geffen School of Medicine UCLA, California.
[12]Tartu University Hospital, Tartu.
[13]Groote Schuur Hospital and University of Cape Town, Cape Town.
[14]University of Sydney, Sydney.
[15]Harvard Medical School, Boston

Introduction**:** Daprodustat (Dapro), an oral investigational hypoxia-inducible factor prolyl hydroxylase inhibitor, has been shown to be noninferior to conventional erythropoietin-stimulating agents in renal anaemia treatment of dialysis and non-dialysis patients (pts). This pre-specified subgroup analysis of the ASCEND-D trial examined the efficacy and cardiovascular (CV) safety of Dapro vs darbepoetin-alfa (Darbe) in end-stage kidney disease (ESKD) pts receiving peritoneal dialysis (PD).

Methods**:** ASCEND-D (NCT02879305) was an open-label, phase 3 trial in ESKD pts on dialysis with screening haemoglobin (Hb) 8.0–11.5g/dL, randomised to Dapro or Darbe. Primary outcomes were mean Hb change from baseline to wks 28 through 52 (noninferiority [NI] margin -0.75g/dL) and first occurrence of a major adverse CV event (MACE: a composite of death from any cause, nonfatal myocardial infarction [MI], or nonfatal stroke [NI margin 1.25]). Mean Hb change was analysed via an analysis of covariance model adjusting for baseline Hb, treatment, dialysis modality, and geographic region. MACE was analysed via a Cox proportional-hazards model adjusting for treatment, dialysis modality, and geographic region.

Results**:** Overall, 340 PD pts (Dapro n=171; Darbe n=169) were randomised (baseline [Dapro/Darbe]: mean age 54/53 years; % male 56/54; % dialysis vintage >5 years 18/22; Hb 10.25/10.23 g/dL; % stroke 5/5; and % MI 8/7). For Dapro and Darbe respectively, the mean change in Hb was 0.38 and

0.23g/dL (adjusted mean difference 0.15 95% confidence interval [CI] -0.04–0.34); a first occurrence of adjudicated MACE occurred in 40 (23.4%) and 46 (27.2%) pts (hazard ratio 0.84 95% CI 0.55–1.28) and the mean average monthly iron dose was 59.6g and 62.9g (adjusted mean difference -3.3 95% CI -30.7–24.0). There was no heterogeneity between PD and haemodialysis pts for these endpoints. Peritonitis rates were 26% (Dapro) and 22% (Darbe).

Discussion**:** This pre-specified sub-group analysis of the ASCEND-D trial demonstrates comparable efficacy and CV safety of Dapro vs Darbe in PD pts, supporting use of this novel oral agent in anaemic PD pts.

Encore statement: This abstract is an encore of abstract #TH-PO688 presented at the American Society of Nephrology (ASN) 2022 meeting (Orlando, FL, USA, and Virtual, 3–6 Nov 2022). The full citation is as follows: I Dasgupta, S Mallett, P Bhatt, A Acharya, M Aarup, R Correa-Rotter, S Gupta, V Kher, O Viera Neto, A Rastogi, M Ots-Rosenberg, B Rayner, MG Wong, AK Singh: Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial [Abstract]. J Am Soc Nephrol 33, 2022: 234.

Funding**:** This study was funded by GSK.

CKD & pregnancy in 2023 - updates in clinical practice

Submission: 334

Changes in serum creatinine during pregnancy and at delivery are predictive of adverse outcomes – early results from the AKID prospective cohort study

Dr Laura Skinner[1,2], Dr Christy Burden[1,2], Dr Alison Armitage[2], Dr Dominic Taylor[2,1]

[1]Univeristy of Bristol, Bristol.
[2]North Bristol NHS Trust, Bristol

Background: Acute kidney injury(AKI) is an independent risk factor for development of chronic kidney disease(CKD), kidney failure and cardiovascular(CV) and mortality.

Outside pregnancy, AKI is defined as a 50% or ≥26 µmol/L rise in serum creatinine of within 48hrs.6 Physiological changes in healthy pregnancy result in a fall in creatinine in the first trimester, with creatinine rising to pre-pregnancy levels peri-partum. Available reference ranges for creatinine in pregnancy are derived from small studies. Diagnostic criteria for pregnancy-related AKI (PR-AKI) are ill-defined, but its incidence appears to be increasing. Among inpatients, PR-AKI is associated with 13.5-fold higher mortality and 10-fold greater risk of CV events. A recent systematic review identified creatinine >77µmol/L in pregnancy as abnormal.

In initial results from this prospective cohort study, we describe changes in serum creatinine in pregnancy and the association between an increase in creatinine > 77 µmol/L and adverse pregnancy outcomes.

Methods: The Acute Kidney Injury and Late Diabetes in Pregnancy (AKID; IRAS ID 246444) was a prospective cohort study of pregnant individuals ≥16 years, without CKD or diabetes, receiving maternity care in our centre, between December 2019-October 2021. Charitable funding was received from the David Telling Trust. Serum creatinine measurements were recorded at booking, 28 weeks, 36 weeks, at birth and postpartum. Adverse pregnancy outcomes measured included gestational hypertension, pre-eclampsia, instrumental delivery, emergency caesarean section, antepartum haemorrhage, placenta praevia and neonatal ICU admission. Zou's modified Poisson regression was used to exam the association between creatinine values and pregnancy outcomes.

Results: 480 pregnant individuals were recruited. Mean serum creatinine was 52 (σ=7.5) µmol/L, 48 (σ=7.4) µmol/L, 51 (σ=10.2) µmol/L and 59 (σ=10.8) µmol/L at booking, 28 weeks, 36 weeks gestation and postpartum, respectively (Figure 1). In 9.2% of the cohort serum creatinine increased to >77µmol/L and this occurred most frequently at birth. A rise in creatinine ≥26 µmol/L occurred in 2.5% of women between 36 weeks and giving birth.



Figure 1 –The mean creatinine level throughout pregnancy. (Baseline = booking appointment).

Adverse outcomes occurred in 54.9%. Emergency caesarean section was the most frequently occurring, comprising 21.9% of all births. Emergency caesarean section was associated with an increase in creatinine at birth (RR 1.02, 1.01-1.03, P<0.001). Gestational hypertension occurred in 5.2% and was associated with an increase in creatinine at 36 weeks (RR 1.03, 95% CI 1.01-1.05, P<0.001). Pre-eclampsia occurred in 2.7%. Mean birthweight was 3427g and 6.1% of neonates required intensive care admission.

Discussion: This study is the largest of its kind to examine kidney function in pregnancy in the UK population. Higher than expected increases in creatinine at delivery in those with emergency c-section may represent AKI. On-going analyses will determine references ranges for creatinine in pregnancy, further examine the association between change in creatinine in pregnancy and adverse pregnancy outcomes and aim to propose a definition of PR-AKI. Improved understanding of kidney function in healthy pregnancy, will aid in the identification and diagnosis of AKI in pregnancy to ultimately improve outcomes.

CKD & pregnancy in 2023 - updates in clinical practice

Submission: 483

Prevalence of chronic kidney disease in pregnancy: a UK population study

Dr Elizabeth Ralston[1], Dr Yanzhong Wang[1], Mr Steve Childs[2], Professor Chris Farmer[2], Professor Ranjit Akolekar[3], Dr Kate Bramham[1]

[1]Kings College London, London.
[2]University of Kent, Kent.
[3]Medway Fetal and Obstetric Medicine Centre, Medway

Introduction: Women with chronic kidney disease (CKD) are at greater risk of adverse pregnancy outcomes. Historically CKD in has been proposed to affect 3% of all pregnancies (0.13% with 'moderate to severe' CKD) but is based on expert opinion and numbers affected are propose to rise due to the rise of maternal obesity and age and could impact on service planning. However, there are no accurate estimates of CKD prevalence in pregnancy. This study aimed to investigate how many pregnancies may be affected by CKD, according to disease severity, in a UK population cohort.

Methods: Routinely collected pregnancy data from three NHS Trust hospitals in Kent (UK) between 2010 and 2020 were extracted with Research Ethics Committee approval (19/LO/1242 and 18/SC/0158). Local laboratory and health care records were linked and used to identify women between 18 and 50 years of age with a confirmed eGFR measurement (Chronic Kidney Disease Epidemiology Collaboration 2009 without ethnicity correction) within two years prior to conception, and no current pregnancy recorded at the time of sampling. Baseline characteristics and prevalence of CKD at different stages were described.

Results: A total of 76, 755 pregnancies were recorded between 2010 and 2020, including 14,257/76,755 (18.6%) pregnancies with preconception eGFR (median eGFR 115 ml/min/1.73m2 (IQR 21)). There were 1,184/14,257 (8.3%) pregnancies with a preconception eGFR <90ml/min/1.73m^2, including eGFR between 60-89 ml/min/1.73m^2 (1170 /14,257, 8.2%). Only 12/14,257 (0.08%) of pregnancies had an eGFR 30-59 ml/min/1.73m^2 and two pregnancies (0.01%) had an eGFR between eGFR 15-29 ml/min/1.73m^2. There were no pregnancies in the cohort with an eGFR <15 ml/min/1.73m^2. The cohort was majority White ethnicity (12911/13790; 94%) with 6.4% (879/13790) from Black, Asian, Mixed and East Asian ethnicities. Women with pregnancies that were affected with CKD were significantly older at conception (27, SD 5.5, vs 30.8, SD 5.5, p <0.001) and had greater prevalence of chronic hypertension (8.6% vs 11.3%, p = 0.013). Considering the whole cohort, including those without kidney function testing, the proportion of pregnancies affected by CKD was low (1,185/76,755; 1.5%).

Discussion: This is the largest cohort reporting the prevalence of CKD including severity in pregnancies in the UK. Overall the total number of pregnancies affected by CKD was lower than previous estimates, especially for those with advanced disease. This finding may represent reduced fertility in women with CKD, individual decisions not to conceive, negative advice from clinicians or obstetric management at different centres not captured in this cohort. However, only 1 in 5 women prior to pregnancy had an eGFR and gestational changes in creatinine may mask identification of CKD in pregnancy. A further limitation includes only eGFR measurement prior to pregnancy was used thus women with temporary eGFR reduction may have been incorrectly included in the CKD cohort. Finally there were few women from ethnic minority groups who are disproportionately

affected by CKD. Further information regarding kidney function in women of reproductive age and at conception is needed to enable true estimated of CKD prevalence in obstetric care.

A quick trip down the tubule - learning from the physiology of the renal tubule

Submission: 239

Computational Identification of a Novel Furosemide Binding Site in Human Aquaporin 1

Dr Aled Lloyd, Dr Karl Austin-Muttitt, Dr Jonathan Mullins

Swansea University, Swansea

Introduction: Both bumetanide and furosemide have been shown in-vitro to bind to the cytoplasmic surface of animal AQP1 resulting in inhibition of water transport1,2. This is a finding of some interest as it has been conventionally believed that diuretic effects of these medications is due to the inhibition of the sodium/chloride cotransporter, although as furosemide is known to have anti-inflammatory effects and anti-asthmatic effects independently of its diuretic effects, efforts to fully understand the mode of action of these medications which have been extensively used for decades, continue.

Methods: Threading modelling using the I-TASSER server and suite was undertaken to obtain monomeric structures of human AQP1. After converting file formats using Open Babel, PLANTS software was used to establish the compound's most energetically favourable binding positions. Visual inspection of these structures using UCSF Chimera was then planned to establish which compounds were most likely to exhibit an interaction with the protein.

Results: The most energetically favourable conformation of furosemide binding to the cytoplasmic opening of the intrinsic pore of the AQP1 monomer is different to those previously published. One end of the furosemide molecule binds to a pocket on the cytoplasmic surface of the pore opening, the other protruding into the pore in cork like conformation. The sulphamoyl group forms hydrogen bonds with GLN88, ARG93 and ARG159 while the furan ring protrudes into the pore.

We were unable to reproduce the lid like conformation of Migliati and co-workers with respect to the binding of bumetanide2. The 10 most energetically favourable conformations identified in the docking simulation using PLANTS were all away from the pore.

Discussion: Using PLANTS and a model based entirely on human AQP1, we have identified a different orientation of furosemide binding to previously published models. Analysis of the binding site suggests furosemide could impede water flow through the protein by occluding the pore.

The findings with respect to the binding of bumetanide may be the result of limitations within our method, as a relatively wide radius of study was required to ensure that the entire cytoplasmic opening could be included in one simulation. If the binding of bumetanide to the cytoplasmic opening is significantly weaker than furosemide, as suggested by Migilati and colleagues2, this could account for the energetic favourability for Van der Waals interactions, pi stacking or hydrophobic interactions in the membranous region compared with hydrogen bonding at the pore opening.

Conclusion: We have identified a different binding conformation for the interaction between furosemide and AQP1.

1. Ozu, M., Dorr, R. A., Teresa Politi, M., Parisi, M. & Toriano, R. Water flux through human aquaporin 1: inhibition by intracellular furosemide and maximal response with high osmotic gradients. Eur. Biophys. J. EBJ 40, 737–746 (2011).

2. Migliati, E. et al. Inhibition of aquaporin-1 and aquaporin-4 water permeability by a derivative of the loop diuretic bumetanide acting at an internal pore-occluding binding site. Mol. Pharmacol. 76, 105–112 (2009).

A quick trip down the tubule - learning from the physiology of the renal tubule

Submission: 450

Single-nucleus RNA sequencing identifies sex-specific Proximal Tubular Cell differentiation pathways in the developing kidney

Dr Yueh-An Lu[1], Dr Tanya Smith[2,3], Dr Sumukh Deshpande[3], Dr Chia-Te Liao[1], Dr Bnar Talabani[3], Ms Rowan Kitchener[3], Ms Megan Leadley[3], Dr Robert Andrews[3], Dr Timothy Bowen[2,3], Professor Philip Taylor[4], Professor Donald Fraser[2,3]

[1]Division of Nephrology, Kidney Research Center, Linkou Chang Gung Memorial Hospital, Taipei.
[2]Wales Kidney Research Unit, School of Medicine, Cardiff.
[3]Division of Infection and Immunity, School of Medicine, Cardiff.
[4]Dementia Research Institute, Cardiff

Background: Renal proximal tubular cells (PTCs) are responsible for the reabsorption of glomerular filtrate and the excretion of waste products. In mammals, nephron number is fixed at or soon after birth, but the kidneys exhibit marked growth during childhood and early adulthood. Kidney growth is associated with several-fold increases in nephron length, originating primarily in profoundly increased tubular cell number. The cellular states exhibited by PTC's during dedifferentiation, proliferation, and reacquisition of a fully differentiated phenotype are not well characterised. This critical knowledge gap is likely to be of importance for PTC proliferation, physiological growth of the kidney, as well as in recovery from kidney injury. In addition, PTC's exhibit sex differences in propensity for recovery, but sex-specific differences in PTC phenotype are not well characterised. To address this, we performed sequential characterisation of kidney transcriptomes at the single cell level in male and female mouse kidneys.

Methods: Kidneys were harvested from naïve female and male mice at 1, 2, 4, and 12 weeks of age (n=2 per group, 16 mice in total). Libraries were prepared on the 10x platform, and single nuclear RNA sequencing (snRNAseq) was completed using the Illumina NextSeq 550 System. Genome mapping was carried out with high-performance computing and downstream bioinformatics analyses used Seurat.

Results: Unbiased clustering analysis was performed on 68,775 nuclei obtained from whole kidney. All expected cell types were identified in the primary analysis. High levels of proliferation were evident at early time points in some clusters (eg. Tubular cells) but were absent in others (eg. Podocytes). Proliferation was especially evident in Proximal Tubular Cells (PTC's) which are the most abundant cell type in the adult kidney. Uniquely when compared to other kidney cell types, PTC's demonstrated sex-specific expression profiles at 4 and 12 weeks. Mapping of PTC differentiation pathways using techniques including trajectory and RNA Velocity analyses delineated increasing PTC specialization and sex-specific phenotype specification. Trajectory analysis has identified the differentiation pathway for tubular cells. Ongoing work is focussed on ligand-receptor analysis, pathways underpinning stromal-epithelial interaction, and localisation studies employing fluorescence microscopy.

Discussion: For the first time, we have characterised the phenotypical subtypes of proximal tubular cells present in the growing kidney. We have discovered previously underappreciated heterogeneity in male phenotypes which may explain the poor outcome of kidney injury compared to female kidneys. Furthermore, we have identified proximal tubular cell differentiation pathways leading to

sex-specific tubular cell phenotypes. Our new appreciation of how male and female kidney cells differ may provide us with answers of why the female kidney is protected from injury. This insight may help us to develop ways to protect patients from kidney disease and more effectively treat them.

Late-breaking Abstracts

Submission: 494

Kidney Transplantation in Older People (KTOP) study – the frail waitlist candidate's experience.

Dr Amarpreet Thind[1,2], Dr David Wellsted[3], Dr Michelle Willicombe[1,2], Professor Edwina Brown[1,2]

[1]Imperial College London, London.
[2]Imperial College Healthcare NHS Trust, London.
[3]University of Hertfordshire, Herfordshire

Introduction: Older people with kidney failure (KF) are vulnerable to developing frailty, which impacts on clinical and experiential outcomes. As transplantation in older people increases, achieving a more detailed understanding of patient experiences is necessary for guiding appropriate treatment decision making.

The Kidney Transplantation in Older People (KTOP): impact of frailty on outcomes study is a single centre, longitudinal study of older people's experiences whilst awaiting and undergoing transplantation. This work presents the latest available data, specifically describing waitlist experiences.

Methods: From October 2019 to December 2022, all KF patients aged ≥60 being considered for transplantation were eligible for recruitment. Participants completed questionnaires assessing frailty (Edmonton Frail Scale, EFS) and quality of life (QoL) using Short Form-12 (v2) at recruitment, annually on the waitlist, and at 3 and 12 months following transplantation. Descriptive statistics, linear regression, and mixed effect models were used to describe observations and trajectories in frailty and QoL over time. The final transplant assessments will be completed by June 2023.

Results: 210 patients were recruited, 118 of whom were transplanted. At recruitment 63.4% (118) were identified as not frail, 19.4% (36) were vulnerable, and 17.2% (32) were frail. In patients remaining on the waitlist the majority maintained the same frailty status (62.9%), whilst 13.9% experienced an improvement and 22.2% experienced a decline. The mixed model prediction showed that EFS scores decreased slightly whilst on the waitlist (-0.01-point/month) (figure 1).

In relation to QoL, vulnerable and frail candidates reported lower SF-12 mental and physical component scores (MCS and PCS) compared with not frail candidates at all waitlist visits (figure 2). The PCS prediction suggested a slight improvement in not frail patients over time (0.06-point increase/month), but a decline in PCS in the vulnerable/frail patients (coefficient -0.13 points/month) (figure 3). MCS remained stable over time in not frail patients (0.04-point increase/month) and improved in vulnerable/frail patients (coefficient 0.05 points/month) (figure 4).

There was no difference in the likelihood of being transplanted by frailty status (52.5% of not frail vs. 50% of vulnerable/frail). Waitlist mortality and likelihood of suspension was also not significantly different between not frail and vulnerable/frail patients. Vulnerable/frail patients were however more likely to experience a major infection episode (60% vulnerable/frail c.f. 24.4% in not frail, p=0.001), and spend longer suspended (mean total time suspended 434 days vulnerable/frail and 307 days not frail patients, p=0.0246).

Discussion: Frailty appears to remain stable in most older candidates on the waitlist. Frail/vulnerable patients report poorer QoL compared with not frail patients. Over time however, they exhibit some improvement in mental function, whilst physical function declines. Clinical outcomes also vary with increased risk of a major infection episode and longer waitlist suspension in frail/vulnerable candidates, but no difference in mortality, likelihood of transplantation or a suspension episode.

Conclusion: These findings demonstrate that frailty has a varied impact on older candidates whilst on the waitlist. Developing a holistic understanding is necessary for counselling and supporting older people navigating transplantation. On completion, the KTOP study will add more detail to this area by also describing experiences after transplantation.

Figure 1. Predicted change in Edmonton Frail Scale score over time on the waitlist.



EFS – Edmonton Frail Scale. Prediction based on adjustment for age group, Nottingham Extended Activities of Daily Living score, presence of diabetes, peripheral vascular disease, ethnicity, and depression level.

Figure 2. Distribution of Short Form-12 (V2) scores by frailty status at waitlist visits



PCS – physical component score, MFCS – mental component scores. *Difference in scores reached statistical significance between not frail and vulnerable, and not frail and frail participants ($p < 0.05$). **Difference in scores reached statistical significance only between the not frail and frail participants ($p < 0.05$).

Figure 3. Predicted change in Short Form-12 (V2) Physical Component Score over time on the waitlist by frailty status.



SF-12 – Short Form -12 (V2), PCS – physical component score. Prediction based on adjustment for age group, Nottingham Extended Activities of Daily Living score, presence of diabetes, Charlson Comorbidity Index score, SF-12 mental component score, and Palliative Care Outcome Scale – Symptoms Renal score.

Figure 4. Predicted change in Short Form-12 (V2) Mental Component Score over time on the waitlist by frailty status.



SF-12 – Short Form-12 (V2), MCS – mental component score. Prediction based on adjustment Nottingham Extended Activities of Daily Living score, Charlson Comorbidity Index score, Palliative Care Outcome Scale – Symptoms Renal score, Patient Health Questionnaire-9 score, and kidney replacement therapy vintage.

Late-breaking Abstracts

Submission: 638

Effect of a digital self-management programme (My Kidneys & Me) on patient activation and self-management behaviours: results from a multicentre randomised controlled trial

Dr Courtney Lightfoot, Dr Thomas Wilkinson, Ms Gurneet Sohansoha, Ms Ella Ford, Ms Noemi Vadaszy, Dr Matthew Graham-Brown, Prof Alice Smith

University of Leicester, Leicester

Introduction: In order for individuals living with chronic kidney disease (CKD) to take an active role in the self-management of their health, they require the appropriate knowledge, skills, and confidence (patient activation). Evidence-based resources to support education and self-management are currently lacking, but digital health interventions (DHIs) potentially offer a cost-effective way to equitably deliver health and lifestyle education, especially in the post-COVID era. We have developed a 10-week education and self-management DHI for people with CKD not requiring kidney replacement therapy, called 'My Kidneys & Me' (MK&M). Here we report the results from a multicentre randomised controlled trial (SMILE-K; ISRCTN18314195), which completed 10-week follow-up in March 2023.

Methods: Participants were recruited from 26 sites across England and randomised 2:1 to intervention (MK&M) or control. Participants with access to MK&M were provided with online education sessions (underpinned by behaviour change theory), and digital applications to track goals, symptoms, physical activity and clinical measures (e.g., blood pressure). Outcome measures were collected at baseline and 10-weeks. The primary outcome was the Patient Activation Measure (PAM-13). Other outcomes included the CKD Self-Management Knowledge Tool (CKD-SMKT) and Brief Illness Perception Questionnaire (B-IPQ). Access to and usage of MK&M (frequency and length of time spent on each section of the programme) were collected. Within-group changes were estimated using paired t-tests. Linear regression models tested between-group differences, adjusted for baseline values. A per-protocol sensitivity analysis was conducted excluding participants in the intervention group who did not activate their MK&M account or only logged in once.

Results: N=421 participants were randomised to receive MK&M (n=281, 67%) or control (n=140, 33%) between May 2021 and December 2022 (mean age: 59.9±13.4 year, 60% males, 91% White British, eGFR: 39.5±24.6 ml/min/1.73m2). N=57 (20%) people did not activate their account, and n=19 (7%) only logged in once. MK&M was accessed a median 5.0 (IQR: 1.0-17.0.) times over 10-weeks, with a median 12 mins (IQR: 7.25-24.5 mins) per log in. N=285 (67%) (MK&M 60%; control 82%) completed outcome measures at 10-weeks.

In an intention-to-treat analysis, mean PAM-13 score significantly increased in MK&M group (+2.96, P=0.002). No significant change was seen in control group (+1.44, P=0.331). No between-group differences were observed (P=0.321). A greater increase in PAM-13 (+3.33, P=0.002) was observed in a sensitivity analysis of those logging in more than once.

Kidney health knowledge (CKD-SMKT) significantly improved in both groups (P<0.001), with sensitivity analysis showing greater changes in MK&M group vs control (P=0.043). Perceived threat of CKD (B-IPQ) was significantly reduced for MK&M group (-2.49, P=0.002), with a significant difference observed between groups (P=0.020).

Discussion: For people living with CKD, access to the MK&M DHI increased patient activation and kidney health knowledge whilst decreasing perceived threat of CKD. Greater improvements were observed in those who accessed and used MK&M. DHIs may be an appropriate means to improve patient activation and self-management behaviours in people with CKD. Higher levels of patient activation are associated with better outcomes; thus MK&M has the potential to improve outcomes and reduce healthcare costs in people with CKD.

Late-breaking Abstracts

Submission: 654

Why do people say "no" to a kidney transplant? Understanding patient decision-making and choice: an interpretative phenomenological study

Mrs Emma Jones[1], Dr Kate Shakespeare[2], Dr Leah Mclaughlin[1], Professor Jane Noyes[1]

[1]Bangor University, Bangor, Wales, UK.
[2]Betsi Cadwaladr University Health Board, Glan Clwyd Hospital, UK

Introduction: Kidney transplantation offers benefits for people with end stage chronic kidney disease (CKD) by improving quality of life, when successful providing freedom from dialysis, and reducing co-morbid complications associated with being on dialysis. However, little is known about the reasons why some people with kidney disease decline kidney transplantation when they are otherwise medically suitable. The aim of this study is to develop an in-depth understanding of the lived experiences of people living with kidney disease, their experiences of decision-making and the reasons which led them to decline a kidney transplant.

Methods: Interpretative Phenomenological Analysis (IPA) was used. Convenience sampling to recruit a minimum of 30 adults with kidney disease from 6 regional nephrology units within the United Kingdom (3 in Wales, 3 in England), and advertising on social media from August 2022 (ongoing). Individuals were eligible if they had declined a kidney transplant whilst otherwise being medically suitable to receive one.

Semi-structured interviews were conducted face to face, by telephone or via video call and were digitally audio recorded, transcribed verbatim and entered into NVivo 11. Transcripts were read and analysed using IPA methods, emergent themes were clustered into tables, connections and comparisons across individual participants were made. Interpreting the experiences and decision-making of individual participants.

Findings: Preliminary findings from 25 interviews (female 7, male 18 aged 34years-77years), across all kidney replacement modalities (Pre-dialysis CKD stages 4 and 5, Haemodialysis in centre and satellite unit, Home Haemodialysis, Nocturnal Home Haemodialysis, Continuous Ambulatory Peritoneal Dialysis, Automated Peritoneal Dialysis, 2 participants had been previously transplanted).

Initial theme structure of preliminary findings revealed pre-conceived ideas and negative perceptions towards kidney transplant was reported by all participants regardless of age, gender, or kidney replacement modality. This resulted in the belief they would be worse off and assumed a kidney transplant would fail. Age-biased perceptions included being too old to undergo kidney transplantation. Altruistic decision-making was reported particularly amongst older people who believed younger people would benefit more from being transplanted. Uncertainties concerning complications, side effects of medication also deterred people. Being adjusted and unrestricted on dialysis and feeling well knowing what dialysis involved, seeing others living a long life on dialysis was reassuring. Avoiding deciding, uncertainties of kidney transplantation outcomes further delayed decision-making, people not on dialysis with CKD stage 4 and 5 who felt 'well' with no symptom burden were reluctant to make decisions. Past negative experiences and fear of hospitals affected participants well-being and ability to make decisions. During COVID participants diagnosed with end stage chronic kidney disease, or who had a deterioration in kidney function or who needed to start dialysis reported feeling unsupported and unprepared to make transplant decisions. Participants

who refused the offer of a kidney transplant or who removed themselves from the kidney transplant waiting list reported feeling relieved.

Discussion: This study is one of the first to explore reasons for declining kidney transplantation. When completed the findings and recommendations will be used to further evolve clinical practice, patient education and could support targeted personalised interventions.

Best clinical abstracts

Submission: 222

The clinical demographics and natural history of rare kidney diseases in the UK: A longitudinal descriptive analysis using data from the National Registry of Rare Kidney Diseases (RaDaR)

Dr Katie Wong[1,2], Mr David Pitcher[1,2], Mr Lewis Downward[1], Ms Retha Steenkamp[1], Ms Fiona Braddon[1], Mr Garry King[1], Ms Kate Osmaston[1], Mr Andrew Atterton[1], Professor Dorothea Nitsch[3], Dr Kate Bramham[1,4], Professor Daniel Gale[1,2]

[1]Rare Renal Disease Registry, UK Renal Registry, Bristol.
[2]Department of Renal Medicine, University College London, London.
[3]London School of Hygiene and Tropical Medicine, London.
[4]King's College Hospital, London

Introduction: Rare kidney diseases include over 150 different conditions. The presentation and clinical course of these disorders are often incompletely characterized. The National Registry of Rare Kidney Diseases (RaDaR) was formed in 2010, to gather longitudinal data from rare kidney disease patients across the UK, to better under the natural history of these conditions. RaDaR currently recruits from 108 renal units across all 4 UK nations. Patients are recruited into Rare Disease Groups (RDGs), either single diseases or groups of renal diagnoses. Here we use RaDaR data to describe the clinical demographics, disease characteristics, renal and patient outcomes for individuals with rare kidney diseases in the UK.

Methods: Data were extracted from the RaDaR database linked to the UK Renal Registry for Renal Replacement Therapy (RRT) initiation and death data, and to renal IT systems for routine test results. End Stage Kidney Disease (ESKD) was defined as the first occurrence of chronic RRT, an eGFR <15 mL/min/1.73m2 for >4 weeks, or CKD 5 recorded in RaDaR. Each patient's date of diagnosis is entered into RaDaR by research nurses at the time of recruitment. Kaplan Meier survival estimates were calculated for a) age at RRT start b) age at death c) time from diagnosis to certain eGFR estimates. The latter were used to calculate time between last eGFR ≥75 and first eGFR <30 with no subsequent higher eGFR values ("therapeutic window").

Results: The total RaDaR population included 28,206 patients in 19 RDGs. Diseases frequently diagnosed in childhood were Autosomal recessive polycystic kidney disease (median age at diagnosis 8.7 years [IQR 0.1-29.9]), Shiga toxin associated haemolytic uraemic syndrome (3.4 years [1.7-7.0]), cystinosis (1.9 years [0.7-9.9]), Bartter syndrome (4.6 years, [0.3-24.4]), Dent Disease and Lowe syndrome (9.4 years [1.0-29.0]), and other tubulopathies (15.5 years [6.9-41.9]). There was significant heterogeneity in median age at RRT start between RDGs (Figure 1). For instance, individuals with cystinosis reached ESKD in childhood (median age at RRT start 15.4 years (95% CI 14.2-16.3)), whereas individuals with Idiopathic Nephrotic Syndrome reached ESKD at median age 79.0 years (95% CI 75.9-81.7). Median age at death was either inestimable due to too few events occurring in that RDG to calculate a median estimate, or >75 years for all RDGs, except for cystinosis where median age at death was 56.4 years (95% CI 40.9- not estimated). Time in therapeutic window varied between 20.0 years in Retroperitoneal Fibrosis to 1.3 years in Monoclonal Gammopathy of Renal Significance (Figure 2).

Discussion: We have estimated age and renal function at diagnosis, patterns of eGFR decline and age at ESKD and death for 19 rare kidney disease groups. These data provide real world insight into the presentation and natural history of rare kidney diseases in the UK and will help inform individual disease prognostication, healthcare service and resource planning, and future research strategies.

Figure 1: Kaplan Meier Survival analyses of age at RRT start in a) glomerular b) cystic c) metabolic d) tubular e) other kidney conditions f) Alport syndrome



Figure 2: Kaplan Meier plots of time from diagnosis to reach eGFR estimate for a) glomerular b) cystic c) metabolic d) other kidney conditions e) Alport syndrome



Best clinical abstracts

Submission: 109

Proteinuria and its association with disease progression in IgA nephropathy: analysis of the UK national RaDaR IgA nephropathy cohort

Mr David Pitcher[1], Ms Fiona Braddon[1], Professor Bruce Hendry[2], Dr Alex Mercer[3], Ms Kate Osmaston[1], Professor Moin Saleem[4], Dr Retha Steenkamp[1], Professor Neil Turner[5], Dr Kaijun Wang[2], Professor Jonathan Barratt[6], Dr Daniel Gale[7]

[1]UK Renal Registry, Bristol.
[2]Travere Therapeutics, Inc., San Diego.
[3]JAMCO Pharma Consulting, Stockholm.
[4]University of Bristol and Bristol Royal Hospital for Children, Bristol.
[5]University of Edinburgh, Edinburgh.
[6]University of Leicester and Leicester General Hospital, Leicester.
[7]Royal Free Hospital and University College London, London

Introduction: Primary IgA nephropathy (IgAN) is the most common form of glomerulonephritis worldwide and a major cause of renal failure. Here we investigate the relationship between proteinuria measured over follow-up and rate of renal function loss and renal survival in patients from the UK National Registry of Rare Kidney Diseases (RaDaR) IgAN cohort. Since 2013, patients with biopsy-proven IgAN and eGFR <60 ml/min/1.73m^2 or proteinuria ≥0.5g/24h have been enrolled from 87 kidney units across the UK, with automated collection of retrospective and prospective laboratory data.

Methods: 923 patients met the eligibility criteria, including diagnosis date, proteinuria measurements in follow-up (within 2 years from diagnosis and ≥2 values if follow-up >3 years), no ESKD (CKD stage 5 or renal replacement therapy) or death within 6 months from diagnosis or prior to first proteinuria value. Longitudinal proteinuria, assessed as time-average protein-to-creatinine ratio (TA-PCR), and eGFR slope were calculated over the full duration of follow-up or until ESKD or death. For survival analyses, ESKD/death was applied, with survival time calculated from diagnosis to last follow-up.

Results: Characteristics at diagnosis and clinical outcomes of the study population are summarized in Table 1. Increasing grades of TA-PCR were associated with more rapid decline in eGFR (ANOVA p<0.001, Fig.1b) and greater risk of ESKD/death (Log-rank p<0.001, Fig.1a; Cox regression p<0.001, Fig.1b).

Discussion: Proteinuria exposure over time is significantly associated with disease progression and renal outcomes in IgAN. In particular, TA-PCR below 100 mg/mmol (~1g/24h) is very strongly associated with slower loss of renal function and lower risk of ESKD or death.

Table 1. Characteristics at diagnosis and clinical outcomes

	n (%)	**Value**
Age, median (IQR)	923 (100)	41.7 (30.3–53.3)

	n (%)	Value
Paediatric, n (%)	923 (100)	36 (4)
Gender (female), n %	923 (100)	294 (32)
PCR (mg/mmol), median (IQR)	515 (56)	172 (73–356)
eGFR (ml/min/1.73m^2), median (IQR)	565 (61)	49.8 (33–78.2)
Duration of follow up (years), median (IQR)	923 (100)	4.5 (2.5–6.8)
ESKD or death event, n (%)	923 (100)	355 (39)
Rate of loss of eGFR (ml/min/1.73m^2/year), median (IQR)	856 (93)	2.6 (0.4–6.1)

Figure 1. Kaplan Meier survival curves (including 95% CI) (a) and outcomes (b) for patients categorized by TA-PCR

(a)



(b)

	eGFR slope (ml/min per 1.73m^2/year)			ESKD/Death risk		
TA-PCR	n	Mean	SD	n	Hazard ratio	95% CI

	eGFR slope (ml/min per 1.73m^2/year)			**ESKD/Death risk**		
<100mg/mmol	385	-0.35	7.15	405	Ref	Ref
100 to <200mg/mmol	247	-3.32	10.09	264	2.83	(2.09–3.82)
200 to <300mg/mmol	113	-6.67	5.73	128	4.82	(3.49–6.66)
≥300mg/mmol	111	-12.41	11.28	126	9.00	(6.56–12.34)

Best clinical abstracts

Submission: 494

Kidney Transplantation in Older People (KTOP): a qualitative study.

Dr Lina Johansson[1,2], Dr Shone Surendran[2], Miss Nicola Evans[3], Dr Annabel Rule[1], Dr Amarpreet Thind[1,2], Prof Nicola Thomas[4], Dr Michelle Willicombe[2,1], Prof Edwina Brown[1,2]

[1]Imperial College Healthcare NHS Trust, London.
[2]Imperial College London, London.
[3]Guy's and St Thomas' NHS Foundation Trust, London.
[4]London South Bank University, London

Introduction: Rates of kidney transplantation in older people are increasing together with increased clinical risks yet there is a dearth of research around the experience of coping with the process of transplantation. The Kidney Transplantation in Older People (KTOP) project is a longitudinal, single-centre study based on a mixed methods design seeking to understand the impact of frailty on clinical outcomes and to better understand the challenges faced by this group relating to their expectations and ability to cope with the transition. Our study reports on the qualitative aspect of the KTOP project.

Methods: This was a qualitative longitudinal study that spanned 20 months. Purposive sampling was used to draw participants from the larger KTOP observational quantitative study. Selected participants were aged ≥60 years, vulnerable to or with frailty (Edmonton Frailty Scale score ≥6), on dialysis and active on the national kidney transplant waiting list. Semi-structured interviews were conducted with informed consent at baseline for all participants and after 12 months for those who remained on dialysis. Transplant recipients were interviewed at both 3 and 12 months post-transplantation. Interviews were audio-recorded and transcribed. The data was analysed using framework thematic analysis.

Results: Twenty one participants were recruited, 10 of whom were transplanted (one withdrew). The remaining participants were on dialysis: one withdrew, one was lost to follow-up and one died.

Transplantation, in the short term, may aggravate frailty but in the longer term the experience of living with frailty day-to-day remained similar to that of life on dialysis. Transplantation, however, does provide some relief from the daily burden of having to attend dialysis, improving the quality of time available to spend with others, independent of frailty issues. Transplant recipients with a social network, spiritual beliefs and positive worldview appear more resilient and are better able to cope with the trauma of transplantation. Those, however, with a lower support network encountered greater responsibility for self-care and were finding that transplantation leads to a life with different challenges compared to those on dialysis. COVID has played a critical role in limiting social interactions and experiences outside the home and impinging on physical activities which would have otherwise been undertaken. The participants who remained on dialysis over the course of a year expressed resignation and acceptance. They may have experienced being de-activated and reactivated which impacts their sense of hope of undergoing successful transplantation.

Discussion: Receiving a transplant is not necessarily associated with experiencing an improved quality of life in frail older people. Participation in communities and being situated within a rich

socio-cultural network, mediates the burden of coping with frailty which may ease the adjustment to living with a transplant.

Conclusion: The findings describe the challenges older people with frailty face in post-transplant life. It also highlights the significance of socio-cultural resources when coping with the constraints imposed by post-transplant life. The study alerts us to the need to attend to patient's personal and environmental context which is critical to improving services for older people in the future.

Best clinical abstracts

Submission: 157

A targeted gene panel illuminates pathogenesis in young people with unexplained kidney failure

Dr Felicity Beal[1], Dr Natalie Forrester[2], Dr Maggie Williams[2], Dr Andrew Buckton[3], The UK Gene Panel Study Group[4], Professor Adrian Woolf[5,6], Professor Moin Saleem[7], Dr Caroline Platt[7]

[1]Birmingham Children's Hospital, Birmingham.
[2]North Bristol NHS Trust, Bristol.
[3]Great Ormond Street Hospital for Children NHS Foundation Trust, London.
[4]National, UK.
[5]Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester.
[6]Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester.
[7]Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol

Introduction: The aetiology of young-onset end stage renal disease (ESRD) is often undefined. Genetic analysis has proven itself to be an essential tool in facilitating a diagnosis in a significant proportion of these cases.

The National Genomic Test Directory provides a comprehensive list of tests that are nationally commissioned by NHS England for patients with rare disease and cancer. Included in this directory is the R257 panel, which uses next generation sequencing techniques to analyse 175 genes associated with unexplained ESRD in patients up to 36 years of age. This test was introduced in 2021.

This is the first study to evaluate the efficacy of a novel ESRD gene panel delivered comprehensively within a national health service.

Methods: R257 panel testing is undertaken through the South West and North Thames Genomic Laboratory Hubs. All R257 results were reviewed, relevant phenotypic data was extracted and referring clinicians were contacted if clinical details were unavailable.

Results: Between October 2021- February 2022, 71 patients with unexplained ESRD underwent R257 panel testing. 25/71 (35%) were reported to have either a pathogenic or likely pathogenic variant. NPHP1 (4/25, 16%) and COL4A3/COL4A4 (4/25, 16%) were the most common pathogenic variants identified. Other pathogenic variants detected include: PKHD1 (three patients), PAX2 (CAKUT/renal coloboma syndrome in two patients) and ACTG2 (megacystitis microloan intestinal hypoplasia in two patients.)

Of those patients with a positive genetic result, 18/25 (72%) were suspected to have an underlying genetic disorder at the point of referral, 14/25 (56%) had a family history of renal disease and 13/25 (52%) had extra-renal manifestations.



Discussion: Preliminary results from the R257 panel are encouraging, identifying a monogenic diagnosis in 35% patients with previously unexplained ESRD. The target reporting time for a genetic result was 84 calendar days. Key features pertaining to a genetic diagnosis include a positive family history, suspected ciliopathy, and extra-renal manifestations.

The implications of a molecular diagnosis are not only significant for the patient (avoidance of invasive tests such as renal biopsy, ability to screen for extra-renal manifestations in the case of a syndromic diagnosis for example), but also the wider family (prenatal counselling for a parent and screening for a potentially affected sibling).

Since April 2022 the R257 service has transitioned to using whole genome sequencing, and it is anticipated that this will improve the rate at which relevant genetic variants are detected for this group of patients.

UK Gene Panel Study Group :

- Andrew Maxted –Nottingham
- Abhijit Dixit - Nottingham
- Charlotte Bebb –Nottingham
- Helen M. Stuart –Manchester
- Katherine A. Hillman –Manchester
- Mohan Shenoy –Manchester
- Kay Metcalfe - Manchester
- Nicholas Plant –Manchester
- Emma Burkitt –Manchester
- Judith Vandervoort –Cardiff
- Caroline Jones –Liverpool
- Richard Holt –Liverpool
- Matko Marlais –London
- Wesley Hayes –London
- Emma Wakelin –London

- Harry Leitch –London
- Deirdre Cilliers - Oxford
- Mordi Muorah –Birmingham
- Denise Williams –Birmingham
- Joanna Jarvis –Birmingham
- Fiona Beecroft - Birmingham
- Arveen Kamath –Swansea
- Rajesh Krishnan –Cardiff
- Alison Kraus –Leeds
- Mira Kharbanda - Southampton
- Jack Galliford – Southmead

Best clinical abstracts

Submission: 387

Non-invasive assessment of liver stiffness, hepatic fibrosis risk markers and outcomes in a dialysis population

Dr Oscar Swift[1], Dr Malcolm Finkelman[2], Dr Yonglong Zhang[2], Miss Eunice Doctolero[1], Mrs Chadd Javier[1], Mr Mikky Gilbert[1], Dr Kieran McCafferty[3], Dr Jonathan Wong[4], Dr Paul Warwicker[5], Dr Jean Patrick[6], Dr Richard Warburton[1], Dr Sivakumar Sridharan[1], Professor Ken Farrington[1], Dr Enric Vilar[1]

[1]East and North Hertfordshire NHS Trust, Stevenage.
[2]Associates of Cape Cod, Inc, East Falmouth.
[3]Barts Health NHS Trust, London.
[4]Mid and South Essex NHS Foundation Trust, Chelmsford.
[5]Lancashire Teaching Hospitals NHS Foundation Trust, Preston.
[6]James Paget University Hospitals NHS Foundation Trust, Great Yarmouth

Introduction: People with end stage kidney disease (ESKD) commonly co-exhibit multiple risk factors (type 2 diabetes mellitus, obesity and hypertension) for non-alcoholic fatty liver disease (NAFLD) and its progressive, fibroinflammatory form non-alcoholic steatohepatitis (NASH). NAFLD and NASH both associate with increased risk of fatal cardiovascular events. NASH will additionally soon become the leading cause of cirrhosis both in the UK and worldwide.

The cause of systemic inflammation in patients with ESKD is unclear. Liver disease can contribute to inflammation due to reduced reticuloendothelial function and subsequent penetration of gut-derived toxins into the systemic circulation. Very little is currently known about prevalence of NAFLD and NASH in ESKD, or how these conditions affect patients.

This study aims to help better understand the extent of NAFLD and NASH and their links to clinical outcomes in advanced kidney disease.

We report interim results from this study looking non-invasively for liver disease in patients with ESKD.

Methods: This prospective study involves prevalent patients with ESKD treated with dialysis (for >3 months) at five participating UK kidney centres. Results from this study are derived from analysis of the first 238 patients (final recruitment target 450).

A FibroScan (Echosens) device measured hepatic steatosis using controlled attenuation parametrography (CAP) and fibrosis using transient elastography. A fibrosis-4 index score was calculated to assess fibrosis risk. These results were supplemented by baseline clinical and radiological data, serum beta-D-glucan levels taken pre- and post-dialysis, clinical assessment of fluid status, and bioimpedance spectroscopy (Fresenius Medical Care).

Survival analyses were performed using Kaplan-Meier estimates.

Results: The mean age of participants was 63 years (67% male). Mean body mass index was 27.8kg/m2. 97% of participants had hypertension, 53% diabetes mellitus and 65% hyperlipidaemia.

231 participant FibroScan scores (97%) were valid (interquartile range less than 30% over 10 consecutive readings) and available for analysis. 74 participants (31%) had suspected hepatic steatosis of grade S1-S3 and 72 participants (30%) had suspected hepatic fibrosis of grade F2-F4. 53 participants (22%) had suspected F2-F3 fibrosis (moderate fibrosis) and 19 (8%) had suspected F4 fibrosis (advanced fibrosis/cirrhosis).

There was increased mortality associated with suspected hepatic fibrosis/steatosis (9.1% absolute risk of mortality with an abnormal CAP or fibrosis score compared to 1.6% in those with normal FibroScan imaging). The majority of mortality in people with suspected hepatic fibrosis was from cardiovascular disease. Overall mortality in participants with suspected hepatic fibrosis remained significant even after adjustment for univariate predictors of survival (median CRP, baseline BDG levels and age) (Figure 1). Other univariate predictors of survival were Charlson Comorbidity Score and diabetes status.

Discussion: These results demonstrate a significant burden of suspected hepatic steatosis and hepatic fibrosis in people with ESKD. Suspected hepatic fibrosis assessed by FibroScan imaging is an independent risk factor for mortality based on this interim analysis and strategies to improve liver health in the setting of advanced kidney disease may be of benefit to this group of patients.

Figure 1 Kaplan-Meier survival analysis for participants with ESKD by suspected hepatic fibrosis stage



Best clinical abstracts

Submission: 156

Regional variation in COVID-19 hospitalisation and outcomes in adults in England

Dr Nitin Kolhe[1], Dr Richard Fluck[1], Prof Maarten Taal[2,1]

[1]University Hospitals of Derby and Burton NHS Trust, Derby.
[2]University of Nottingham, Derby

Introduction: The possibility that population demographic characteristics, changes in viral strain and therapeutic advances in management of COVID-19 might influence clinical outcomes is of great interest given potential regional variations. The aim of our study was to describe regional variation in COVID-19 hospitalisation rates in England and factors affecting in-hospital mortality as well as acute kidney injury (AKI).

Method: In this retrospective cohort study using hospital episode statistics, we collected data from all adult hospitalised patients with COVID-19 infection (diagnostic code U07.1 in any of the 20 diagnoses codes) between 1st March 2020 and 31st March 2021, to end of discharge period. We also extracted all available secondary diagnoses and procedure codes. Patients with codes for chronic dialysis were excluded. We divided the observation period as per the dominant SARS CoV-2 variant and further, in relation to publication of the RECOVERY trial. SARS CoV-2 "Other" strain was prevalent between 1st March 2020 and 21st December 2020 and "Alfa" between 22nd December 2020 to 17th May 2021. The end date of each phase was based on more than 50% decline in each variant.

Results: We extracted 3,24,748 finished consultant episodes (FCE) for all patients with U071 code in any of the 20 diagnoses codes and admitted during the study period. After exclusion of multiple FCEs within same spell, chronic RRT and patients not residing in England, there were 749,844 unique admission spells with ICD10 code of U071 in one of the diagnoses codes in 337,029 patients. London had the highest number of COVID-19 admissions at 131,338 (18%) followed by North-west region with 122,683 admissions (16%). Population incidence of COVID-19 hospital admissions was highest in North-west at 21,167 per million population (pmp) and lowest in South-west at 9,292 admissions pmp. Patients with COVID-19 were younger (67.0 ± 17.7 years) in London as compared to patients in East of England (72.2 ± 16.8 years). Length of stay was lowest in North-east (12.2 ± 14.9 days) and highest in North-west (15.2 ± 17.9 days). As compared to London, all eight regions had higher odds of death, ranging from OR of 1.04 (95% CI 1.00, 1.07) in South-west to OR 1.24 (95% CI 1.21, 1.28) in North-west. Odds of death were lower in patients with COVID-19 in post-RECOVERY period, both with “Other” (OR 0.72, 95% CI 0.71, 0.74) and Alfa strain of SARS CoV-2 (OR 0.75, 95% CI 0.74, 0.76). Overall, AKI incidence was 30.3%. All eight regions in England had lower odds of developing AKI as compared to London. Post-RECOVERY periods with the “Other” variant (OR 0.87, 95% CI 0.85, 0.88) and “Alfa variant (OR 0.87, 95% CI 0.86, 0.88) both had lower odds of developing AKI.

Discussion: This large national study of COVID-19 found a high hospital admission rate and AKI incidence but lower odds of death in London compared with other regions in England. The incidence of AKI and mortality due to any cause were lower in the post-RECOVERY period irrespective of the prevalent SARS CoV-2 strain.

Enhanced Supportive Care - understanding the need, identifying the resource

Submission: 139

Effect of ethnicity and socioeconomic deprivation on uptake of renal supportive care and dialysis decision making in older adults.

Dr Kerry-Lee Rosenberg, Professor Aine Burns, Professor Ben Caplin

Department of Renal Medicine, University College London, London

Introduction: Renal supportive care has become an increasingly relevant treatment option as the renal patient population ages. Prevalence of chronic kidney disease is high amongst ethnic minority and low socioeconomic groups and previous studies have shown reduced access to advance care planning and palliative care amongst these patients. However, evidence focused on access to supportive care and dialysis decision making in these groups is limited.

We aimed to describe the demographics of a cohort of older patients with advanced CKD, as it relates to their treatment choice, to evaluate the socioeconomic factors associated with choosing supportive care treatment and to examine surrogate markers for the success of dialysis decision making, amongst a diverse population of patients.

Methods: This retrospective study selected patients over 65 years of age referred to a low clearance or supportive care service between 1 January 2015 and 31 December 2019. Data collected included age, sex, ethnicity, comorbidities, clinical frailty scores, Index of Multiple Deprivations deciles, treatment modiality and hospital admissions. A descriptive analysis of clinical and socioeconomic characteristics according to treatment choice was carried out and multivariate logistic regression models used to identify predictive factors for choosing supportive care. Surrogate markers for the success of decision making processes were evaluated, including time taken to reach a supportive care decision and risk of death without making a treatment decision or within 3 months of starting kidney replacement therapy (KRT). Finally, the association between ethnicity and socioeconomic status and hospital admission rates were compared between treatment groups.

Results: Amongst 1768 patients, 515 chose supportive care and 309 chose KRT. Predictive factors for choosing supportive care included age, frailty and a diagnosis of cognitive impairment. However, there was no association with ethnicity or deprivation. Similarly, these factors were not associated with time taken to make a supportive care decision or with death before making a decision or within 3 months of starting KRT. Amongst those on KRT, less socioeconomically deprived patients had decreased rates of hospital admissions compared with those more deprived (IRR 0.96, 95% CI 0.92 – 0.99). However, whilst on a supportive care pathway, admission rates were higher amongst less deprived patients (IRR 1.39, 95% CI 1.01 – 1.93).

Discussion: Our findings provide evidence against the hypothesis that ethnic minority patients and those in lower socioeconomic groups are less likely to choose supportive care treatment. The major predictive factors for choosing supportive care were in fact clinical, rather than socioeconomic.

Lower socioeconomic status was associated with increased rates of hospitalisation in the KRT group. This is a possible signal that these groups experienced greater morbidity on KRT versus supportive care, an association not demonstrated amongst higher socioeconomic groups.

Table 1: Clinical and socioeconomic characteristics of patients as defined by treatment choice

	Supportive Care	KRT	Died prior to decision	Remain in LCC/discharged	Total	p-value
Age (mean +- SD)	82.6+- 6.7	73.3+-5.5	78.6+-7.4	76.4+-6.8	77.8 +- 7.42	**<0.001**
Sex						**0.001**
Female	246	105	73	326	750	**<0.001**
%	*32.8*	*14*	*9.73*	*43.47*	*100*	
Male	269	204	116	429	1,018	
%	*26.42*	*20.04*	*11.39*	*42.14*	*100*	
Baseline GFR						
Mean +- SD	22.09+-7.82	19.69+-7.02	21.72+-7.34	24.62+-8.38	22.71+-8.39	**0.005**
Ethnicity						
White	255	152	98	373	878	
%	*29.04*	*17.31*	*11.16*	*42.48*	*100*	
Black	39	38	21	63	161	
%	*24.22*	*23.6*	*13.04*	*39.13*	*100*	
South Asian	73	53	32	101	259	
%	*28.19*	*20.46*	*12.36*	*39*	*100*	
Other	50	23	8	45	126	
%	*39.68*	*18.25*	*6.35*	*35.71*	*100*	
Unknown	98	43	30	173	344	
%	*28.49*	*12.5*	*8.72*	*50.29*	*100*	
Primary Renal Disease						**<0.001**
Glomerular Disease	9	23	3	14	49	
%	*18.37*	*46.94*	*6.12*	*28.57*	*100*	
Tubulointerstitial Disease	12	14	5	35	66	
%	*18.18*	*21.21*	*7.58*	*53.03*	*100*	
Systemic disease effecting the kidney - non diabetes	77	55	29	91	252	
%	*30.56*	*21.83*	*11.51*	*36.11*	*100*	
Diabetic Kidney Disease	102	109	38	168	417	
%	*24.46*	*26.14*	*9.11*	*40.29*	*100*	
Familial / hereditary nephropathies	2	7	3	8	20	
%	*10*	*35*	*15*	*40*	*100*	
Miscellaneous renal disorders	313	101	111	439	964	
%	*32.47*	*10.48*	*11.51*	*45.54*	*100*	
Comorbidities						
Diabetes Mellitus	297	174	101	488	1060	**0.005**
%	*28.02*	*16.42*	*9.53*	*46.04*	*100*	
Cardiovascular disease	333	155	140	377	1005	**<0.001**
%	*33.13*	*15.42*	*13.93*	*37.51*	*100*	
Cancer diagnosis	111	62	56	160	389	**0.189**
%	*28.53*	*15.94*	*14.4*	*41.13*	*100*	
Cognitive impairment	78	11	10	19	118	**<0.001**
%	*66.1*	*9.32*	*8.47*	*16.1*	*100*	
Baseline frailty score						**<0.001**
Mean +- SD	4.76+-1.63	3.72+-1.53	4.52+-1.5	3.5+-1.47	3.99+-1.63	
Index of multiple deprivations (deciles)						**0.183**
Mean +- SD	5.3 +- 2.39	4.97 +- 2.45	5.17 +- 2.49	5.06 +- 2.52	5.1 +- 2.47	**0.949**
Reported Religion						
Yes	154	98	59	229	540	
%	*28.52*	*18.15*	*10.93*	*42.41*	*100*	
No	361	211	130	526	1,228	
%	*29.4*	*17.18*	*10.59*	*42.83*	*100*	
Use of interpreter						
Yes	36	18	13	29	96	
%	*37.5*	*18.75*	*13.54*	*30.21*	*5.44*	
No	479	291	176	726	1672	
%	*28.65*	*17.4*	*10.53*	*43.42*	*94.56*	
Living arrangements						**0.591**
Lives with family	82	131	30	161	404	
%	*20.3*	*32.43*	*7.43*	*39.85*	*100*	
Lives alone or no NOK	75	100	19	116	310	
%	*24.19*	*32.26*	*6.13*	*37.42*	*100*	
Missing data	358	78	140	478	1054	
%	*33.9*	*7.4*	*13.3*	*45.4*	*100*	
Time spent in LCC clinic (Number of days)						
Mean +/- SD	212+-328	423+-360	347+-298	812+-578	519+-524	**<0.001**
Total:	**515**	**309**	**189**	**755**	**1768**	
%	**29.13**	**17.48**	**10.69**	**42.7**	**100**	

Physical activity, rehabilitation, and exercise in kidney disease: 5 years later, where are we now?

Submission: 412

The stark landscape of kidney rehabilitation services in the UK: Is the kidney therapy workforce really a priority?

Ms Lisa Ancliffe[1], Dr Ellen Castle[2], Dr Thomas Wilkinson[3], Dr Hannah Young[4]

[1]Royal Free London NHS Foundation Trust, London.
[2]Physiotherapy, Department of Health Sciences, Brunel University, London.
[3]University of Leicester, London.
[4]University Hospitals of Leicester, London

Introduction: Therapy interventions and rehabilitation to improve outcomes in chronic kidney disease (CKD) are recommended within national guidance (Baker et al., 2022). Previous research reported that access to kidney specific therapists and rehabilitation programmes was limited, with inconsistencies across the UK (Greenwood et al., 2014). A decade later, current national provision of occupational therapy (OT), physiotherapy and clinical exercise physiologists remains largely unknown, but this data is key to achieving the aims of the Renal Services Transformation Plan and Getting It Right First Time (Jenkins, 2021; Lipkin and McKane, 2021). The aims of this national survey were to:

- identify variation and good practice in therapy provision; and
- understand barriers to therapy provision.

Methods: A bespoke online survey was created to capture the provision of rehabilitation services provided across UK kidney units, the professions involved, and the barriers to rehabilitation provision. Therapy leads at all 87 hub units in the UK were identified via the UK Kidney Association (UKKA) database (UKKA, 2021) and invited to complete the survey between June 2022 and January 2023. Further invitations were sent to the Clinical Directors of unresponsive units and also disseminated via UKKA channels.

Results: As of January 2023, a total of 34 responses from 29/87 (33%) individual sites were received. 15/29 (52%) sites reported having a physiotherapist and 14/29 (48%) reported an OT with the majority of their caseload focused on kidney care. Four sites (14%) offered intradialytic exercise, consisting of a mixture of aerobic and resistance-based exercise. Three sites (10%) offered other forms of meaningful activity during haemodialysis, including art (n=3) and reading (n=1). Three sites (10%) offered specialist outpatient rehabilitation for kidney patients. Eight (28%) referred kidney patients to other established rehabilitation programmes as an alternative. Services were offered both face-to-face and remotely. Other forms of services provided included mobility assessments (5/29, 17%) and symptom management (4/29, 14%). One site (3%) provides access to another form of 'exercise practitioner'. Less than a third of responders (11/34, 32%) were aware of the 2022 UKKA 'Clinical practice guidelines exercise and lifestyle in CKD'. The most frequently reported barriers to the delivery of kidney therapy were 'lack of money/funding '(29/34, 85%), lack of time (27/34, 79%), lack of physical resources (24/29, 71%), and prioritisation of other services (24/29, 71%). No responders believed 'health and safety concerns 'were a barrier.

Discussion: Across the UK, a dearth in access to kidney specific therapy services is evident, with marked variation in the provision of these services where they do exist, despite evidence for the beneficial effect of such therapy in the CKD population. The low response rate may indicate a lack of kidney therapy presence in these units, and that the size of this issue may be under-represented. More must be done to improve equity of access to kidney specific therapies to ensure that all may be supported to ‘live well’ with kidney disease.

Cystinosis

Submission: 086

Rare variants in SLC34A3 explain missing heritability of urinary stone disease

DR Omid Sadeghi-Alavijeh[1], Dr Melanie Chan[1], Dr Shabbir Moochhala[1], Ms Sarah Howles[2], Professor Daniel Gale[1], Professor Detlef Böckenhauer[2]

[1]University College London, London.
[2]Oxford University, Oxfrod

Introduction: Urinary stone disease (USD) is a major health burden affecting >10% of the UK population at some time. While stone disease is strongly associated with lifestyle, genetic factors also predispose to USD: common genetic variants at multiple loci from genome-wide association studies account for 5% of the estimated 45% heritability of the disorder. We investigated the extent to which rare genetic variation contributes to the unexplained heritability of USD.

Methods: Among participants of the UK 100,000 genome project, we identified 374 unrelated individuals assigned diagnostic codes indicative of USD. We performed whole genome gene-based variant burden testing and polygenic risk scoring against a control population of 24,930 genetic ancestry matched controls.

Results: We observed (and replicated in an independent dataset) exome-wide significant enrichment (P=2.61x10-07) of monoallelic rare, predicted damaging variants in SLC34A3 (previously associated with autosomal recessive hereditary hypophosphataemic rickets with hypercalciuria) present in 19 (5%) cases compared with 1.6% of controls. The risk of USD with a monoallelic SLC34A3 variant (OR=3.75, 95% CI 2.27-5.91) was greater than the top decile of polygenic risk (OR=2.31, 95% CI 1.12-3.51). Addition of the SLC34A3 variant binary to a linear model including polygenic score increased the estimated variance explained, increasing the liability adjusted pseudo-R2 from 5.1% to 14.2%. We also observed significant association at OR9K2, an olfactory receptor, but this signal was not replicated.

Conclusion: In this cohort rare variants in SLC34A3 were the most important genetic risk factor for USD, with levels of pathogenicity intermediate between the fully penetrant rare variants linked with Mendelian disorders and the weaker effects of common variants associated with USD. These findings explain some of the heritability unexplained by prior common variant GWAS.

Genetic kidney diseases - lessons from the old, & new opportunities

Submission: 202

JAK2 inhibition reduces proliferation and protects renal function in experimental polycystic kidney disease

Dr Fiona Macleod[1,2], Dr Maria Fragiadaki[1,2], Professor Jon Sayers[2]

[1]Queen Mary University London, London.
[2]University of Sheffield, Sheffield

Introduction: Autosomal Dominant Polycystic Kidney Disease (ADPKD) leads to bilateral renal cyst formation, proliferation and inflammation leading to loss of function and renal failure. ADPKD is caused primarily by mutation of the polycystin genes, either PKD1 or PKD2. Dysfunction of the polycystins leads to abnormal signalling of the evolutionarily conserved Janus Kinase and Signal Transducers and Activators of Transcription (JAK/STAT) pathway. Growth hormone (GH) is a polypeptide hormone responsible for stimulating postnatal somatic growth, fatty acid metabolism and protein synthesis. Elevated growth hormone has been observed in murine ADPKD and aberrantly activated JAK2/STAT5 activity, the predominant downstream pathway stimulated by GH. Yet, the GH-JAK2/STAT5 signalling effect on kidney function in ADPKD is not well understood.

We hypothesise that inhibiting JAK/STAT activity with small molecule inhibitors will reduce proliferation and improve renal function.

Methods: We generated human recombinant rGH and GH receptor antagonists (GHA). 3D cystogenesis and proliferation assays were carried out in the presence of rGH. To inhibit GH signalling, we took a threefold approach using either: (i) GHA, (ii) Ruxolitinib, a small molecule inhibitor of JAK2 or (iii) siRNA-mediated silencing of either GHR or STAT5. Levels of GH were measured by ELISA, while proliferation was measured by flow cytometry and histone H3 staining. Inhibition of GH signalling in vivo was using of the small molecule JAK inhibitor Ruxolitinib in Pkd1nl/nl mice (n=10 per dose group).

Results: Circulating GH is significantly elevated in Pkd1nl/nl (~3-fold, $P<0.01$). GHR is expressed in cystic human renal epithelial cells and Pkd1nl/nl mouse kidneys, including strong expression in cyst-lining cells. Stimulation with rGH activates STAT5 phosphorylation and transcriptional activity, including the mitogenic STAT5 target gene cyclin D1 (~4-fold, $P< 0.0001$), which can be reversed by GHA or Ruxolitinib treatment. Importantly, GH triggers a statistically significant increase in cell cycle progression and p(ser10) Histone H3 ($P<0.01$), which was effectively antagonised by Ruxolitinib ($P<0.05$) or GHA ($P<0.001$). GH also significantly increased the growth rate of cysts in vitro, an effect fully antagonised by Ruxolitinib, or GHA, or silencing of GHR or STAT5, suggesting that the somatic growth effects of GH are mediated by GHR/JAK2/STAT5.

In vivo, JAK/STAT inhibition with Ruxolitinib treatment (50mg/kg) led to a significant improvement of renal function ($P<0.05$), measured by blood urea nitrogen, and reduced kidney size ($P<0.05$).

Discussion: Using a multi-parametric analysis, we conclusively show that inhibition along the GH/GHR/JAK2/STAT5 benefits human cellular and mouse models of ADPKD. Specifically, antagonism of GH signalling leads to reduced proliferation, reduced numbers of cysts and improved renal

function. Therefore, we propose GH antagonism as a strategy to slow down the progression of ADPKD.

Scientific advances in understanding glomerulonephritis

Submission: 090

Mathematical tools to leverage high resolution spatial data for kidney pathology: Multiscale topology applied to subcellular spatial transcriptomics reveals ring shaped glomerular immune cell distribution in a model of lupus nephritis

Ms Katherine Benjamin[1], Ms Aneesha Bhandari[2,3], Dr Zhouchun Shang[4,5], Ms Yanan Xing[4,5], Ms Yanru An[4], Dr Nannan Zhang[6], Dr Yong Hou[4], Professor Ulrike Tillmann[1,7], Professor Heather Harrington[1,3], Dr Katherine Bull[2,3]

[1]Mathematical Institute, University of Oxford, Oxford.
[2]Nuffield Department of Medicine, University of Oxford, Oxford.
[3]Wellcome Centre for Human Genetics, University of Oxford, Oxford.
[4]Beijing Genomics Institute, Shenzhen.
[5]College of Life Sciences, University of Chinese Academy of Sciences, Beijing.
[6]Beijing Genomics Institute, Qingdao.
[7]Isaac Newton Institute for Mathematical Sciences, Cambridge

Introduction: Spatial transcriptomics could transform our understanding of renal cellular pathology, capturing heterogeneity, cellular cross-talk and context, but techniques have hitherto involved a trade-off between spatial resolution, transcript depth and sample size. Existing methods to predict cell types from lower resolution data rely on imputation or decomposition of multicellular readings, detecting broad cortical and medullary domains based on more abundant cell types. The inception of subcellular-resolution technologies offers the potential to study cell distribution within glomeruli, including small or rare cells such as immune infiltrates, but this necessitates the development of bespoke mathematical methods for cell type identification. Since the high spatial resolution of subcellular technologies is associated with low per-spot transcriptional abundance, the opposite approach to decomposition is required: reads from neighbouring spots must be aggregated to the single-cell level. The conventional 'fixed-window' approach applies decomposition to a coarsely binned grid, discarding the advantages of the high-resolution platform. Moreover, the fixed size and offset of the grid leads to under-detection of sparsely dispersed cells.

Methods: Balb/C mice were treated with 8 weeks topical Imiquimod / vehicle. Isolated renal nuclei were prepared (10x Genomics) for single nuclei RNA sequencing (snRNA-Seq) (Illumina NovoSeq). Kidney spatial transcriptomics was performed on the Stereomics platform (Beijing Genomics Institute). Bioinformatic analysis used R packages (Seurat, RCTD). We developed a mathematical method for topological automatic cell type identification (TopACT) and combined this with multiparameter persistent homology (MPH) to quantify the multiscale spatial cell type organisation. TopACT independently classifies the cell type of each spot using a local neighbourhood, dynamically choosing neighbourhood size based on the amount of information available around the spot. The end result is spot-level cell type annotation.

Results: On synthetic subcellular resolution data imputed from renal snRNA-Seq, TopACT produced spot-level cell type annotations with high accuracy, recovering single-cell-level structure that is inaccessible from fixed-window approaches. We then applied TopACT to kidney spatial transcriptomic data in murine class II lupus nephritis. TopACT spatially resolved individual immune cells. Within glomeruli, the average MPH landscape of treated kidneys indicated large loops of

immune cells (Figure 1A). This leads to the prediction, driven entirely by spatial data, of a peripheral ring structure in immune cells infiltrating glomeruli in lupus nephritis. This distribution was confirmed by immunofluorescent staining for CD45 in Imiquimod treated kidney and control (Figure 1B and C).

Discussion: Immune cells in the diseased kidney can be rare or dispersed, but their location and gene signature can illuminate their role in pathogenesis. High resolution spatial transcriptomics technology is developing rapidly. Our multiscale method for topological automatic cell classification resolves cell type information in spatial transcriptomic data at subcellular resolution, and zeros in on the locations of elusive sparsely dispersed cells, with higher accuracy than a fixed window approach. Applied to nano-scale resolution, whole transcriptome measurement of murine kidney, we can detect the spatial arrangement of glomerular immune cells in lupus nephritis, demonstrating the power of this approach for renal pathology and the potential of the generalisable and flexible TopACT method to identify and annotate cells.



MicroRNAs as biomarkers and regulators in kidney disease

Submission: 287

Reduced tubular miR-190a-5p a novel biomarker for stratification of patients with Chronic Kidney Disease.

Dr David Baird[1], Dr Jinnan Zang[2], Dr Ryan Wong[2], Dr Katie Connor[1], Mrs Carolynn Cairns[1], Mr Maximilian Reck[1], Prof Jeremy Hughes[1], Prof Patrick Mark[3], Prof Alexander Maxwell[2], Dr Gareth McKay[2], Dr David Simpson[2], Dr Laura Denby[1], Dr Bryan Conway[1]

[1]University of Edinburgh, Edinburgh.
[2]Queen's University Belfast, Belfast.
[3]University of Glasgow, Glasgow

Background: Circulating microRNA (miRNAs) have been proposed as potential diagnostic and prognostic biomarkers and are functionally important in disease pathogenesis. In this study, we used an unbiased measurement of circulating miRNAs in patients with type 2 diabetes to identify a miRNA differentially expressed in kidney disease before moving to a larger, unselected cohort of patients with CKD to assess its potential to predict progression in CKD.

Methods: MiRNA next generation sequencing (NGS) studies were undertaken to measure differential expression of plasma miRNAs in a discovery cohort of 3 groups; individuals with type 2 diabetic kidney disease (T2DKD, n = 9), age and sex matched patients with type 2 diabetes mellitus and normal renal function (T2DNRF, n = 13) and patients without diabetes and with normal renal function (NDNRF, n = 11). Differentially expressed miRs were validated in a separate cohort of the same groups (each n=10). The prognostic value of miR-190a-5p in a general CKD population was assessed using the seNSOR cohort (n=395, excluding patients on RRT, with an eGFR of <=20 ml/min/1.73 m2 or AKI at recruitment). The primary outcome of CKD progression was defined as reaching ESKD (starting RRT or maintaining an eGFR <15mls/min) or >30% reduction in renal function from eGFR at baseline. Reaching ESKD alone was used as a secondary outcome.

Results: MiR-190a-5p was the only miRNA differentially expressed between T2DKD and both control groups in both the discovery and validation cohorts. In the seNSOR cohort, miR-190a-5p levels correlated positively with eGFR (rho = 0.12, p=0.04) and inversely with age (rho = -0.12, p=0.04). MiR-190a-5p levels below the median predicted CKD progression in individuals with minimal and moderate albuminuria (ACR < 3mg/mmol and 3-300mg/mmol respectively) but not in those with severe albuminuria (ACR>300mg/mmol, see figure).



Figure. CKD Progression stratified by miR-190-5p expression and ACR stage.

In those without severe albuminuria, miR-190a-5p levels predicted CKD progression in multivariate Cox proportional hazards models (HR 0.8, 95% CI: 0.66-0.96, p=0.015), independently of baseline eGFR, ACR, age, SBP, DBP and sex. When participants with an ACR > 300mg/mmol were included, miR-190a-5p was not predictive of the composite CKD progression endpoint (multivariate HR 0.86, p=0.064) but was predictive for reaching ESKD alone (multivariate HR 0.68, 95% CI: 0.5-0.93, p=0.015).

Analysis of miR-190 expression in individual renal cell types in the reversible unilateral ureter obstruction mouse model revealed that it is enriched in proximal tubule cells and falls significantly following injury before increasing again the repair phase.

Discussion: MiR-190a-5p is expressed by healthy proximal renal tubular cells and serum miR-190a-5p levels correlate positively with eGFR. Low serum miR-190a-5p levels may predict progression of CKD in patients with low or moderate proteinuria independently of existing risk factors.

Late-breaking Abstracts

Submission: 062

How do renal clinicians present treatment options to older patients with advanced kidney disease and what difference does it make? A Conversation Analytic study

Dr Lucy Selman[1], Dr Chloe Shaw[1], Dr Ryann Sowden[1], Prof Fliss Murtagh[2], Prof Fergus Caskey[1], Prof Ruth Parry[3], Dr Rebecca Barnes[4]

[1]University of Bristol, Bristol.
[2]Hull York Medical School, Hull.
[3]Loughborough University, Loughborough.
[4]University of Oxford, Oxford

Introduction: For older people with kidney failure, especially those with comorbidities or poor performance status, the survival benefits of dialysis are uncertain and its quality of life impact greatest. There is significant variation in the uptake of the alternative treatment option, conservative kidney management (CKM). How clinicians communicate about treatment options strongly influences patients' decision-making, but this has been under-researched. This study aimed to identify and describe how treatment options are discussed in talk between older people (age 65+) with advanced chronic kidney disease (eGFR <20) and renal clinicians.

Methods: Outpatient consultations between kidney consultants, registrars or education nurses and eligible patients were video-recorded at 4 UK renal units, transcribed and subject to Conversation Analysis, which enables detailed, direct investigation of verbal and non-verbal interaction.

Results: 112 consultations were video-recorded, involving 95 patients (mean age 76.9 years, mean eGFR 15.4). Several interactional features were identified that conveyed dialysis as normative and CKM as less favourable: conflation of kidney failure with dialysis when introducing the decision; CKM not presented as a clear treatment option (e.g. not named as CKM, minimal/no presentation of the details of what CKM involves); sequential delay (CKM presented last, often appended to the main decision-making sequence); differing ways of presenting dialysis and CKM, e.g. framing of CKM as negative or a minority preference; clinician resistance to non-dialysis as a future course of action. The conversational implications of this include the patient's perspective not being explicitly invited, a lack of interactional space for the patient to consider and/or evaluate not having dialysis as a real option, and the patient being unlikely to evaluate having dialysis as a valid option.

Discussion: Despite evidence that dialysis does not reliably extend older patients' lives at acceptable costs to their quality of life, clinicians' conversations with patients about treatment options often push towards dialysis, with patients having to work hard within consultations to promote a preference for CKM. Findings will form the basis of a new communication training intervention for clinicians.

Funder: National Institute of Health Research (UK)

Late-breaking Abstracts

Submission: 063

Kidney Patient Reported Experience Measure 2022: Reported differences in 'change in experience of care' according to treatment modality

Ms Amanda Busby[1], Dr Shalini Santhakumaran[2], Ms Ranjit Klare[3], Miss Rebecca Flanagan[1], Miss Lucy Mackintosh[1], Prof Ken Farrington[1,4]

[1]University of Hertfordshire, Hatfield.
[2]The UK Renal Registry, Bristol.
[3]The UK Kidney Association, Bristol.
[4]Lister Hospital, Stevenage

Table 1: Change in patient experience over the past year by treatment type: 2022, 2021, 2020

		N	Worse	Same	Better	Not receiving care a year ago[1]
Chronic Kidney Disease (non-KRT)	2022	1190	200 (16.8%)	742 (62.4%)	248 (20.8%)	108
	2021	1594	388 (24.3%)	896 (56.2%)	310 (19.4%)	-
	2020	1711	494 (28.9%)	1011 (59.1%)	206 (12.0%)	-
Peritoneal	2022	503	90 (17.9%)	286 (56.9%)	127 (25.2%)	66
	2021	716	83 (11.6%)	406 (56.7%)	227 (31.7%)	-
	2020	584	114 (19.5%)	343 (58.7%)	127 (21.7%)	-
Haemodialysis	2022	4801	1146 (23.9%)	2452 (51.1%)	1203 (25.1%)	501
	2021	7209	647 (9.0%)	3976 (55.2%)	2586 (35.9%)	-
	2020	4765	430 (9.0%)	2912 (61.1%)	1423 (29.9%)	-
Transplant	2022	1551	312 (20.1%)	928 (59.8%)	311 (20.1%)	24
	2021	2043	490 (24.0%)	995 (48.7%)	558 (27.3%)	-
	2020	2038	540 (26.5%)	1104 (54.2%)	394 (19.3%)	-
Total	2022	8045	1748 (21.7%)	4408 (54.8%)	1889 (23.5%)	699
	2021	11562	1608 (13.9%)	6273 (54.3%)	3681 (31.8%)	-
	2020	9098	1578 (17.3%)	5370 (59.0%)	2150 (23.6%)	-

Worse: -1 to -3 (much worse), Same: 0 (no change), Better: +1 to +3 (much better)
KRT: Kidney Replacement Therapy
[1] 2022 was the first year participants were asked to indicate if they were not receiving care a year ago

Figure 1: Changes in patient experience over past year for 2022, 2021 and 2020, by treatment



Introduction: Since 2016, the validated Kidney Patient Reported Experience Measure (Kidney PREM) has given people living with kidney disease across the UK the opportunity to share their experiences of care received. In 2020 and 2021, alongside standard questions, Kidney PREM respondents were asked to rate the impact of the COVID-19 pandemic on their experience of care. This question was reframed in 2022, capturing all aspects of change: 'Overall, how much better or worse was your kidney care experience during the last year?'. This abstract describes how change in experience differs according to the respondent's treatment modality.

Methods: Individuals were shown the 'change in experience' question at the end of Kidney PREM, immediately after rating their overall experience of care. Responses were recorded using a 7-point Likert scale from -3 (much worse) through 0 (no change) to +3 (much better), or participants could indicate that they were not receiving care a year ago. Results were combined according to treatment modality, calculating frequencies and proportions for each response option.

Results: Participation in Kidney PREM was from 1st October until 11th November 2022, receiving 11,063 responses. Of these, 8,960 (81.0%) completed the 'change in experience' question. Across all treatments (Figure 1, Table 1), participants reported that the care they received was the same (54.8%) or better (23.5%) in 2022 than the previous year, with over a fifth (21.7%) reporting a 'worse' experience, an increase from both 2021 (13.9%) and 2020 (17.3%).

Over the past three years, though scores for most have remained the same, apparent trends suggest differences in patient experience of care between modalities. Individuals not receiving kidney replacement therapy reported the worst change in experience in 2020, but seem to have improved in subsequent years. The same is true, to a lesser extent, in those with a functioning transplant. However, for those receiving centre- and satellite-based haemodialysis, patient experience of care seems to have deteriorated in 2022, with notable increases in the number of those reporting their experience to be 'much worse' (-3), 15.5% and 22.7% respectively. Reported patient experience for those receiving home therapies (peritoneal dialysis and haemodialysis at home) has remained more stable across years.

Discussion: In 2022, most Kidney PREM respondents reported that their experience of care had not changed in the past year. However, both improved and worsened changes in experience was reported by a significant proportion of participants, with differences seen according to their treatment modality.

These findings may reflect several issues. The impact of changes in kidney services enforced by the pandemic is known to have varied by treatment modality. Those not receiving KRT and, to a lesser extent, transplanted individuals were impacted by reduced outpatient provision, whilst centre- and satellite- based haemodialysis recipients experienced some benefits, notably changes in transport arrangements. The return to pre-pandemic service levels has potentially had a 'levelling out' effect, although pressures within the system remain high. There may be other factors in force, which individual centres might explore to help maintain or enhance the patient experience of care.

Late-breaking Abstracts

Submission: 064

The effect of a novel, digital physical activity and emotional well-being intervention on health-related quality of life in people with chronic kidney disease: A multicentre, prospective, wait-list randomised controlled trial (Kidney BEAM).

Dr Sharlene Greenwood[1,2], Dr Elham Asgari[3], Ms Caitlin Balkin[1], Prof Sunil Bhandari[4], Ms Roseanne Billany[5], Dr Nicolette Bishop[6], Dr Kate Bramham[2], Ms Juliet Briggs[1], Prof James Burton[5], Prof Jackie Campbell[7], Dr Ellen Castle[8], Dr Joseph Chilcot[2], Prof Cooper Nicola[5], Mr Vashist Deelchand[9], Ms Lynda Haggis[1], Dr Matthew Graham-Brown[5], Dr Alexander Hamilton[10], Dr Mark Jesky[11], Prof Philip Kalra[12], Dr Pelagia Koufaki[13], Dr Kieran McCafferty[14], Dr Andrew Nixon[15], Prof Maarten Taal[11], Dr Helen Noble[16], Dr Zoe Saynor[17], Dr James Tollitt[12], Mr Christy Walklin[1], Dr Thomas Wilkinson[5], Prof David Wheeler[18], Dr Hannah Worboys[5], Dr Hannah Young[5], Dr Jamie Macdonald[19]

[1]King's College Hospital NHS Trust, London.
[2]King's College London, London.
[3]Guy's and St Thomas' NHS Trust, London.
[4]Hull university Teaching Hospital, Hull.
[5]University of Leicester, Leicester.
[6]Loughborough University, Loughborough.
[7]University of Northampton, Northampton.
[8]Brunel University, London.
[9]Royal free Hospital, London.
[10]Devon and Exeter Hospitals, Exeter.
[11]University of Nottingham, Nottingham.
[12]Salford Royal Hospital, Salford.
[13]Queen Margaret University, Edinburgh.
[14]Parts Health NHS trust, London.
[15]Lancashire Hospital, Lancashire.
[16]Queens University, Belfast.
[17]University of Portsmouth, Portsmouth.
[18]University College London, London.
[19]Bangor University, Bangor

Introduction: Interventions to enhance physical and mental health are of global interest. Remote digital health interventions that deliver evidence-based physical activity interventions provide a potential solution for the sedentary behavior of patients with chronic kidney disease (CKD). Large clinical trials in the CKD population examining lifestyle interventions are rare. There is currently both low quality and insufficient evidence for DHIs to guide clinical practice. This is a major obstacle to improving lives of CKD patients who have high multi-morbidity and without properly designed randomised controlled trials this will be difficult to implement. The KIDNEY BEAM multi-centre randomised controlled trial investigates the novel digital health intervention delivery approach. Our trial was initiated in response to the COVID-19 pandemic and is an example of agile research activity, being a remotely delivered trial, which has lasting implications for both research and clinical delivery of lifestyle interventions.

Methods: In a multicenter (11 UK centres), randomised controlled trial, we assigned 340 adult participants with CKD to either KIDNEY BEAM intervention or control. The trial primary end point was a powered 3-point difference in the Kidney Disease Quality of Life Short Form 1.3 Mental Component Summary (KDQoL-SF1.3 MCS) between baseline and 12-weeks. Secondary outcomes included KDQoL-SF1.3 physical Component Summary, physical function (sit-to-stand 60, STS60), and fatigue (Chalder Fatigue Scale, CFS). Outcomes, as per pre-specified statistical analysis plan, were first analysed by an intention-to-treat (Last Observation Carried Forward) approach using an analysis of covariance model, with baseline measures and age as covariates. Per protocol analyses were also completed to assess efficacy under ideal conditions (i.e. in those who complied with the specified intervention protocol).

Results: Of the 340 participants, 258 completed the trial (106 in the intervention arm, 152 control arm). There was a significant mean between-group difference in the KDQoL MCS score at 12-weeks ($p<0.001$) (intervention group (mean [95% CI]): 47.5[46.6 to 48.4]; control: 44.4 [43.5 to 45.3] points) and in the STS60 test of 4 repetitions ($p<0.001$) (Intervention group (mean [95% CI]): 27 [26 to 28] repetitions); control: 23 [22 to 24] repetitions). The mean between-group differences in mean CFS and KDQoL PCS score at 12 weeks were non-significant ($p=0.334$ and $p=0.353$ respectively) but per protocol between-group analyses at 12 weeks was significant for CFS ($p=0.014$).

Conclusion: Our results demonstrate that the KIDNEY BEAM physical activity and emotional wellbeing digital health intervention is an effective innovation to enhance HRQoL (mental health and physical function) of people living with CKD. The results of this trial will inform future clinical practice and guidelines.